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Lung cancer, a global health concern 
 
Cancer poses a major burden to society worldwide. Due to significant improvements in 
the treatment and prevention of cardiovascular diseases, cancer has become the number 
one cause of death in Europe and the USA. Lung cancer is a common type of cancer and 
with nearly 2.09 million new cases of lung cancer worldwide, showing a high case fatality 
and the highest absolute mortality of all cancer types (1). Non-small cell lung cancer 
(NSCLC) is the most common histological type of lung cancer and accounts for 87% of 
all lung cancers. When fit for surgery, patients with early-stage NSCLC (stage I and stage 
II) can be treated with curative surgery as the initial modality with a 5-year survival rate of 
80%. However, a substantial number of patients (∼78%) present with advanced (stage III) 
or metastatic disease (stage IV) with a dismal prognosis. For locally advanced NSCLC the 
standard of care is concurrent platinum-based chemotherapy and radiotherapy up to 60–
66 Gy, with the recent addition of adjuvant immunotherapy (2). In stage IV disease 
palliative chemotherapy is the cornerstone of treatment. For a significant number of 
patients, the treatment is unlikely to succeed and is associated with low survival rates (5-y) 
of less than 10%. 
 
Personalised medicine in NSCLC 
 
In the past, the treatment of NSCLC followed a ‘one size fits all’ approach deriving 
treatment options from tumour stage and performance score. However, it is increasingly 
recognised that NSCLC is a heterogeneous and complex disease, being subdivided into 
histological type to optimise chemotherapeutic strategies. With targeted therapies focused 
on oncogenes (i.e., epidermal growth factor receptor, anaplastic lymphoma kinase) the 
treatment options for subgroups of NSCLC have expanded considerably (3-9), but they 
benefit only a minority of patients. It remains challenging to identify patients who may 
benefit from radiotherapy, chemotherapy or immunotherapy. Currently, with overall low 
response rates of 40% in all NSCLC patients, most patients will eventually relapse. Due to 
an initial intrinsic resistance or resistance after initial treatment, the prescribed treatment 
will fail to either induce disease regression or slow down disease progression. Possibly, a 
significant number of patients will undergo toxic side effects without a benefit from 
treatment. As treatment becomes more individualised, early identification of responders 
and non-responders is increasingly important to optimise treatment and to minimise the 
toxicity of ineffective treatment in patients. This drives the need for identification of 
predictive factors for tumour response at an early stage during therapy and this is 
fundamental for cancer treatment adaptation and individualisation. Identification of early, 
in-treatment predictive factors would enable faster adaptation of therapy. This could 
1 
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improve patient management by avoiding unnecessary side effects and could reduce the 
costs of ineffective treatment. Traditionally, the evaluation of the effectiveness of treatment 
is performed by imaging after the treatment has been given, when potentially ineffective 
treatment is already completed. The implementation of morphological measurements for 
response monitoring led to response criteria in solid tumours (RECIST) (10) and is often 
used to monitor the cytotoxic effects of therapy on malignancies. A therapy-induced 
reduction of tumour size is measured with computed tomography (CT) and is based on 
the percentage reduction in ‘target lesions’ and it includes a definition of complete 
response, partial response, stable disease and progressive disease. However, for early, in-
treatment evaluation, tumour volume is an unreliable marker of response. One limitation 
is that non-malignant tissue components (e.g. atelectasis, fibrosis) contribute to the 
apparent tumour volume. Another limiting factor is the timing of CT, as response rates 
may vary and markedly CT evaluation is advised to be established as early as 6-8 weeks 
after the start of treatment (11). Since some targeted therapies may show a cytostatic rather 
than a cytoreductive response, especially in those cases, successful treatment may not result 
in a decrease of tumour size. 
For optimal management of response to treatment, it is essential to have an evaluation 
as early as is feasible. For this purpose, instead of morphological imaging with CT, 
molecular imaging with 18F-fluoro-deoxy-glucose positron emission 
tomography/computed tomography (FDG-PET/CT) could be used to evaluate therapy-
induced changes in glucose metabolism during treatment (12).  
For staging, the introduction of FDG-PET/CT has improved detection of lymph 
node metastases and distant metastases and has become part of the standard of care in lung 
cancer, as well as many other types of cancer. 18F-Fluoro-2-Deoxy-2-D glucose is a glucose 
analogue radiolabelled with 18F that is transported by glucose transporters (predominantly 
GLUT-1) over the cell membrane and is phosphorylated by hexokinase to 
FDG-6-phosphate. Since FDG-6-phosphate cannot be catabolised further intracellularly, 
it is trapped. Since cancer cells tend to favour metabolism via anaerobic glycolysis over 
oxidative phosphorylation (the Warburg effect), it results in higher net glycolysis. Based on 
this principle, with PET it is possible to characterise indeterminate lesions and to detect 
malignant lymph nodes and distant metastases.  
The use of FDG-PET/CT is not only limited to initial staging and restaging but can 
also be used for (early) in-treatment response evaluation. One advantage is that change in 
cellular glucose metabolism may be faster during treatment than tumour size. Possibly the 
treatment evaluation can be brought forward to be performed before treatment is 
completed, even before any significant changes in size have occurred. With serial 
FDG-PET/CT studies it is possible to measure metabolic changes during treatment, 
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enabling analysis of subsequent treatment effects and ultimately capturing intrinsic 
mechanisms of resistance to treatment and treatment-induced resistance.  
The feasibility of serial FDG-PET/CT for treatment response to chemotherapy has 
been widely evaluated (13) and has led to several initiatives for response monitoring studies 
with FDG-PET/CT. One benefit is that FDG-PET/CT provides an opportunity to 
investigate in a non-invasive way the biology of cancer in vivo, in a whole-body approach 
(and not only a single lesion). This holds true for patients with multiple metastases in whom 
pathological characterisation is limited to one or a few lesions. These harbours the inherent 
risk of sampling error, intra-tumour heterogeneity and inter-tumour heterogeneity.  
The ability of FDG-PET/CT to indirectly assess the molecular mechanisms involved 
in the tumour process make it a valuable tool. The basis of metabolic imaging is that therapy 
response can be quantified due to an alteration in oncogenic signalling that (indirectly) 
affects glucose metabolism.  
A decrease in glucose metabolism may reflect the cytotoxic effects and a loss of viable 
cells associated with effective treatment. On the other hand, a persistent increased FDG-
uptake is associated with treatment resistance. Consequently, especially patients with 
metabolic disease progression may benefit from an early change of treatment to a more 
effective treatment. Therefore, FDG-PET/CT seems a suitable non-invasive tool for 
response evaluation and prediction of response and patient outcome.  
 
Outline of the Thesis 
 
FDG-PET/CT is considered as the standard of care in the work-up and management of 
NSCLC. In Chapter II the clinical impact of FDG-PET/CT on the guidance of invasive 
diagnostic procedures, staging and therapy selection is highlighted. The predictive 
performance of FDG-PET/CT of treatment response is discussed. For treatment 
personalisation Chapter III describes the predictive value of FDG-PET/CT in locally 
advanced NSCLC patients treated with concurrent chemoradiotherapy. Early, in-treatment 
evaluation performed after two weeks of treatment was correlated with the reduction of 
FDG-uptake expressed as total lesion glycolysis (TLG, the product of SUV and metabolic 
tumour volume). The predictive performance of FDG-PET/CT was further discussed in 
Chapter IV. In Chapter V FDG-PET/CT image derived indices are discussed and the 
different techniques for (automatic) image segmentation algorithms for segmentation of 
the metabolic active tumour volume. Also, the aggregation process of inclusion of the 
primary tumour alone versus a whole-body TLG approach (with affected lymph nodes) is 
evaluated. Apart from staging, FDG-PET/CT is frequently used in radiation oncology to 
optimise the radiation fields. In Chapter VI, early, in-treatment FDG-PET/CT is used to 
direct treatment to the more treatment-resistant subvolumes of the tumour, based on 
1 
  
 
18 | Chapter I 
 
persistent FDG-uptake. The feasibility of a stereotactic boost is evaluated in this planning 
study. In Chapter VII early in-treatment response monitoring with FDG-PET/CT was 
studied in inoperable stage III or stage IV patients treated with chemotherapy and 
bevacizumab. In Chapter VIII differences in histological subtype and gender differences, 
concerning metastatic patterns, are studied in a nationwide autopsy study in NSCLC. In 
Chapter IX the general discussion and future prospects are provided.  
 
 
1 
  
General Introduction | 19 
 
References 
 
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for 
clinicians. 2019;69(1):7-34. 
2. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall 
Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New 
England journal of medicine. 2018;379(24):2342-50. 
3. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. 
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung 
Cancer. The New England journal of medicine. 2015;373(2):123-35. 
4. Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. 
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. The 
New England journal of medicine. 2018;378(22):2078-92. 
5. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, 
et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational 
Burden. The New England journal of medicine. 2018;378(22):2093-104. 
6. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus 
chemotherapy in advanced ALK-positive lung cancer. The New England journal of 
medicine. 2013;368(25):2385-94. 
7. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line 
crizotinib versus chemotherapy in ALK-positive lung cancer. The New England 
journal of medicine. 2014;371(23):2167-77. 
8. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, 
et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung 
Cancer. The New England journal of medicine. 2018;378(2):113-25. 
9. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. 
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung 
Cancer. The New England journal of medicine. 2016;375(19):1823-33. 
10. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST 
guideline version 1.1: What oncologists want to know and what radiologists need to 
know. AJR American journal of roentgenology. 2010;195(2):281-9. 
11. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). 
Eur J Cancer. 2009;45(2):228-47. 
12. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung 
cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 
2009;50 Suppl 1:31S-42S. 
1 
  
 
20 | Chapter I 
 
13. de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, 
Timmer-Bonte JN, et al. Chemotherapy response evaluation with 18F-FDG PET in 
patients with non-small cell lung cancer. Journal of nuclear medicine : official 
publication, Society of Nuclear Medicine. 2007;48(10):1592-8. 
 
1 
  
General Introduction | 21 
 
1 
  
 
Read online 
  
CHAPTER II 
 
The Role of FDG-PET/CT in  
Non-Small Cell Lung Cancer  
 
 
 
 
Edwin A. Usmanij, Lioe-Fee de Geus-Oei, Johan Bussink, Wim J. G. Oyen 
Adapted from: Current Opinion in Pulmonary Medicine. 2015 Jul;21(4):314-21 
  
 
2 
  
FDG-PET/CT in NSCLC | 25 
 
 
 
 
ABSTRACT 
 
The aim of this review is to provide an outline of current evidence for the use of 18F-
fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG-
PET/CT) in non-small cell lung cancer (NSCLC) for diagnosis, staging, radiotherapy 
planning, response assessment and response monitoring.  
Management of patients with non-small cell lung cancer requires a multimodality 
approach to diagnose and stage patients accurately. In this approach, FDG-PET/CT 
has become a standard staging instrument in lung cancer. FDG-PET/CT is, in addition 
to staging, also valuable for the characterisation of the solitary pulmonary nodule. 
Increased uptake in the nodule as compared to mediastinal blood pool is suspected of 
malignancy. In radiotherapy planning, FDG-PET/CT can assist the radiation 
oncologist for optimal dose delivery to the tumour, while sparing healthy tissues. 
Evidence of the prognostic and predictive implications of FDG-PET/CT is 
accumulating. Volumetric parameters of PET, such as metabolic active tumour volume 
and total lesion glycolysis, are promising predictive and prognostic biomarkers. 
However, for implementation of metabolic response parameters in clinical practice 
more randomised PET-based multicentre trails are necessary. The introduction of 
integrated PET and magnetic resonance imaging (PET/MR) scanners did not change 
the pivotal role of standard FDG-PET/CT yet, since with current technology 
PET/MR did not show superior performance in thoracic staging. 
 
Keywords 
non-small cell lung cancer, positron emission tomography, F-18-fluoro-deoxy-glucose, 
staging, prediction 
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INTRODUCTION 
 
In the Western world, lung cancer is the leading cause of cancer-related death. Non-small 
cell lung cancer (NSCLC) accounts for 87% of all lung cancers (1). Adequate diagnosis and 
staging of NSCLC are of pivotal importance for clinical decision-making given that 
locoregional disease is treated with curative intent, while for disseminated disease the 
prognosis is dismal. Already before the introduction of hybrid scanners, that combined 
computed tomography (CT) and positron emission tomography (PET), the advent of PET 
with F-18-fluoro-deoxy-glucose (FDG) significantly improved the diagnostic accuracy of 
imaging. FDG-PET/CT has made a significant impact on both the guidance of invasive 
diagnostic procedures as well as on the selection of treatment options. Nowadays, FDG-
PET/CT with contrast-enhanced CT has become a standard modality in the work-up of 
NSCLC (2). In this short review, we will focus on the most recent and pertinent progress 
in the application of PET/CT in non-disseminated NSCLC. We will summarise the 
indications of FDG-PET/CT for early diagnosis, the evaluation of pulmonary lesions and 
staging, and we will review the emerging evidence of FDG-PET/CT in (early) response 
monitoring and in radiation treatment planning. We end with the potential role of PET/CT 
in targeted therapy and follow-up. 
 
Evaluation of lung lesions with FDG-PET/CT 
 
Currently, we are frequently confronted with incidental findings of solitary pulmonary 
nodules (SPN), which can be partly explained by the increasing use of CT for indications 
other than cancer, e.g. cardiac CT for assessment of coronary artery disease or CT 
angiography for diagnosis of pulmonary embolism. Due to the relatively low specificity of 
CT, various risk assessments are available to predict the chance of malignancy of the 
nodules (3, 4). When the pretest chance of malignancy is 5-60% and the nodule is at least 
8-10 mm, the evidence-based recommendation from Gould et al. (5) states that FDG-
PET/CT is recommended to characterise the nodule. In nodules measuring <8-10 mm 
PET is less sensitive in detecting malignancy (e.g. with decreasing size of the nodule the 
false-negative rate rises). A recent meta-analysis by Deppen et al. 70 FDG-PET and FDG-
PET/CT (6) studies were included showing a pooled sensitivity of 89% (95%-CI 86%-
91%) and a specificity of 75% (95%-CI 71%-79%) for the detection of malignancy of the 
SPN. Ten studies, reporting a high prevalence of inflammatory pulmonary disease, showed 
an adjusted pooled specificity of 61% (95%-CI 49%-72%). It is important to realise that in 
populations with endemic lung disease FDG-PET/CT suffers from lower specificity. 
Overall, the results of this meta-analysis support the role of PET in the detection of 
pulmonary malignancy in SPN and showing a similar performance compared to a previous 
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meta-analysis by Gould et al. (7) who reported in 2003 a sensitivity and specificity of 96.8% 
and 77.8%. Nevertheless, evolving technology (e.g. the introduction of PET/CT, 
improving spatial and contrast resolution of PET) has resulted in a significantly better 
performance of modern FDG-PET/CT compared to stand-alone FDG-PET as when it 
was introduced in the clinic 15 years ago. Combining information from FDG-PET/CT 
and CT may lead to further improvement as shown by Asharf et al. (8). They reported that 
the combination of a volume doubling time (VDT) of the tumour in less than one year and 
FDG-uptake higher than the mediastinal blood pool was highly predictive of a malignant 
SPN. All ten nodules with high FDG uptake and VDT of less than one year were 
malignant, while only 2 of 30 nodules (7%) with low FDG uptake and long VDT were 
malignant. The combination of FDG-PET/CT and VDT resulted in a sensitivity of 90% 
and a specificity of 82%. In a multivariate analysis, both FDG uptake and VDT were 
independently associated with malignancy. In the evaluation of SPN, the inclusion of 
FDG-PET/CT has proven to be a cost-effective imaging modality (9-14). 
 
Staging of NSCLC using FDG-PET/CT 
 
Accurate staging of NSCLC is crucial for the management in NSCLC. The principal 
advantage of staging with FDG-PET/CT, over CT alone, is the superior performance in 
terms of mediastinal staging and the detection of distant metastases. Consequently, 
implementation of FDG-PET/CT resulted in a lower rate of futile thoracotomies (15). 
Nowadays, FDG-PET/CT has become a routine investigation in preoperative staging. The 
introduction of FDG-PET/CT improved the detection of distant metastasis, leading to a 
stage migration resulting in an increase of 8.4% stage IV disease in NSCLC (16). 
Numerous studies investigated the role of FDG-PET/CT in the detection of 
metastatic lymph nodes (17-24). In a recent meta-analysis by Lv et al. (25), including 
fourteen studies with a total of 2550 patients, the pooled weighted sensitivity was 76% 
(95%-CI 65%-84%) and specificity was 88% (95%-CI 82%-92%). In mediastinal staging, a 
meta-analysis by Schmidt-Hansen (26) including 45 studies on integrated FDG-PET/CT 
for mediastinal staging reported a sensitivity and specificity of 77.4% (95%-CI 65.3%-
86.1%) and 90.1% (95% CI 85.3%-93.5%), respectively. Fisher et al. (27) randomised 189 
patients between workup without and with FDG-PET/CT, showing that FDG-PET/CT 
is false negative in 4% of the cases where nodes are not significantly enlarged on CT. 
Several studies showed that FDG-PET/CT is sensitive for the detection of metastasis in 
adrenal glands (28) and bone (29-32).  
A new development is the arrival of integrated PET and magnetic resonance imaging 
(PET/MR), currently introduced in just a few institutions worldwide. However, PET/MR 
scanners did not change the pivotal role of FDG-PET/CT as the standard of care in 
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staging. Heusch et al. (33) reported no advantage of PET/MR over PET/CT in thoracic 
staging. No differences were found for the detection of metastatic lymph nodes or T-stage 
of the primary tumour. While only a few studies are published on this subject, these studies 
do not show a clear benefit of FDG-PET/MR over FDG-PET/CT yet. 
Concluding, FDG-PET/CT is considered standard of care for non-invasive 
mediastinal staging and detection of distant metastasis in NSCLC. For the detection of 
brain metastasis, FDG-PET/CT has limited value as the high physiologic uptake of FDG 
in the cerebral cortex may obscure pathological uptake.  
 
FDG-PET/CT in Radiotherapy 
 
Radiotherapy plays an important role in the treatment of lung cancer (34). For defining the 
treatment target (e.g. the gross tumour volume or GTV), CT is the standard imaging 
modality required to determine electron density for dose calculation. A robust definition 
of the tumour volume to be irradiated is a prerequisite for successful radiotherapy, which 
can be quite challenging with CT, e.g. in centrally located tumours or in case of concomitant 
atelectasis. Therefore, FDG-PET/CT was explored to provide better data for tumour 
delineation and to improved local treatment. Selective irradiation of FDG-positive nodes 
is proposed, based on the high sensitivity for staging of mediastinal lymph nodes. De 
Ruysscher et al. (35) showed in a prospective study that selective nodal irradiation resulted 
in only low isolated nodal failure. The same group showed that this would allow an increase 
of dose delivery to the tumour (36). 
For defining the primary tumour, incorporation of FDG-PET data in target volume 
delineation leads to significant changes in the shape and the volume of the target and allows 
shaping of the radiotherapy dose distribution accordingly (37). FDG-PET/CT can provide 
useful information on the extent of the tumour involvement and hypermetabolic regional 
lymph nodes. It prevents the inclusion of normal tissue, for example atelectasis. In those 
cases, FDG-PET/CT allows a reduction of the target volume by separating atelectasis from 
viable metabolic active tumour tissue (38). An example of FDG-PET/CT radiotherapy 
planning is shown in Figure 1. 
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A number of issues may arise upon introduction of FDG-PET/CT data in radiation 
treatment planning. The spatial resolution of FDG-PET/CT is lower as compared to CT. 
However, with modern PET/CT scanners, this drawback has mostly been overcome. 
When tumour delineation is performed manually, it is subjective by definition and 
dependent on the experience of the radiation oncologist. FDG-PET/CT, however, 
significantly reduced inter-observer variations in tumour delineation (39, 40). Different 
approaches for (semi-) automatic delineation methods are proposed, based on the 
standardised uptake value (SUV), such as absolute threshold- (SUV ≥ 2.5) and relative 
threshold based methods (e.g. 40% - 50% of maximum SUV, signal to background (41). 
All methods are dependent on sufficiently high signal-to-background ratios and the 
FIGURE 1. FDG-PET/CT radiotherapy planning. Stage cT1bN3M0 NSCLC treated by 
concurrent chemo radiotherapy to a total irradiation dose of 66 Gy at 2 Gy per fraction. Left 
transversal, coronal and sagittal images of fused FDG-PET/CT images those were used for 
delineation of the gross tumour volume. Right same sections with radiation dose distribution (red 
line is PTV). 
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heterogeneity of the FDG-uptake in tumours (42-44). Therefore, other techniques, such as 
Watershed and Clustering algorithms (45) are proposed to overcome these issues. One 
important uncertainty in tumour volume delineation is caused by respiratory motion. FDG-
PET/CT of the chest cannot be performed during a single breath hold but has to be 
acquired during shallow free breathing. Therefore, FDG-PET/CT is prone to respiratory 
motion-induced mismatches between PET and CT (46). The result can cause inaccuracies 
in the quantification of FDG-PET/CT. Several methods for respiratory-gated FDG-
PET/CT have been developed (47, 48). Further clinical studies are needed to evaluate the 
added value in routine clinical practice.  
 
Prognostic value of FDG-PET/CT 
 
To quantify a lesion on PET, the most commonly used parameter is SUV. This semi-
quantitative parameter reflects the radioactivity concentration in a tumour, normalised to 
injected dose and body weight. SUVmax reflects the voxel with the highest radioactivity 
concentration. The SUV parameter has been recognised as an important prognostic factor 
in NSCLC (49-53). Recently, a large prospective multicentre study by Machtay et al. (54) 
showed in 250 stage III NSCLC patients, that pre-treatment SUVmax was not associated 
with survival. Only the post-treatment SUV was predictive of overall survival in a 
multivariate Cox proportional hazards analysis (HR 1.125, 95% CI 1.049-1.206). As SUVmax 
only reflects the uptake in one voxel, volumetric parameters (representing the total tumour 
metabolism) have been considered as a prognostic biomarker. Metabolic tumour volume 
(MTV) is defined as the volume of the delineated tumour on PET. To delineate the tumour 
several methods exists, such as specific threshold, gradient (45) or adaptive threshold 
methods (41). Total lesion glycolysis (TLG) is calculated as the product of MTV and the 
mean SUV of all voxels. An increasing body of evidence underlines the prognostic value 
of TLG (55-58) and MTV (59-62). A recent meta-analysis by Im et al. (63) showed for MTV 
a pooled hazard ratio for overall survival (OS) of 2.31 (95%-CI 1.54–3.47). It is indicating 
that a high MTV is associated with worse survival rates compared to a low MTV. Also, 
patients with a high TLG show worse survival (pooled HR for OS of 2.94 (95%-CI 1.94–
3.18). In multivariate analysis for OS, MTV (64) and TLG (65) showed to be independent 
prognostic markers regardless of tumour size and disease stage. 
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Response Assessment with FDG-PET/CT 
 
The role of FDG-PET/CT in response assessment in NSCLC has been extensively studied 
in the past years. Traditionally response assessment is done by size criteria, for which CT 
is the method of choice in NSCLC. However, several limitations can be identified when 
using the tumour diameter as a measure for response. Morphological changes tend to occur 
relatively late during treatment and may suffer for limitations to differentiate residual viable 
tumour from fibrosis or necrosis. Molecular imaging using FDG can depict metabolic 
changes in the tumour at an early stage during treatment (Figure 2). Ultimately, an in-
treatment assessment with PET can offer the opportunity for treatment adaptation in the 
individual patient. In this personalised medicine approach, patients, who may not benefit 
from therapy, might be spared unnecessary toxicity of ineffective treatment. Switching to 
another treatment can be considered. This can lead to improved tumour control and avoid 
futile costs of ineffective treatment. 
 
In early response monitoring, metabolic change is evaluated during treatment with the 
objective to predict clinical outcome. In patients with locally advanced NSCLC treated with 
concomitant chemoradiotherapy, the evolution of TLG is predictive of progression-free 
survival (PFS) (66) and OS (67). Yossi et al. (67) showed that a decrease of >15% TLG 
after 30 Gy (up to a total dose of 66–70 Gy in 2 Gy fractions) was associated with a better 
OS (P = 0.007 HR 7.439; 95%-CI 1.168–28.897) and PFS (P = 0.010; HR 5.695; 95%-CI 
1.506–21.537). Huang et al. (68) showed in locally advanced NSCLC that decrease of MTV 
after 40 Gy (was predictive for local recurrence-free survival (LRFS). 40 Gy was given 
conventionally at 2 Gy fractions and late-course accelerated hyper-fractionated with 1.4 Gy 
twice daily up to a total dose of 62.4 to 76.4 Gy. A decrease in MTV of more than 29.7% 
(optimal cut-off) was associated with a median LRFS of 35 months, compared to a decrease 
in MTV of less than 29.7% with a median LRFS of 13 months (P < 0.001).  
Several studies investigated FDG-PET/CT to address metabolic response (69-71) in 
NSCLC patients treated with epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKI). Takahashi et al. (69) showed that in 19 patients (stage IIIA, IIIB, IV) after 
two days of treatment a ≥20% decrease in maximum SUV (optimal cut-off) was associated 
with a significantly longer PFS. Another study by O’Brien et al. (70) showed in 38 patients 
(stage IIIB – IV) that a decrease in SUV ≥ 25% after six weeks showing significantly longer 
survival in patients treated with EGFR-TKI. A study by Bengtsson et al. (71) showed that 
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after two weeks of EGFR-TKI treatment, new lesions on PET were independent and 
significant predictors of overall survival. While FDG is a widely used radiotracer, other 
tracers for early response prediction for EGFR-TKI’s are promising, such as F-18-fluoro-
thymidine (FLT), which reflects cellular proliferation. In patients with advanced NSCLC, 
a marked decrease in FLT uptake under erlotinib treatment was a strong predictive factor 
for PFS (72).  
The mentioned studies show the predictive implications of (early) in-treatment FDG-
PET/CT in NSCLC. However, implementation of these FDG-PET/CT data in clinical 
practice is not straightforward. First of all, variations in measurements of response and 
response criteria exist (73, 74). The proposed PET Response Criteria in Solid Tumours 
(PERCIST) (75) could serve as structured criteria in PET response studies. Also, the lack 
FIGURE 2. Early FDG-PET/CT response during concomitant chemo radiotherapy. Patient 
with a tumour in the right upper lobe, affected lymph nodes hilar right and contralateral mediastinal 
lymph node (N3 node not shown), staged cT2N3M0. Patient was treated with concomitant chemo 
radiotherapy with a total irradiation dose of 66 Gy at 2 Gy fractions. Pre-treatment scan is shown 
in the left column while the in-treatment scan 20 Gy into concomitant chemo-radiotherapy is 
shown on the right. The in-treatment scan showed significant reduction in FDG-uptake of the 
tumour, while no size reduction was seen on CT. 
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of consensus on measurement method and PET parameters is hampering clinical 
implementation. Furthermore, harmonisation of optimal in-treatment timing of 
FDG-PET/CT is important to compare studies (76). Consequently, adequately powered, 
prospective interventional trials, in which the PET-data are used to modify treatment, 
prove to be very difficult to organise. 
 
FDG-PET/CT in follow-up 
 
Currently, routine surveillance FDG-PET/CT after definite therapy is not included as a 
part of follow-up. When recurrent disease on conventional imaging is suspected, 
FDG-PET/CT is useful for the detection of recurrence. In a meta-analysis including 13 
articles, FDG-PET/CT was a superior modality compared to conventional imaging for the 
detection of recurrent lung cancer (77). A recent retrospective study of surveillance 
FDG-PET/CT during follow-up more than six months after treatment showed that FDG-
PET is a prognostic marker of OS (78). Patients with a negative FDG-PET/CT for 
recurrence had a median survival time of 81.6 months versus 32.9 months in patients with 
an FDG-PET/CT suspected of recurrence (P < 0.0001). 
 
CONCLUSION 
 
In this review we discussed recent and clinically most relevant progress in the use of FDG-
PET/CT in NSCLC. FDG-PET plays an important role in the staging and restaging of 
NSCLC, providing complementary information to conventional morphological imaging 
modalities. Furthermore, FDG-PET/CT is useful for characterisation of solitary 
pulmonary nodules. FDG-PET/CT can aid the radiation oncologist in treatment planning 
for optimal dose delivery to the tumour, while sparing healthy tissues. Evidence is 
accumulating for the prognostic and predictive implications of FDG-PET/CT. FDG-
PET/CT is promising as a useful biomarker for response assessment. However, validation 
with adequately powered prospective studies is still needed. FDG-PET/CT after primary 
therapy is recommended when recurrent disease on conventional imaging is suspected. 
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Key Points 
- FDG-PET/CT is recommended to characterise the solitary pulmonary nodule. 
- FDG-PET/CT is a standard staging instrument for mediastinal staging and detection 
of distant metastasis in non-small cell lung cancer. 
- The use of FDG-PET/CT in radiotherapy planning leads to significant changes in the 
GTV of the primary tumour and involved lymph nodes, providing valuable data for 
improved tumour delineation. 
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ABSTRACT 
 
Objectives 
The potential of 18F-fluorodeoxyglucose-positron-emission-tomography (18F-FDG 
PET) changes was evaluated for prediction of response to concomitant 
chemoradiotherapy in patients with locally advanced non-small cell lung cancer 
(NSCLC). 
 
Methods 
For 28 patients, 18F-FDG PET was performed before treatment, at the end of the 
second week of treatment, and after the completion of treatment (after two weeks and 
three months). Standardised uptake value (SUV), maximum SUV (SUVmax), metabolic 
tumour volume (MTV), and total lesion glycolysis (TLG) were obtained. Early 
metabolic changes were defined as fractional change (ΔTLG) when 18F-FDG PET at 
the end of the second week was compared with pretreatment 18F-FDG PET. In-
treatment metabolic changes, as measured by serial 18F-FDG PET, were correlated with 
standard criteria of response evaluation of solid tumours by means of CT imaging 
(Response Evaluation Criteria In Solid Tumours 1.1). Parameters were analysed for 
stratification in progression-free survival (PFS). 
 
Results 
When compared with early metabolic non- responders, a ΔTLG decrease of 38% or 
more was associated with a significantly longer PFS (1-year PFS 80% vs 36%, P = 0.02). 
Pre-treatment TLG was found to be a prognostic factor for PFS. 
 
Conclusion 
The degree of change in TLG was predictive for response to concomitant 
chemoradiotherapy as early as the end of the second week into treatment for patients 
with locally advanced NSCLC. Pre-treatment TLG was prognostic for PFS. 
 
Key Words 
early response prediction, non-small cell lung cancer; concomitant radiotherapy 
chemotherapy; 18F-FDG PET, standardised uptake value; total lesion glycolysis 
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INTRODUCTION 
 
Management of patients with locally advanced non-small cell lung cancer (NSCLC) has 
changed significantly in the past few years (1, 2). Concomitant chemo-radiotherapy (CRT) 
is the standard of care in fit patients (ECOG performance status grade 0 – 1) (3). However, 
intensification of treatment significantly increases morbidity while yielding modest 
improvements in terms of overall survival (3). If a good response is obtained after CRT, 
surgery with curative intent can be beneficial (4), but only if a complete eradication of vital 
tumour cells in involved lymph nodes is achieved. On the other end, there are some 
patients that do not respond to CRT while they do experience the side effects (3). With 
recent developments in dose escalation in NSCLC, a further increase in toxicity is reported 
(5, 6). Therefore, a need arises to predict therapy response at an early phase on an individual 
patient basis. This could lead to improved tumour control, reduction in side effects and 
eventually avoid futile costs of ineffective treatment (7).  
Imaging of treatment response is mainly static, based on the assessment of tumour 
size on CT and classification of metric changes using international Response Evaluation 
Criteria In Solid Tumours (RECIST) (8). However, these morphologic methods are of 
limited value for the detection of early therapy response. Anatomic imaging cannot 
distinguish atelectasis or fibrotic tissue from residual tumour (9,10). Consequently, a 
radiographic response does not show correlation with histopathologic regression after 
neoadjuvant chemoradiotherapy in NSCLC (11). Thus, response assessment by standard 
radiologic imaging is only meaningful after the end of therapy, when the opportunity to 
modify possible ineffective treatment has passed. Functional imaging using 18F-FDG 
PET/CT has gained widespread acceptance for diagnosis and staging in oncology and has 
proven prognostic value for NSCLC (12). The application of 18F-FDG PET/CT for the 
prediction of therapy response and treatment outcome has been shown in advanced stage 
NSCLC during induction chemotherapy (13–16), during radiotherapy (17), and after 
neoadjuvant chemotherapy (18). Data for response prediction of 18F-FDG PET/CT in 
locally advanced NSCLC treated with concomitant therapy are limited. The aim of this 
study was to assess the predictive value of 18F-FDG PET/CT in locally advanced NSCLC, 
performed after two weeks of concomitant chemoradiotherapy. We hypothesised that early 
treatment-induced glucose metabolic changes, measured by 18F-FDG PET/CT scans, can 
predict clinical outcome. 
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MATERIALS AND METHODS 
 
Patients 
 
From January 2008 to January 2012, patients with newly diagnosed locally advanced 
NSCLC eligible for concomitant chemoradiotherapy were enrolled in this study. Inclusion 
criteria were cytologically or histologically proven NSCLC stage IIIA (TNM sixth edition, 
Union for International Cancer Control [UICC], T3 or N2) or stage IIIB (TNM sixth 
edition, UICC, T4 or N3); age, 18–80 y; and ECOG performance status grade, 0–1. The 
exclusion criterion was previous thoracic radiotherapy. The study was approved by the 
Institutional Review Board of the Radboud University Nijmegen Medical Centre. All 
patients gave written informed consent. 
 
Treatment 
 
Patients were treated with chemoradiotherapy in a concomitant scheme. An intensity-
modulated radiotherapy technique (IMRT) was delivered to a total dose of 66 Gy in 33 
fractions of 2 Gy, five fractions per week, using 10-MV photons. The gross tumour volume 
consisted of the primary tumour and involved hilar or mediastinal lymph nodes (i.e., PET-
positive or cytologically proven lymph nodes). The clinical target volume contained gross 
tumour volume plus a 1.0-cm margin for the primary tumour and 0.5-cm margin for the 
lymph nodes. The planning target volume consisted of the clinical target volume plus a 
0.5-cm margin. The chemotherapy regimen consisted of two cycles of cisplatin (50 mg/m2 
of body surface area [days 1 and 8 of the first cycle and days 22 and 29 of the second cycle]) 
and etoposide (100 mg/m2 of body surface area intravenously [days 1–3 of the first cycle 
and days 22–24 of the second cycle]), starting on the first day of radiotherapy. The planned 
overall treatment period was 45 days. 
 
Staging and Follow-up 
 
All patients underwent diagnostic work-up, including contrast-enhanced CT of the thorax 
and upper abdomen; whole-body 18F-FDG PET/CT; MR imaging of the brain; 
bronchoscopy with transbronchial needle aspiration (TBNA), esophageal ultrasound fine-
needle aspiration (EUS-FNA), or endobronchial ultrasound with TBNA (EBUS-TBNA); 
and mediastinoscopy in the case of PET-positive, cytologically negative mediastinal lymph 
nodes. After work-up, all patients were discussed in a thoracic oncology multidisciplinary 
board. Before chemoradiotherapy, 18F-FDG PET/CT of the thorax was performed in 
radiotherapy position for radiotherapy planning (median interval, 11 d; range, 1–27 d).  
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Early response measurement, using 18F-FDG-PET/CT, was performed at the 
beginning of week three (after a median dose of 20 Gy, range 20-24 Gy), always prior to 
the second chemotherapy cycle. All attending physicians were blinded to the results of this 
18F-FDG-PET/CT, which was part of the study protocol. Therefore, the study data did 
not affect treatment decisions. The study design is shown in Figure 1. 
Two to three weeks after the end of therapy (median 19 days, range 14 – 21 d), patients 
were re-staged with a whole body 18F-FDG-PET/CT and a contrast-enhanced CT of the 
chest/upper abdomen. All tumour response assessment was done according to 
RECIST 1.1 criteria (8). If findings indicated an objective response to therapy and the 
primary tumour was considered resectable by lobectomy and if patients were considered 
operable, a restaging of mediastinal nodes by EUS or EBUS was performed, followed by 
mediastinoscopy in the case of negative cytology (normal cytologic lymph node punctate 
or non-representative punctures). Patients underwent lobectomy in the case of complete 
mediastinal histopathologic response (i.e., cytologically or histologically no vital tumour 
cells in previously affected nodes). In the case of persistent N2 disease or if patients were 
not eligible for surgery (tumour unresectability or inoperable patients), follow-up was 
performed. 
Final treatment response after chemoradiotherapy was assessed using 18F-FDG PET 
3 months after treatment (range, 2–5 months) in the nonsurgical group. Follow-up during 
and after treatment for all patients consisted of standard follow-up according to the 
following international guidelines: clinical examination at regular intervals (every three 
months in the first year), chest X-rays, and chest CT scans if clinically indicated. 
 
18F-FDG-PET/CT scan 
 
All PET investigations were performed with a hybrid PET/CT scanner (Biograph Duo 
Siemens Medical Solutions USA, Inc.) according to guidelines of the European Association 
of Nuclear Medicine (19). Patients fasted for at least six hours. Blood glucose levels were 
lower than 8.2 mmol/L in all patients (mean, 6.0 mmol/L). According to protocol, 60 min 
(mean ± SD, 77.94 ± 9.1 min) after intravenous injection of 18F-FDG (3.45 MBq/kg; 
Covidien) and furosemide (10 mg), static emission scans in 3-dimensional mode were 
obtained, covering the neck, thorax, abdomen, and pelvis.  
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The PET acquisition time was 4 min per bed position. The second and third 18F-FDG 
PET/CT scans were obtained covering the thorax only. PET scans were processed using 
iterative reconstruction with the ordered-subsets expectation maximisation algorithm 
(image matrix size, 128 · 128; 4 iterations, 16 subsets; and a 5-mm 3-dimensional Gaussian 
filter). The reconstructed images were corrected for injected dose, the decay of 18F-FDG, 
patient body weight, and attenuation using a low-dose CT scan. 
 
FIGURE 1. Study design. CRT = chemoradiotherapy. 
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Standardised Uptake Value (SUV) and Total Lesion Glycolysis (TLG) 
 
PET and CT scans were imported into Pinnacle3 (version 8.0d; Philips Radiation Oncology 
Systems). All SUVs were derived from the 18F-FDG PET/CT scans using semiautomatic 
delineation techniques. 18F -FDG uptake was calculated as maximum SUV (SUVmax) within 
the metabolic active tumour volume (MTV) of the primary tumour and mean SUV. MTVs 
were delineated using 50% isocontour thresholds based on a fixed percentage of the 
maximum activity within the lesion, without background correction. Metastatic lymph 
nodes were analysed separately using a 50% method. Volume-weighted mean values of 
SUV in all 18F-FDG–avid lesions per PET scan were derived to provide one value for each 
study. TLG was calculated using a summation of SUV · MTV (cm3), including both the 
primary tumour and all metastatic lymph nodes. 
 
Clinical Follow-up 
 
The patient outcome data for time to progression was defined as the interval between the 
start of treatment and the date of documented disease progression as confirmed by imaging 
or biopsy. If a patient was progression-free at the closeout date (May 29, 2012), time to 
progression was censored to that date. Overall survival was measured from the date of 
treatment start to death. Patients still alive at the closeout date were censored for survival 
at that date. 
 
Data and Statistical Analysis 
 
All CT images were read by one experienced radiologist, who was masked for the early 
response PET data. The PET scans were read by consensus of 2 experienced nuclear 
medicine physicians. Regions of interest were defined using semiautomatic scripts, after 
input of target region of interest. The radiologists and nuclear physicians were masked to 
clinical outcome. Variation in parameters in sequential scans was normalised to baseline: 
Δ = (pre-treatment – in treatment)/pre-treatment x 100%  
Univariate analysis for progression-free survival (PFS) was performed on TLG, SUV, 
and TNM parameters. All SUV and TLG parameters were analysed as continuous 
variables. Variable selection for multivariate analysis was performed by both forward and 
backward stepwise covariate selection. The hazard ratio (HR) per unit parameter change 
and its 95% confidence interval were reported unless indicated otherwise. Survival curves 
were generated using the Kaplan–Meier method. Log-rank statistics were performed at 
different dichotomisation levels. All statistical analyses were performed using SPSS 18.0 
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(SPSS Inc.) for Windows (IBM). The level of statistical significance was defined as a P-value 
of less than 0.05 based on 2-sided tests. 
 
RESULTS 
 
Patients Characteristics and Follow-up 
 
Thirty patients were included. Two patients were excluded because they did not receive an 
appropriate early in-treatment 18F- FDG PET scan. Patient characteristics are summarised 
in Table 1. All patients received 60–66 Gy of radiotherapy and 2 cycles of chemotherapy. 
Total median treatment time was 45 days (range, 43–49 d). The end-of-treatment 
reassessment according to RECIST 1.1 revealed 16 patients as responders (complete 
responders, 0; partial responders, 16) and 12 patients as non-responders (stable disease, 11; 
progressive disease, 1). Seven patients, successfully pathologically downstaged and 
considered resectable, received a lobectomy. Protocol violation took place in 1 patient with 
persistent N2 disease (1 level). Thus, a total of 8 patients underwent lobectomy, with 
complete tumour resection (R0) in 7 of 8 patients. Pathologic assessment showed 
ypT0N0M0 status in 4 of 8 patients. Four patients showed residual viable tumour cells in 
the resected lobe, including the patient with persistent N2 disease. 
Median follow-up was 16 months (range, 4–34 months), for the surviving patients 17 
months (range, 4–34 months), and for deceased patients ten months (range, 4–23 months). 
During follow-up, nine patients died, all related to cancer progression. Overall survival at 
one and two years was 76% and 28%, respectively. Sixteen patients developed recurrent 
disease, three with progression of local disease, whereas distant metastases were detected 
in 13 patients (cerebral, n = 9; liver, n = 1; adrenal gland, n = 1; skin, n = 1; and bone, 
n = 1). Median time to progression was 12 months. PFS after treatment start was 62% after 
one year and 19% after two years.  
 
 
TLG and Progression Free Survival  
 
Pre-treatment TLG was 250.48 (±274.54) for the whole study group, whereas in-treatment 
TLG was 158.96 (±224.33). In stage IIIA patients, mean pre-treatment and in-treatment 
TLG were 176.51 (±171.59) and 108.66 (±147.26), respectively, whereas stage IIIB patients  
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  TABLE 1. Patient Characteristics 
Characteristic Value 
Age (y) 
 
 Mean 59 
 Range 41−77 
 Age < 65 15 (54%) 
 Age ≥ 65 13 (46%) 
Sex 
 
 Male 18 (64%) 
 Female 10 (36%) 
Histology 
 
 Squamous cell carcinoma 11 (39%) 
 Adenocarcinoma 14 (50%) 
 Non–small cell not otherwise specified 3 (11%) 
TNM stage (sixth edition) 
 
 IIIA 17 (61%) 
 T0N2 1 (4%) 
 T1N2 3 (11%) 
 T2N2 8 (29%) 
 T3N2 5 (18%) 
 IIIB 11 (39%) 
 T1N3 3 (11%) 
 T2N3 1 (4%) 
 T4N0 3 (11%) 
 T4N2 2 (7%) 
 T4N3 2 (7%) 
Performance score (ECOG) 
 
 0 20 (71%) 
 1 8 (29%) 
Smoking status 
 
 Current smoker 12 (43%) 
 Former smoker 16 (57%) 
Previous malignancy 
 
 No 24 (86%) 
 Yes 4 (14%) 
Adjuvant surgery 
 
 No surgery 20 (71%) 
 Lobectomy 8 (29%) 
 
3 
  
Response monitoring with PET in NSCLC | 53 
 
 
had a mean TLG of 364.81 (±364.30) and 236.70 (±300.38). An overview of baseline TLG, 
in-treatment TLG, and ΔTLG for all patients is shown in Table 2. Univariate Cox regression 
analysis for PFS was used to analyse the relationships between covariates of interest 
(Table 3). Significant parameters for PFS were pre-treatment TLG, in-treatment TLG, 
MTV and ΔTLG. When ΔTLG for pre-treatment TLG was corrected, both factors 
remained significant for PFS (Table 4). A 10% less decrease in ΔTLG was associated with 
HR 1.169 (P = 0.033) for PFS. Every 10-unit increase from baseline TLG index was 
associated with HR 1.047 (P = 0.009).  
To avoid data-driven significance for cut-off, ΔTLG was stratified at the median level. 
At a median level of 45% cut-off, patients with less than 45% decrease in ΔTLG (n = 14) 
had median PFS of 9.8 months, while patients with ≥ 45% decrease in ΔTLG (n = 14) had 
median PFS of 15.9 months (P = 0.032, log-rank test). PFS beyond 2 years occurred only 
in patients with ≥45% decrease in ΔTLG. Survival data and Kaplan-Meier curve for PFS 
at a median cut-off ΔTLG is shown in Figure 2, and PFS data at various cut-off points are 
shown in Table 5. 
The following three risk groups were stratified: Favourable (baseline TLG < 500 and 
≥ 38 % decrease in ΔTLG), intermediate (baseline TLG < 500 or ≥ 38 % decrease in 
ΔTLG) and unfavourable risk (baseline TLG ≥ 500 and < 38 % decrease in ΔTLG). A 
Kaplan-Meier of stratified risk groups is shown in Figure 3. Median survival in the 
favourable group was 17 months (range, 45.9–34.0 months), whereas in the intermediate 
group median survival was 11.8 months (range, 3.3–31.7 months). The unfavourable group 
had a median survival of 2.3 months (range, 2.1–4.5 months). 
Figure 4 shows an example of two patients with sequential scans. Because ΔSUV 
showed a similar decrease, the difference in ΔTLG was apparent. 
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TABLE 2. TLG Evolution Sorted by TNM Subgroups 
 
TNM stage 
(sixth edition) 
n Pre-treatment 
TLG 
In-treatment 
TLG 
ΔTLG (%) 
IIIA (n = 17)  
    
 T0N2 1 (4) 83.60 26.93 −67.79 
 T1N2 3 (11) 27.35 15.34 + 43.91   
127.97 108.18 −15.46   
6.33 3.27 −48.31 
 T2N2 8 (29) 156.81 59.93 −61.78   
323.93 278.08 −14.16   
199.1 48.63 −75.57   
31.83 30.05 −5.59   
60.21 76.13 +26.45   
92.89 51.88 −44.15   
72.18 45.47 −37.00   
243.41 92.01 −62.20 
 T3N2 5 (18) 188.80 145.7 −22.83   
339.14 68.61 −79.77   
95.80 64.47 −32.70   
233.48 108.07 −53.71   
717.87 624.52 −13.00 
IIIB (n = 11)  
    
 T1N3 3 (11) 263.68 398.50 +51.13   
49.79 20.44 −58.94   
163.20 74.16 −54.56 
 T2N3 1 (4) 224.42 84.67 −62.27 
 T4N0 3 (11) 77.19 36.98 −52.10   
199.84 26.00 −86.99   
676.20 416.06 −38.47 
 T4N2 2 (7) 489.18 174.15 −64.40   
1319.04 1042.25 −20.98 
 T4N3 2 (7) 339.64 177.56 −47.72   
210.71 152.9 −27.43 
Data in parentheses are percentages. 
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TABLE 3. Univariate Analysis Covariates and Effect on PFS (per Unit Change) 
 
PET parameter HR 95% confidence interval p 
Pre-treatment TLG 1.005 1.002–1.007 0.004 
In-treatment TLG 1.005 1.003–1.008 0.001 
ΔTLG 1.016 1.002–1.030 0.025 
Pre-treatment SUV Not significant 0.999–1.002 0.575 
In-treatment SUV Not significant 0.999–1.003 0.327 
ΔSUV Not significant 0.995–1.022 0.231 
Pre-treatment SUVmax Not significant 0.999–1.000 0.447 
In-treatment SUVmax Not significant 0.999–1.002 0.579 
ΔSUVmax Not significant 0.998–1.027 0.087 
TNM (IIIA–IIIB) Not significant 0.299–2.136 0.655 
 
TABLE 4. Analysis of PFS, with ΔTLG Corrected for Pre-treatment TLG (per 10 
Unit Change) 
 
PET parameter HR 95% confidence interval P 
ΔTLG 1.169 1.013–1.350 0.033 
Pre-treatment TLG 1.047 1.020–1.076 0.009 
 
TABLE 5. PFS at Various Cut-off Points in ΔTLG 
  
Median PFS 
(mo) 
1-y PFS 
(%) 
2-y PFS 
(%) 
P 
All patients 15.7 76 28 
 
ΔTLG decrease < 38% (n = 12)  6.3 36 0 0.020 
ΔTLG decrease ≥ 38% (n = 16)  15.9 80 33 
 
ΔTLG decrease < 45% (n = 14)  9.8 46 0 0.032 
ΔTLG decrease ≥ 45% (n = 14)  15.9 73 40 
 
ΔTLG decrease < 52% (n = 16)  9.8 47 0 0.035 
ΔTLG decrease ≥ 52% (n = 12)  17.1 82 44 
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FIGURE 2. Kaplan–Meier analysis of PFS at median cutoff in ΔTLG. Median, 1-y, and 2-y 
PFS was 15.9 mo, 73%, and 40%, respectively, for ΔTLG decrease ≥ 45% vs. 9.8 mo, 46%, and 
0%, respectively, for ΔTLG decrease < 45% (log-rank test, P = 0.032).  
  
TLG decrease ≥ 45% 
TLG decrease < 45% 
FIGURE 3. Kaplan–Meier analysis of favourable, intermediate, and unfavourable risk groups 
(log-rank test, P < 0.02).  
 
favourable 
intermediate 
unfavourable 
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FIGURE 4. Typical example of 2 patients with stage III NSCLC and their sequential 18F-FDG 
PET/CT scans: pre-treatment (D0), in-treatment (D15), and end of treatment (D66). Two weeks 
into concomitant chemoradiotherapy, patient A showed 14% decrease in in-treatment SUV, and 
54% decrease in TLG, censored for both overall survival and PFS at 19 mo. Patient B showed 14% 
decrease in in-treatment SUV and TLG, PFS of 12 mo, and overall survival of 16 mo. All series are 
shown using equal window scaling.  
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DISCUSSION 
 
In the present prospective study, we investigated the predictive value of metabolic change 
assessed by 18F-FDG PET/CT in locally advanced NSCLC treated with concomitant 
chemoradiotherapy. Pre-treatment and early in-treatment 18F -FDG PET scans were 
compared with clinical outcome. Proportional hazards analysis revealed that a smaller 
decrease in ΔTLG was associated with earlier disease progression. Despite our relatively 
small study group of 28 patients, ΔTLG showed significant association with PFS. For a 
broad range of cut-off points in ΔTLG, with a corresponding range of 38%–52% decrease 
in ΔTLG, a significantly different log-rank probability between strata for PFS was 
repeatedly found (P < 0.05). However, an early metabolic response did not show a 
significant association with overall survival (P = 0.10). The absence of a significant 
correlation can at least partly be explained by the relatively short follow-up in this study. 
Another finding was that pre-treatment TLG was prognostic for PFS. Only recently 
has the prognostic value of TLG in NSCLC been elucidated (20–22). Chen et al. (20) 
demonstrated that a whole-body TLG is a potentially useful indicator for PFS in NSCLC, 
because a high whole-body TLG (>655) is associated with poor prognosis. Concerning our 
study, one might reasonably question whether pre-treatment TLG was correlated with 
ΔTLG, arguing that a high-baseline TLG tends to show more decrease during treatment 
than lesions with low TLG. However, expression as a fractional change overcomes this 
issue by expressing ΔTLG as a fractional change from baseline. Furthermore, we showed 
in Cox regression that both ΔTLG and pre-treatment TLG remained significant for PFS. 
This significance indicates that both factors are independently associated with PFS, pre-
treatment TLG being prognostic for survival before treatment, whereas ΔTLG is predictive 
of treatment response. 
We can only hypothesise about the different trends in ΔTLG between patients. As 
treatment starts, the time course in 18F-FDG uptake is dependent on many factors. First, a 
decrease in 18F-FDG tumour uptake is expected from both tumour cell kill and a reversible 
metabolic effect (caused by quiescence of tumour cells) while the cells remain viable (23). 
Second, an increase in metabolic activity is expected from increased tumour cell 
repopulation, inflammation, and tumour-resistance mechanisms. Because radiation 
requires oxygen for its cytotoxic effects, cellular metabolism is changed under hypoxic 
conditions. Via upregulation of hypoxia-inducible factor -1α, change in cellular metabolism 
under hypoxic conditions leads to increased glycolysis, with a subsequent increased 
demand of glucose leading to upregulation of glucose transporters and eventually increased 
18F-FDG uptake (24–26). Because a high hypoxia-inducible factor-1α expression in 
NSCLC is associated with an earlier disease progression (27), we suspect resistance 
mechanisms to be correlated with less decrease in ΔTLG. 
3 
  
Response monitoring with PET in NSCLC | 59 
 
Unreliable outcome prediction of the end-of-treatment 18F-FDG PET scans was 
most likely caused by postradiotherapy changes (28): 18F-FDG uptake is not limited to 
accumulation in tumour tissue, but it also accumulates in macrophages, neutrophils, 
fibroblast, and granulation tissue (29). Multiple biologic processes such as proliferation, cell 
repair, and inflammation may conceal vital tumour residue. Serial follow-up PET/CT 3 
and 6 months after treatment was performed to evaluate the evolution of 18F-FDG uptake 
and post-irradiation inflammation. Using an in-treatment scan as early as 2-weeks of 
therapy possibly avoids confounding effects of multiple biologic processes. We suggest 
that in the second week, a metabolic tumour effect is at play, whereas other non–tumour-
related biologic processes have a less significant role in the second week. A substantial 
decrease in 18F-FDG uptake and volume might suggest tumour response to therapy. 
The number of studies addressing response prediction using early in-treatment 18F-
FDG PET in locally advanced (stage III) NSCLC treated with concomitant therapy is 
limited. A previous study by Huang et al. (30) in stage III and IV NSCLC found that 18F-
FDG PET after three weeks (and 40 Gy) of concomitant chemoradiotherapy had preceded 
morphologic response. However, no effect on PFS and overall survival was presented. 
Macchessi et al. (31) showed in unresectable stage II and III NSCLC no correlation for 
metabolic change on in-treatment 18F-FDG PET and clinical outcome. The relatively wide 
range (10–25 days relative to 10–12 days in our study) of the second scan may have 
hampered the study. By applying TLG, both volumetric (MTV) and metabolic information 
(SUV) are incorporated, resulting in a more sensitive method for detection of treatment 
response relative to SUV alone. The general concept of using TLG and ΔTLG for tumour 
treatment response was first introduced by Larson et al. (32), who calculated ΔTLG as a 
response index, also called the Larson–Ginsberg index. To our knowledge, the present 
study is the first study to show the predictive value of ΔTLG for early response monitoring 
in locally advanced NSCLC treated with concomitant chemoradiotherapy. Despite the 
promising results, the small number of patients and large heterogeneity in metabolic 
tumour activity are limiting factors. We could not investigate the reliability of response 
monitoring in small tumours (i.e., <1 cm) or tumours with low metabolic uptake, in which 
a variety of technical factors may hamper adequate and reproducible calculation of the 
fractional change in tumour lesion glycolysis. However, by implementing standard methods 
of data analysis, the use of 18F-FDG PET early during treatment seems clinically feasible. 
One major restriction of the current study was the relatively small number of patients 
included. Even though TLG displayed prognostic and predictive potential in univariate 
analysis, a robust multivariate analysis, correcting for known prognostic factors (i.e., age, 
histology, disease stage, performance status), remained unexplained. Therefore, other 
confounding factors cannot be fully excluded in this study. 
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Consequently, confirmation of our findings is needed in larger study populations. 
Also, research is needed to further individualise treatment in stage III non–small cell lung 
cancer. Patients showing early metabolic nonresponse could prove to be candidates for 
dose escalation regimes, possibly improving clinical outcome (33). These kinds of studies 
set the basis for PET-based response–adapted treatment algorithms, which are the promise 
of the near future; the choice of therapy, its intensity, and its duration will become better 
adjusted to the biology of the individual patient. 
 
CONCLUSION 
 
The current study in locally advanced NSCLC patients treated with concomitant 
chemoradiotherapy indicates that early in-treatment 18F-FDG PET can be used to predict 
outcome. The effect of combined treatment does not preclude its predictive capabilities, 
because we found ΔTLG was predictive of PFS. Both pre-treatment TLG and the degree 
of change in TLG may be useful tools for individualising treatment in locally advanced 
NSCLC. 
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Lung cancer - Metabolic activity measured by FDG PET predicts 
pathological response in locally advanced superior sulcus NSCLC  
 
To the Editor, 
We commended Bahce et al. for their excellent paper entitled “Metabolic activity measured 
by FDG PET predicts pathological response in locally advanced superior sulcus 
NSCLC” (1). This study shows the prognostic and predictive performance of FDG PET 
in non-small cell lung cancer (NSCLC) in correlation with the post-induction pathological 
response. Metabolic activity after chemoradiotherapy correlated with the amount of 
residual tumour cells. In this letter, we will discuss the moment of reassessment of response 
using FDG-PET/CT. 
 
Many studies support the importance of reassessment using FDG-PET/CT for neo-
adjuvant therapy before surgery, published in a review of Hicks (2). However, post-
induction response assessment does not allow for early treatment adaptations. There is 
growing evidence of the usefulness of an early in-treatment measurement for response 
prediction: recent studies in locally advanced NSCLC show that in-treatment response 
measurement using functional information by means of FDG-PET is able to identify 
patients with long-term progression-free survival (3-6). In a series of 28 patients with locally 
advanced NSCLC, we showed that a change in FDG uptake, in terms of total lesion 
glycolysis, was associated with a significantly longer progression-free survival (1-y PFS 80% 
vs 36%, P = 0.02). We concluded that the degree of change in glycolysis at the end of the 
second week of chemoradiotherapy was predictive of response (6). Early in-treatment 
assessment may offer the opportunity to make response adapted-treatment decisions. An 
intensified scheme of induction radiotherapy can be offered to patients that are likely to 
fail locally, or adaptation of systemic treatment can be offered to patients who are at higher 
risk for distant relapse. 
 
Therefore, we would like to underline the importance of early in-treatment response 
assessments, at a time point that treatment can still be adjusted. This might accelerate the 
adoption of personalised medicine in the field of advanced NSCLC. PET-guided treatment 
algorithms are the promise of the near future; the choice of the treatment regimen, its 
intensity, and its duration will become better adjusted to the biology of the individual 
patient. Today's primary challenge is to investigate the impact on patient outcome of 
personalised response-adapted treatment concepts. 
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ABSTRACT 
 
Objectives 
This study evaluated the use of total lesion glycolysis (TLG) determined by different 
automatic segmentation algorithms, for early response monitoring in non-small cell 
lung cancer (NSCLC) patients during concomitant chemoradiotherapy. 
 
Materials and methods 
Twenty-seven patients with locally advanced NSCLC treated with concomitant 
chemoradiotherapy underwent 18F-fluorodeoxyglucose (FDG) PET/CT imaging 
before and in the second week of treatment. Segmentation of the primary tumours and 
lymph nodes was performed using fixed threshold segmentation at (i) 40% SUVmax 
(T40), (ii) 50% SUVmax (T50), (iii) relative-threshold-level (RTL), (iv) signal-to-
background ratio (SBR), and (v) fuzzy locally adaptive Bayesian (FLAB) segmentation. 
Association of primary tumour TLG (TLGT), lymph node TLG (TLGLN), summed 
TLG (TLGS = TLGT + TLGLN), and relative TLG decrease (ΔTLG) with overall 
survival (OS) and progression-free survival (PFS) was determined using univariate Cox 
regression models. 
 
Results 
Pre-treatment TLGT was predictive for PFS and OS, irrespective of the segmentation 
method used. The inclusion of TLGLN improved disease and early response 
assessment, with pre-treatment TLGS more strongly associated with PFS and OS than 
TLGT for all segmentation algorithms. This was also the case for ΔTLGS, which was 
significantly associated with PFS and OS, with the exception of RTL and T40. 
 
Conclusion 
ΔTLGS was significantly associated with PFS and OS, except for RTL and T40. The 
inclusion of TLGLN improves early treatment response monitoring during concomitant 
chemoradiotherapy with FDG-PET. 
 
Keywords 
Early response prediction, locally advanced non-small lung cancer, segmentation 
algorithms 
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INTRODUCTION 
 
Non-small cell lung (NSCLC) cancer remains a disease with a generally poor prognosis (1). 
At the time of diagnosis, one-third of patients with NSCLC present with locally advanced 
non-metastatic disease (1). For these patients, radiotherapy in combination with 
chemotherapy is the accepted standard of care. With the aim of improving patient 
outcome, combined and intensified treatment approaches are increasingly being 
investigated. However, not all patients equally benefit from these treatment approaches 
and rational selection of available treatment options in a personalised medicine framework 
is required (2). 
Positron emission tomography (PET) in combination with X-ray computed 
tomography (CT) with the glucose analogue 18F-fluorodeoxyglucose (FDG) has proven to 
be a valuable tool to personalise treatment for this patient group (2). Firstly, the 
incorporation of FDG-PET images into the radiotherapy planning algorithm improves the 
definition of gross tumour volume (GTV) (3-5) and might facilitate the concept of selective 
nodal irradiation (6). Secondly, it has been shown that FDG-PET can identify areas that 
are at risk of local relapse (7, 8), permitting to use the concept of molecular imaging-based 
dose painting (9). Thirdly, several studies emphasise the ability of FDG-PET to monitor 
therapy response at an early treatment stage using quantitative PET indices (10-14). Early 
response monitoring during treatment can facilitate clinical decision-making and improve 
patient management through early treatment adaptation and thereby avoidance of 
unnecessary side effects and costs of ineffective treatment. 
However, employing the concept of FDG-PET-guided treatment decisions requires 
robust and standardised methods to derive these quantitative indices from PET images. 
Particularly, the strong dependence of most image-derived response indices on 
quantification of lesion volume emphasises the need for standardised and consistent 
determination of these volumes in PET images. In this regard, there has been widespread 
interest in the development of automated segmentation algorithms for PET. Over the 
years, there has been a rapid growth of segmentation algorithms for PET reported in the 
literature (15), an event which is also referred to as “yapetism” (“yet another PET 
segmentation method”) (16). Difficulties encountered by these algorithms for automatic 
lesion segmentation in PET images are local contrast variations due to heterogeneous FDG 
uptake in the lesion, adjacent FDG-avid anatomy and lymph nodes, and relatively high 
noise content of PET images, often rendering the task of automatic lesion delineation 
challenging (15). This becomes even more difficult when automatic segmentation has to 
be performed on low contrast interim and end-of-treatment PET images, where radiotracer 
uptake can be considerably reduced due to therapy effects. However, up until this day, 
there is no standardised method for automatically determining lesion volume on PET 
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images and many studies consider different segmentation algorithms for this 
purpose (17, 18). The purpose of this study was to evaluate this clinical applicability and 
performance of several established segmentation algorithms for generating plausible 
segmentation volumes that can be applied specifically to predict therapy response during 
treatment for patients with locally advanced stage IIIA or IIIB NSCLC treated with 
concomitant chemoradiotherapy. The predictive value of total lesion glycolysis (TLG), as 
determined by these different algorithms, for progression-free survival (PFS) and overall 
survival (OS) was evaluated. 
 
MATERIALS AND METHODS 
 
Patients 
 
A total of 27 patients with newly diagnosed stage IIIA or stage IIIB NSCLC were 
prospectively included in this study, as described before (10). Patients were treated with 
concomitant radiotherapy and chemotherapy. This study was approved by the institutional 
review board (IRB) of the Radboud university medical centre. Written informed consent 
was obtained from every patient. Patient characteristics are summarised in Table 1. 
 
Treatment and follow-up 
 
Intensity-modulated radiotherapy (IMRT) was performed (10 MV photons), consisting of 
33 fractions of 2 Gy (5 fractions a week for 6 weeks and 3 days) resulting in a total dose of 
66 Gy on the primary tumour and affected lymph nodes (i.e. pathologically proven or 
FDG-avid lymph nodes). Chemotherapy consisted of two cycles of cisplatin 50 mg/m2 
intravenously (day 1, 8, 22, and 29) and etoposide 100 mg/m2 intravenously (day 1–3, and 
day 22–24). Median overall treatment time was 45 days (range 43–48 days). Patients with 
progressive disease during follow-up received palliative treatment. Follow-up during and 
after treatment consisted of clinical examination at regular intervals. When residual or 
recurrent disease was suspected, chest X-ray and chest CT-scans were performed. For each 
patient, sequential FDG-PET/CT imaging was performed before and during treatment. 
The pre-treatment scan was obtained before treatment (median 11 days, range 1–28 days) 
whilst interim FDG-PET imaging was performed in the second week during concomitant 
treatment (median 14 days, range 13–16 days), always before the second cycle of 
chemotherapy after 20 Gy radiotherapy. According to the treatment protocol all patients 
started with radiotherapy on the first day of the first cycle of chemotherapy, i.e. no neo-
adjuvant treatment was applied. 
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TABLE 1. Patients characteristics. 
 
Characteristics of patient population 
 
Male (Female) 18 (9) 
Median age (range) [y] 58 (42–77) 
Histological type 
 Non-small cell lung cancer (NSCLC) 
 
  Squamous cell carcinoma 10 
  Adenocarcinoma 14 
  NSCLC not otherwise specified 3 
Disease stage 
 IIIA 20 
 IIIB 7 
Performance-score (ECOG) 
 
 0 20 
 1 7 
Smoking status 
 Current smoker 11 
 Former smoker 16 
Lesion location 
 Right upper lobe 10 
 Right middle lobe 4 
 Right lower lobe 2 
 Left upper lobe 7 
 Left lower lobe 2 
Pre-treatment PET acquisition 
 Number of bed positions 7–8 
 Administered FDG activity [MBq] 267 ± 48 
 Incubation time [min] 75 ± 7.5 
 Acquisition time per bed position [min] 4 
Interim PET acquisition 
 Number of bed positions 3–4 
 Administered FDG activity [MBq] 269 ± 49 
 Incubation time [min] 78 ± 8.0 
 Acquisition time per bed position [min] 4 
 
Data are reported as mean ± standard deviation. PET = positron 
emission tomography, FDG = 18F-fluorodeoxyglycose. 
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Patient preparation and FDG PET imaging 
 
Imaging was performed using a hybrid Biograph Duo PET/CT scanner (Siemens Medical 
Solution, Knoxville, TN, USA). The PET scanner was accredited by the Research 4 Life 
(EARL) initiative for quantitative FDG-PET/CT studies (19). Before image acquisition, 
patients fasted for at least six hours and blood glucose levels were lower than 8.2 mmol L-1 
in all patients. The amount of activity administered to the patient was adjusted to the 
patient’s weight and was 3.45 MBq kg-1. Details regarding the PET acquisition protocol are 
summarised in Table 1. No respiratory gating was performed. For the purpose of 
attenuation correction and anatomical reference, a low dose (LD) CT scan was acquired 
with a reference tube current time product of 40 mA s. LDCT scans were acquired during 
timed unforced expiration breath-hold. Modulation of X-ray tube current was performed 
using CARE Dose 4D. Reconstruction of PET images was performed with a 2D ordered 
subset expectation maximization (2DOSEM) algorithm using a matrix size of 128 × 128, 
4 iterations and 16 subsets. Post-reconstruction filtering was performed using a three-
dimensional Gaussian filter kernel with a full width at half maximum of 5 mm. 
 
Image segmentation 
 
The primary tumour and FDG positive lymph nodes were delineated on the pre-treatment 
and interim PET images. Firstly, delineation was performed using a fixed threshold region 
growing segmentation at 40% (T40) and 50% (T50) of the maximum standardised uptake 
value (SUVmax) value. Furthermore, adaptive threshold algorithms were used for image 
segmentation. These included the iterative relative-threshold-level (RTL) (20) and signal-
to-background ratio (SBR) (21) approach. For the SBR method, the background for 
segmentation of the primary tumour was defined by placing a volume of interest (VOI) in 
the parenchyma of the contralateral lung. For lymph node segmentation, the background 
was defined by placing a VOI near the aortic root in the mediastinum. The seed-point for 
the T40, T50, RTL, and SBR segmentation was the SUVmax voxel of either the primary 
tumour (SUVT,max) or the corresponding lymph nodes (SUVLN,max). The threshold-based 
segmentations were performed using the Inveon Research Workplace (IRW) 4.1 Software 
(Preclinical Solutions, Siemens Medical Solutions USA, Knoxville Tennessee, USA). In 
addition to threshold-based segmentation, image segmentation was performed using the 
fuzzy locally adaptive Bayesian (FLAB) algorithm (22). Segmentation with this algorithm 
is performed using custom in-house developed software (ImageD, LaTIM Université de 
Bretagne Occidentale, Brest, France). The number of classes for segmentation was limited 
to two and parameters were automatically determined by the software. 
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Image analysis 
 
The TLG of the primary tumour (TLGT), defined as the product of the mean tumour FDG 
uptake (SUVT,mean) and metabolic tumour volume (MTV), was calculated on the pre-
treatment and interim PET images. Similarly, lymph node TLG (TLGLN) was defined as 
the mean uptake of the lymph nodes (SUVLN,mean) and the corresponding metabolic 
volumes of the lymph nodes. Furthermore, a summed TLG (TLGS = TLGT + TLGLN) 
was calculated. Evaluation of therapy response was performed by calculating the fractional 
decrease in TLG between pre-treatment and interim PET images (ΔTLG). Segmentation 
performance of the different algorithms was evaluated through visual assessment by a 
nuclear medicine physician experienced in thoracic imaging. Segmentation failures were 
visually identified and were defined as the propagation of segmentation into other 
anatomical structures, or premature termination of the algorithm resulting in only partial 
segmentation of the primary tumour and lymph nodes. Lesions that could not be properly 
segmented according to these criteria were omitted from the analysis. In addition, the 
similarity between MTVs obtained with different segmentation algorithms was quantified 
by calculating the spatial overlap using a generalization of the Jaccard Index (JI), as 
described in Eq. (1). 
 
 
 
Eq. (1) 
 
 
 
Here the numerator |A∩B∩…∩n|  denotes the intersection between segmented 
volumes (in this study, five in total), whilst the denominator |A∪B∪…∪n|  represents 
the union of the segmented volumes. Perfect spatial overlap is indicated by a value for the 
JI of 1.0, whilst a value of 0 indicates no spatial overlap of the volumes. 
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Clinical outcome and statistical analysis 
 
Statistical analysis was performed using SPSS Statistics 20 (IBM, Armonk, New York, USA) 
and GraphPad Prism, version 4.0c (GraphPad Software Inc, La Jolla, California, USA). 
PFS was defined as the interval between the start of treatment and the date of documented 
disease progression as confirmed by imaging or biopsy. If a patient was progression-free at 
the closeout-date (January 2015), the patient was censored for PFS at that date. Similarly, 
if patients were still alive at the closeout-date, patients were censored for OS. The 
predictive value of pre-treatment TLG and ΔTLG was determined for different 
segmentation algorithms using univariate Cox regression analysis. Correlation between the 
MTVs and TLGs of different segmentation algorithms was calculated using Spearman rank 
correlation. Statistical significance was defined for P < 0.05. 
 
RESULTS 
 
The median follow-up time for this patient population was 23.4 months (range 3.5–61.9). 
During follow-up eighteen patients died, all related to cancer progression. Three patients 
were lost during follow-up. A total of twenty patients developed disease recurrence during 
follow-up; seven patients developed progression of local disease, whilst metastases were 
seen in 13 patients. Median time to disease progression was 21 months. PFS after study-
baseline at 1 year was 63% (17 out of 27). 
Of the 27 patients, 25 had a visible primary tumour. For the other two patients, there 
was no radiological evidence for a primary tumour (i.e. cT0). The smallest pre-treatment 
MTVs were obtained when segmentation was performed with the T50 segmentation 
algorithm (24.7 ± 30.8 mL), compared to T40 (34.8 ± 39.1 mL), SBR (38.7 ± 42.4 mL) 
RTL (30.7 ± 34.0 mL). Segmentation with FLAB resulted in the largest MTVs 
(42.3 ± 42.1 mL). Interim PET MTVs showed similar trends with the smallest MTV for 
the T50 (20.8 ± 32.6 mL) method, followed by T40 (31.6 ± 44.6 mL), RTL 
(26.8 ± 37.0 mL), SBR (36.2 ± 50.2 mL) and FLAB (37.6 ± 48.2 mL). For the pre-
treatment PET images, an excellent correlation was found between delineation methods 
for MTV (range ρ 0.97–1.0, P < 0.0005), TLGT (range ρ 0.95–1.0, P < 0.0005) and 
SUVT,mean (range ρ 0.98–1.0, P < 0.0005). Similarly, for in-treatment PET images, an 
excellent correlation was found between delineation methods for MTV (range ρ 0.93–1.0, 
P < 0.0005), TLGT (range ρ 0.94–1.0, P < 0.0005) and SUVT,mean (range ρ 0.94–1.0, 
P < 0.0005). 
Quantitative and visual analysis of the MTVs obtained with different segmentation 
algorithms revealed that the MTVs were highly similar regarding the shape and spatial 
overlap. Furthermore, the algorithms revealed a similar trend in SUVT,mean and MTV 
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change between pre-treatment and interim FDG-PET (Supplementary data). The T50 
volumes were always entirely enveloped by the other volumes. The generalised JI for all 
MTVs on the pre-treatment and interim PET was 0.58 ± 0.13 (range 0.31–0.78) and 
0.53 ± 0.16 (range 0.20–0.86). When the T50 volumes were omitted from the analysis, the 
mean JI for pre-treatment and interim PET volumes was 0.74 ± 0.12 (range 0.46–0.89) and 
0.71 ± 0.14 (range 0.47–0.96). In tumours with heterogeneous FDG uptake, the T50 
algorithm yielded contours that were more erratic and sensitive to discontinuities within 
the tumour, whilst FLAB, SBR, RTL, and T40 algorithms would segment patches with 
FDG-uptake continuously throughout the entire lesion, giving an improved representation 
of the total volume with FDG-uptake. 
In the pre-treatment PET images, FLAB segmentation resulted in one segmentation 
failure of the primary tumour in one patient due to the small size and low contrast. In this 
patient, all segmentation methods failed to segment the primary tumour in the interim PET 
images. Furthermore, the T40, T50, RTL, and SBR methods failed to segment the primary 
tumour in an additional patient that presented with a large lesion with extended growth 
into the central mediastinum on interim PET images. The FLAB algorithm could segment 
the primary tumour in this patient and did not show uncontrolled propagation of 
segmentation into the mediastinal background. 
Of the 27 patients, 18 patients had FDG positive lymph nodes on the pre-treatment 
PET images. Given the smaller volumes and in general lower contrast of mediastinal and 
hilar lymph nodes, there were considerably more segmentation failures when performing 
automatic segmentation of lymph nodes. The T40 and RTL algorithms failed to segment 
14 and 17 of the 41 lymph nodes on the pre-treatment PET images, respectively. The 
number of segmentation failures for the T50 and FLAB algorithms in the pre-treatment 
PET images was 9 and 8, respectively. The SBR algorithm had the fewest segmentation 
failures, with only 6 lymph node segmentation failures in the pre-treatment PET images. 
Reduction of lymph node contrast due to therapy effects on the interim PET images 
resulted in more segmentation failures for the T40, T50, RTL and FLAB algorithms. Of 
the 41 lymph nodes in the interim PET, there were 24 segmentation failures for the T40 
and RTL algorithms. For the T50 and FLAB method, 12 and 14 lymph node segmentation 
failures occurred in the interim PET, respectively. Similar to the pre-treatment PET, the 
SBR algorithm had the fewest segmentation failures, with 5 segmentation failures. Failure 
of lymph node segmentation was usually due to uncontrolled propagation of the 
segmentation algorithm in the mediastinal background or primary tumour. Figure 1 depicts 
the TLGS on pre-treatment and interim PET images in box-whisker plots. 
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Pre-treatment SUVT,max, interim SUVT,max, and a relative decrease in SUVT,max was not 
significantly predictive for PFS and OS. Similarly, pre-treatment SUVT,mean, interim 
SUVT,mean, and a relative decrease in SUVT,mean of the primary tumour was not significantly 
predictive for PFS and OS in this cohort. However, pre-treatment TLGT was significantly 
associated with PFS and OS for all segmentation methods. The ΔTLGT was significantly 
predictive with PFS for all methods except for FLAB. Furthermore, ΔTLGT was 
significantly associated with OS for the T50 and SBR methods. Hazard ratios (HRs) and 
FIGURE 1. Box and whisker plots of summed total lesion glycolysis (TLGS) of the primary tumour 
and the lymph nodes in pre-treatment and interim 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) scans obtained with different segmentation algorithms. Bottom and 
top of each box are lower and upper quartiles. The horizontal line near middle of the box is median. 
Whiskers are drawn down to the 5% percentile up to the 95% percentile, whilst the outliers are 
indicated by a dot. T40 = Fixed level threshold segmentation at 40% of the maximum standardised 
uptake value (SUVmax), T50 = Fixed level threshold segmentation at 50% of SUVmax, 
RTL = Relative level thresholding, SBR = Signal-to-background segmentation, FLAB = Fuzzy 
locally adaptive Bayesian segmentation.  
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corresponding 95% confidence interval (CI) of TLGT and ΔTLGT in the univariate Cox 
regression analysis for PFS and OS are summarised in Table 2. 
Only TLGLN obtained with the SBR and T50 methods was significantly predictive for 
PFS and OS. Furthermore, the inclusion of TLGLN improved early response assessment 
using PET, with pre-treatment TLGS more strongly associated with PFS and OS than 
TLGT. Figure 2 depicts pre-treatment and interim FDG-PET images of two patients with 
a different lymph node response, as reflected by ΔTLGS. 
The differences in lymph node segmentation performance were reflected in the significance 
levels of TLGS measurements in the univariate analysis for PFS and OS. The HRs and 
corresponding 95% CI of TLGS and ΔTLGS in the univariate Cox regression analysis for 
PFS and OS are summarised in Table 3. 
 
DISCUSSION 
 
In this study we showed that TLG is a robust metric to monitor early therapy response in 
patients undergoing concomitant chemoradiotherapy for locally advanced NSCLC. 
Furthermore, the inclusion of TLGLN improves early assessment of treatment response in 
this patient population. Results of this study are in line with available data in the literature 
and emphasise the role of FDG-PET imaging for early response monitoring 
NSCLC (10-14). In particular, TLG outperformed the more traditional SUVT,max and 
SUVT,mean for predicting PFS and OS. This is probably due to the fact that TLG contains 
information about disease load as well as the metabolic activity of involved lesions. 
In general, all segmentation algorithms had similar performance for segmenting the 
primary tumour in different anatomical locations. The presence of adjacent anatomical 
structures (e.g. lymph nodes, mediastinum, liver), did not result in large differences in 
segmentation performance. Furthermore, lower contrast of the interim PET images 
resulted in a minimal increase in the number of segmentation failures.  
Absolute differences in TLG obtained by the different segmentation methods did not 
influence its predictive value. Due to the limited size and lower contrast, there were 
considerably more lymph node segmentation failures. The number of lymph node 
segmentation failures increased in the interim PET images owing to a further reduction in 
image contrast. Nevertheless, adequate lymph node segmentation is of importance, with 
TLGS having a stronger association with PFS and OS. Out of all the segmentation 
algorithms, the SBR method demonstrated the lowest number of segmentation failures. 
The number of FLAB lymph node segmentation failures could be reduced by using a 
supervised input, with equal performance to that of the SBR method, which is in line with 
results from another study (23). However, in view of standardising response measurements,  
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FIGURE 2. Baseline (a + c) and interim (b + d) 18F-fluorodeoxyglucose (FDG) positron 
emission tomography (PET) images of two non-small cell lung cancer (NSCLC) patients. The 
first patient (a + b) showed a good response to treatment on both the primary tumour and lymph 
nodes. Although the primary tumour of the second patient (c + d) showed a good response to 
treatment, there was a limited response considering the lymph nodes, with more FDG positive 
lymph nodes in the interim PET. The mean summed fractional decrease of total lesion glycolysis 
(ΔTLG) of the first patient for the different segmentation methods was 76 ± 6%, with a 
progression free survival (PFS) of 11 months and overall survival (OS) of 24 months. For the 
second patient, mean ΔTLG was 38 ± 6% with a PFS and OS of 7 and 21 months, respectively. 
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TABLE 2. Hazard ratios (HRs) and 95% confidence interval (CI) of pre-treatment 
primary tumour total lesion glycolysis (TLGT) and relative TLG decrease (ΔTLGT) 
between pre-treatment and interim 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) in a univariate Cox regression analysis for progression-free survival 
(PFS) and overall-survival (OS).  
HR (95% CI) per unit change for PFS Significance level 
Pre-treatment TLGT 
T40 1.002 (1.000–1.004) 0.02∗ 
T50 1.002 (1.000–1.004) 0.03∗ 
RTL 1.002 (1.000–1.004) 0.03∗ 
SBR 1.002 (1.000–1.003) 0.02∗ 
FLAB 1.002 (1.000–1.003) 0.03∗ 
ΔTLGT 
T40 1.02 (1.003–1.03) 0.03∗ 
T50 1.02 (1.003–1.03) 0.03∗ 
RTL 1.02 (1.003–1.04) 0.03∗ 
SBR 1.02 (1.004–1.04) 0.02∗ 
FLAB 1.02 (1.000–1.04) 0.07 
  
HR (95% CI) per unit change for OS Significance level 
Pre-treatment TLGT 
 
T40 1.002 (1.001–1.004) 0.004∗ 
T50 1.003 (1.001–1.004) 0.005∗ 
RTL 1.002 (1.001–1.004) 0.004∗ 
SBR 1.002 (1.001–1.003) 0.004∗ 
FLAB 1.002 (1.001–1.003) 0.006∗ 
ΔTLGT 
T40 1.02 (1.00–1.03) 0.05 
T50 1.02 (1.00–1.03) 0.02∗ 
RTL 1.02 (1.00–1.03) 0.08 
SBR 1.02 (1.00–1.03) 0.04∗ 
FLAB 1.01 (0.99–1.03) 0.3 
T40 = fixed level threshold at 40% of the maximum standardised uptake voxel (SUVmax), 
T50 = fixed level threshold at 50% of SUVmax, RTL = relative level thresholding, SBR = signal-to-
background-ratio, FLAB = fuzzy locally adaptive Bayesian segmentation. Statistical significance is 
indicated by an asterisk ‘*’ 
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TABLE 3. Hazard ratios (HRs) and 95% confidence interval (CI) of pre-treatment summed 
total lesion glycolysis (TLGS) and relative TLG decrease (ΔTLGS) between pre-treatment 
and interim 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a 
univariate Cox regression analysis for progression-free survival (PFS) and overall-survival 
(OS). TLGS is the sum of primary tumour TLG (TLGT) and lymph node TLG (TLGLN).  
HR (95% CI) per unit change for PFS Significance level 
Pre-treatment TLGS 
T40 1.003 (1.001–1.005) 0.002∗ 
T50 1.003 (1.001–1.005) 0.004∗ 
RTL 1.003 (1.001–1.005) 0.003∗ 
SBR 1.002 (1.001–1.004) 0.004∗ 
FLAB 1.002 (1.001–1.004) 0.004∗ 
ΔTLG 
T40 1.02 (1.00–1.05) 0.03∗ 
T50 1.03 (1.02–1.05) 0.001∗ 
RTL 1.01 (1.00–1.02) 0.2 
SBR 1.04 (1.02–1.06) 0.001∗ 
FLAB 1.02 (1.00–1.04) 0.04∗ 
  
HR (95% CI) per unit change for OS Significance level 
Pre-treatment TLGS 
 
T40 1.003 (1.001–1.004) 0.001∗ 
T50 1.003 (1.001–1.005) 0.002∗ 
RTL 1.003 (1.001–1.005) 0.001∗ 
SBR 1.002 (1.001–1.004) 0.001∗ 
FLAB 1.002 (1.001–1.004) 0.002∗ 
ΔTLGS 
T40 1.01 (1.00–1.03) 0.4 
T50 1.02 (1.00–1.04) 0.02∗ 
RTL 1.00 (1.00–1.01) 0.9 
SBR 1.02 (1.00–1.04) 0.03∗ 
FLAB 1.01 (1.00–1.03) 0.02∗ 
T40 = fixed level threshold at 40% of the maximum standardised uptake voxel (SUVmax), T50 = fixed 
level threshold at 50% of SUVmax, RTL = relative level thresholding, SBR = signal-to-background-
ratio, FLAB = fuzzy locally adaptive Bayesian segmentation. Statistical significance is indicated by an 
asterisk ‘*’ 
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such a user dependency should be avoided and we chose only to include the results of 
automatic FLAB segmentation. 
Although the results emphasise that PET could be used for prediction of early 
treatment response in patients with locally advanced NSCLC treated with concomitant 
chemoradiotherapy, employment of PET-guided decisions for personalising treatment was 
not explored. Particularly, the strong association of pre-treatment TLG with PFS and OS 
might merit the choice for treatment intensification in patients with a high pre-treatment 
TLG such as proposed in the PET-boost dose-escalation trial (24). Furthermore, one might 
also consider treatment intensification when interim PET images demonstrate a limited 
decrease in TLG, for instance by dose escalation to metabolically active sub volumes the 
primary tumour (25, 26), in order to improve loco-regional tumour control. However, 
standardising PET-based dose painting approaches is of utmost importance. This is 
emphasised in a study by Knudtsen et al. where the used PET reconstruction algorithm and 
choice of segmentation thresholds significantly influenced treatment plans incorporating 
these dose painting concepts (27). Although threshold-based segmentation is frequently 
used for defining subvolumes for dose painting, the stability of different algorithms under 
varying imaging conditions for this purpose has yet to be investigated. Interestingly, studies 
emphasise that there is high stability of FDG uptake in tumour areas during the course of 
the treatment that can be identified on pre-treatment FDG-PET images (28). Although 
useful, interim PET imaging in a molecularly image-guided ART (IGART) setting would 
still be of great interest to monitor changes during radiotherapy (2). Indeed, the 
employment of IGART using FDG-PET has been shown to be of potential value, where 
the GTV is adapted according to interim FDG-PET imaging (2). Furthermore, results from 
a study conducted by Nygård et al. emphasise that FDG-PET might identify lesion-specific 
response after a single series of chemotherapy in NSCLC and could be a useful addition to 
guide and individualise radiotherapy strategy (29). Although dose redistribution might be 
useful for improving loco-regional tumour control, systemic disease control is also an 
important aspect in this patient group (30). In this setting, interim PET imaging might 
identify a failure of systemic disease control at an early stage (i.e. detection of additional 
lymph node or distant metastasis), making it possible to adapt treatment accordingly. 
A limitation of the current study is that only a small patient cohort was considered. 
However, the advantage is that TLG measurements using different automatic segmentation 
algorithms showed consistent results, with most algorithms yielding TLG values that had 
a similar predictive value in this patient cohort. 
This study emphasises that adequate lymph node segmentation in PET images 
improves the assessment of early treatment response in NSCLC patients treated with 
concomitant chemoradiotherapy. In this regard, given the relative ease of implementation 
and the high number of successful lymph node segmentations, SBR is the method of choice 
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for calculation of TLG in FDG-PET images of patients with locally advanced NSCLC for 
the purpose of assessment of early treatment response. 
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Supplementary data 
The relative decrease in MTV and SUVmean are depicted in Supplementary Figure 1.  
(a) T40 = fixed level threshold at 40% of the maximum standardised uptake voxel (SUVmax),  
(b) T50 = fixed level threshold at 50% of SUVmax, (c) RTL = relative level thresholding,  
(d) SBR = signal-to-background-ratio, (e) FLAB = fuzzy locally adaptive Bayesian segmentation. 
 
Supplementary Figure 1 
 
 
 
 
5 
  
 
Read online 
  
CHAPTER VI 
 
Stereotactic radiotherapy boost after 
definite chemoradiation for non-
responding locally advanced NSCLC 
based on early response monitoring  
18F-FDG-PET 
 
 
 
Tineke W.H. Meijer, Robin Wijsman, Edwin A. Usmanij, Olga C.J. Schuurbiers, 
Peter van Kollenburg, Liza Bouwmans, Johan Bussink, Lioe-Fee de Geus-Oei 
 
Adapted from: Physics and Imaging in Radiation Oncology, July 2018(7):16-22 
  
 
 	
 
 
 
 
 
 
 
 
 
 
 
 
6 
  
PET based stereotactic boost in NSCLC | 95 
 
 
 
ABSTRACT 
 
Objectives 
Prognosis of locally advanced non-small cell lung cancer remains poor despite 
chemoradiation. This planning study evaluated a stereotactic boost after concurrent 
chemoradiotherapy (30 × 2 Gy) to improve local control. The maximum achievable 
boost directed to radioresistant primary tumour subvolumes based on pre-treatment 
fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography 
(18F-FDG-PET/CT) (pre-treatment-PET) and on early response monitoring 18F-
FDG-PET/CT (ERM- PET) was compared.  
 
Materials and Methods 
For ten patients, a stereotactic boost (VMAT) was planned on ERM-PET 
(PTVboost;ERM) and on pre-treatment-PET (PTVboost;pre-treatment), using a 70% SUVmax 
threshold with 7 mm margin to define radioresistant subvolumes. The dose was 
escalated till organ at risk (OAR) constraints were met, aiming to plan at least 18 Gy in 
3 fractions (EQD2 84 Gy/BED 100.8 Gy). 
 
Results 
In five patients, PTVboost;ERM was 9–40% smaller relative to PTVboost;pre-treatment. Overlap 
of PTVboost;ERM with OARs decreased also compared to the overlap of 
PTVboost;pre-treatment with OARs. However, any overlap with OAR remained in 4/5 
patients resulting in minimal differences between planned dose before and during 
treatment. Median dose (EQD2) covering 99% and 95% of PTVboost;ERM was 15 Gy and 
18 Gy respectively. Median boost volume receiving a physical dose of ≥ 18 Gy (V18) 
was 88%. V18 was ≥ 80% for PTVboost in six patients.  
 
Conclusion 
A significant stereotactic boost to volumes with high initial or persistent 18F-FDG-
uptake could be planned above 60 Gy chemoradiation. Differences between planned 
dose before and during treatment were minimal. However, as an ERM-PET also 
monitors changes in tumour position, we recommend planning the boost on the ERM-
PET.  
 
Key Words  
Early response prediction, locally advanced non-small lung cancer, radiotherapy, 
stereotactic boost 
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INTRODUCTION 
 
Dose escalation up to a total dose of 60 Gy yields a greater proportion of disease control 
and better survival compared to 40–50 Gy for the treatment of irresectable locally advanced 
non-small cell lung cancer (NSCLC) (1). However, about 30% of patients treated with 
60 Gy radiotherapy have a locoregional recurrence in the absence of distant metastasis (2). 
A meta-analysis showed that with combined sequential or concurrent chemoradiotherapy, 
dose escalation beyond 60 Gy does not lead to further improvements in overall survival (3). 
The RTOG 0617 trial demonstrated that 74 Gy in 2 Gy fractions concurrent 
chemoradiation might even result in a survival decrement compared to 60 Gy in 2 Gy 
fractions (4). In the case of radiation therapy alone, higher radiation dose results in longer 
survival without an upper dose level above which there is no further benefit (3). Therefore, 
radiation dose intensification combined with chemotherapy should not be discouraged 
based on the RTOG 0617 results. Especially since in RTOG 0617 compliance with normal 
tissue dose constraints was not mandatory, older (less conformal) radiotherapy techniques 
were allowed, and the prolonged overall treatment time could be associated with poorer 
survival because of accelerated repopulation (4,5).  
Intensity-modulated radiation therapy (IMRT) and volumetric- modulated arc therapy 
(VMAT) enable more conformal irradiation, thereby lowering dose to organs at risk 
(OAR) (6). Currently, it is possible to identify subvolumes within the planning target 
volume (PTV) that are more radioresistant (7–9). Usmanij et al. (8) demonstrated that 
NSCLC metabolic non-responders, as determined by a poor decrease in total lesion 
glycolysis (TLG) on fluorine-18-fluorodeoxyglucose positron emission 
tomography/computed tomography (18F- FDG-PET/CT) at the beginning of the third 
week of radiotherapy, have a worse progression-free survival compared to early metabolic 
responders (8). Thus, early response measurement using 18F-FDG-PET/CT enables the 
identification of patients that may benefit most from dose escalation.  
Stereotactic body radiotherapy (SBRT) delivers very conformal high radiation doses 
resulting in excellent local control rates (> 90%) with low toxicity in inoperable stage I-II 
NSCLC patients (10). It was shown that a biologically effective dose (BED) prescription 
of at least 100 Gy is required for acceptable tumour control probability (11). Therefore, an 
SBRT radiation boost directed towards 18F-FDG-PET/CT defined radioresistant 
subvolumes may increase local control in locally advanced NSCLC. Furthermore, by using 
SBRT, high maximum dose (Dmax) within the PTV is achieved with limited dose to OAR 
due to steep dose decline just outside the PTV, enabling higher dose escalation compared 
to other approaches. Limiting prolongation of overall treatment time (OTT) is another 
advantage of SBRT boosting as the booster dose is delivered in only a few fractions.  
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The aim of this study was to compare the maximum achievable dose escalation for 
locally advanced NSCLC treated with concurrent chemoradiation by using a stereotactic 
boost directed to radioresistant subvolumes of the primary tumour as determined by an 
18F-FDG-PET/CT before start of chemoradiation (pre-treatment PET) and an early 
response monitoring 18F-FDG-PET/CT (ERM-PET).  
 
MATERIALS AND METHODS 
 
Patients 
 
18F-FDG-PET/CTs acquired for the ERM study by Usmanij et al. were used for this 
planning study (8). This ERM study was approved by the Institutional Review Board of 
the Radboud university medical centre. All patients gave written informed consent. 
Twenty-eight patients with stage IIIA-B NSCLC eligible for concomitant 
chemoradiotherapy were enrolled in this study. A prescription dose of 60 Gy in 2 Gy 
fractions was applied in this planning study for the entire tumour and involved lymph 
nodes with margin (PTV60Gy). Detailed information upon radiation treatment planning for 
PTV60Gy is described in Supplementary material 1.  
For every patient, a pre-treatment 18F-FDG-PET/CT was acquired with a median 
interval of 11 days (range 1–27 days) before the start of chemoradiation and an ERM 
18F-FDG-PET/CT was performed at the beginning of the third week of treatment (after a 
median dose of 20 Gy; range 20–24 Gy). The timing of the ERM-PET was specifically 
chosen at the beginning of the third week of treatment. A decrease in uptake early during 
chemoradiation reflects tumour response, whereas this decrease in uptake may disappear 
later in the course of chemoradiation due to the onset of treatment-induced 
inflammation (8).  
We selected those fourteen patients with a poor response to treatment as assessed by 
a TLG decrease < 45% on the ERM-PET relative to the pre-treatment PET. These poor 
responders showed worse disease-free survival, possibly due to the fact that they harbour 
more radioresistant tumours (8). Three patients were ineligible for this planning study 
because they had only a small primary tumour with the bulk of gross tumour volume 
(GTV) located in the mediastinum. Furthermore, one radiotherapy CT and radiation 
treatment plan could not be restored. So, ten patients were included in this planning study. 
Patient characteristics are listed in Table 1.  
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18F-FDG-PET/CT image acquisition 
 
All PET scans were performed with a hybrid PET/CT scanner (Biography Duo Siemens 
Medical Solutions, USA, Inc.). Patients fasted for at least six hours. A venous blood sample 
was drawn to measure blood glucose level (< 8.2 mmol/L in all patients, mean 
6.0 mmol/L). Prior to the PET scan, a low dose CT during free-breathing was acquired for 
PET attenuation correction and anatomical matching. Sixty minutes after intravenous 
injection of 18F-FDG (3.45MBq/kg; Covidien) and furosemide (10 mg), static emission 
scans in a three-dimensional mode were obtained with an acquisition time of four minutes 
per bed position. Images were iteratively reconstructed in 128x128 matrices by ordered 
subsets expectation maximisation (OSEM) algorithm using four iterations/sixteen subsets 
(4i/16 s) with a 5 mm Gaussian filter. Correction for photon attenuation (by using the low 
dose CT) and decay of 18F-FDG was performed for images. Rigid co-registration (starting 
with a bone match and visually checking the plausibility of the match regarding tumour 
and surrounding normal tissue) of the PET scans to the radiotherapy planning CT was 
performed.  
 
Boost volume definition 
 
Radioresistant subvolumes of the primary tumour, to which the boost must be directed, 
were delineated on the pre-treatment PET and ERM-PET. For automated segmentation 
of biological target boost volumes (BTVboost), a threshold of 70% of maximum intensity 
level was used to identify tumour subvolumes at greatest risk of relapse (9). Adding a 7 mm 
circumferential margin to BTVboost created PTVboost. Volumes (cm3) of PTVboost based on 
the pre-treatment PET (PTVboost;pre-treatment) and ERM-PET (PTVboost;ERM) were recorded. 
To assess the effect of timing of PET scans on the planned dose to PTVboost, a stereotactic 
boost was planned for all ten patients on both the pre-treatment PET and the ERM-PET. 
 
Organs at risk definition and constraints 
 
The bronchial tree (up to and including lobar bronchi), heart, great vessels, oesophagus, 
lungs minus GTV60Gy (i.e., lung volume minus the volume of the GTV planned to receive 
60 Gy), spinal cord and brachial plexus were considered OAR. Adding a 5 mm margin to 
the first four OAR contours created the planning OAR volumes (PRV) (12). For the latter 
two OAR, PRVs were created adding a 2 mm margin as breathing induced movement is 
assumed to be smaller/absent for this nerve tissue. No PRV margin was used for the lungs. 
The following constraints were applied: Lungs minus GTV60Gy: mean lung dose < 20 Gy, 
V20 < 35% (Vx is the relative volume receiving x Gy); V5 < 65–70% for lungs minus 
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GTV60Gy and V5 < 55% for contralateral lung (‘soft’ constraint) (13–15). PRV oesophagus: 
Dmax 70 Gy equivalent dose in 2 Gy fractions (EQD2) (α/β-value 3 Gy) (16) PRV brachial 
plexus: Dmax 66 Gy EQD2 (α/β-value 2 Gy) (12). PRV heart, great vessels, bronchial tree: 
Dmax 94 Gy EQD2 (α/β-value 3 Gy) (12). PRV spinal cord: Dmax 53 Gy EQD2 (α/β-value 
2 Gy) (12).  
 
Boost planning 
 
Doses to OARs were determined for the 60Gy treatment plan. Except for the Vx doses 
and mean dose to the lungs, these doses can be converted into EQD2 doses using the 
formula EQD2 = total dose*((- fraction dose+ α/β)/(2+α/β)). Thereafter, the extra 
allowed EQD2 dose to OAR was calculated (i.e., maximum allowed EQD2 minus 
maximum EQD2 delivered after 60 Gy). Subsequently, this extra allowed EQD2 was 
converted into a physical dose (planned to be delivered in three fractions). This physical 
dose was calculated for every separate OAR and used as maximum allowed dose for boost 
treatment planning. This strategy was performed for both the whole OAR and the part of 
the OAR in close proximity to the boost volume, to take into account the spatial 
component of the maximum dose of the 60 Gy treatment plan. So, also the maximum dose 
of the OAR subvolume near PTVboost was determined in the conventionally fractionated 
60 Gy radiotherapy plan. This dose was used to calculate the maximum tolerable dose for 
that subvolume of the OAR bordering the PTVboost. Higher dose escalation of the boost 
volume could be achieved with this strategy. Boosts were planned using the Pinnacle3 
(Version 8.0–9.2; Philips Radiation Oncology Systems, Fitchburg, WI) treatment planning 
system.  
A BED prescription dose of at least 100 Gy is required for acceptable tumour control 
probability (11). A dose of 60 Gy in 2 Gy fractions is 60 Gy EQD2 and is equal with a 
BED of 72 Gy (α/β-value = 10 Gy for tumour). Delivering 18 Gy in three fractions results 
in a boost of 24 Gy EQD2 (total EQD2 84 Gy) and a BED of 28.8 Gy (total BED 
100.8 Gy). Therefore, it was attempted to plan a boost with a minimum dose of 18 Gy in 
three fractions. The final planned dose to PTVboost depended on the maximum tolerable 
dose for the OAR. The majority of tumours in this study were located near critical organs 
at risk, as is often the case in irresectable stage III NSCLC, resulting in a small therapeutic 
window for planning a stereotactic radiation boost. Radiation dose was escalated till OAR 
constraints were met. In case a higher dose than 18 Gy could be planned this was done. 
However, in case 18 Gy could not be planned due to critical OAR, a lower dose had to be 
accepted.  
All boost plans were generated using a single VMAT arc avoiding the contralateral 
lung. To ensure a rapid dose decline outside the PTV, a ring contour (1 cm) around the 
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PTV was created. In case of overlap of PTVboost with PRV, two separate PTVs were 
created: PTV inside PRV and PTV outside PRV. This enabled better dose coverage for the 
PTV outside the PRV, thereby limiting suboptimal dosage of the PTV. The optimisation 
objectives for the PTVboost and the ring contours were individually set according to 
calculated constraints for OAR. No hard constraints were set for the maximum allowed 
dose within PTVboost, because the maximum doses reached in this setting will never 
approach the maximum allowed (EQD2) dose that is clinically accepted in SBRT for limited 
stage lung cancer. We allowed a maximum dose as high as needed to enable a steep dose 
decline outside PTVboost, without exceeding the maximum total dose (EQD2) accepted in 
SBRT for limited stage lung cancer.  
 
RESULTS 
 
PTVboost volumes 
 
In only two of ten patients, PTVboost volumes did not overlap with any of the 
PRVs (Table 1). In five of ten patients, PTVboost;ERM was 9–40% smaller relative to 
PTVboost;pre-treatment. However, for the other five patients, PTVboost;ERM remained stable or 
increased compared to PTVboost;pre-treatment (range 0–50%) (Table 2).  
Furthermore, it was examined whether the changes in PTVboost resulted in less overlap 
with PRVs (Supplementary material 2). Overlap did decrease in five patients with 6–100%. 
Unfortunately, overlap with PRVs disappeared in only one of these five patients (Figure 1, 
Supplementary material 2). Overlap with PRVs increased for two patients (Supplementary 
material 2). Dose-limiting OAR for boost planning allowed dose to OAR and planned dose 
to OAR are shown in Table 3 and Supplementary material 3.  
 
PTVboost and CTVboost dose 
 
The dose delivered to 99% of PTVboost (D99; EQD2), dose delivered to 95% of PTVboost 
(D95; EQD2), Dmax (EQD2), and percentage of PTVboost receiving ≥ 18 Gy (V18; 
physical dose) were assessed for PTVboost;pre-treatment and PTVboost;ERM. Median D99 and D95 
of PTVboost;pre-treatment were 17 Gy (range 4–31) and 19 Gy (range 7–42), respectively. 
Median V18 of PTVboost;pre-treatment was 93% (range 56–100). Median D99 and D95 of 
PTVboost;ERM was 15 Gy (range 3–30) and 18 Gy (range 6–32), respectively. Median V18 of 
PTVboost;ERM was 88% (range 51–100). 
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Differences between the planned dose in week 0 and 3 were minimal due to the fact 
that overlap of PTVboost;ERM with PRVs remained in most patients. V18 in week 3 was 
higher in five patients compared to V18 in week 0. However, planning results were 
somewhat worse for four patients in week 3 relative to week 0. For patient number 3, 
differences in coverage of PTVboost;pre-treatment and PTVboost;ERM were very large due to 
changes in atelectasis and thereby a shift in tumour position towards the heart in week 3, 
resulting in overlap of PTVboost;ERM with heart PRV limiting dose escalation (Table 4; 
Figure 2; Supplementary material 2). 
In seven patients, D95 PTVboost was substantially higher than the prescribed dose (74 Gy) 
of the RTOG 0617 study.  The total D95 PTVboost;pre-treatment was  ≥ 80 Gy in  five patients 
FIGURE 1. Boost PTVs of two patients delineated on 18F-FDG-PET/CT scans before start of 
treatment and at the beginning of week 3 during treatment. 18F-FDG-PET/CT scans of patient 
number 4 and 8. The green line represents PTVboost before start of treatment (upper panel), the red 
line represents PTVboost at the beginning of third week of treatment (lower panel). For patient 
number 4 (left), there was a remarkable decrease in PTVboost volume in contrast to PTVboost volume 
of patient number 8 (right) whose PTVboost volume was similar for both time points. The blue line 
indicates the planning organs at risk volumes. 
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and for four patients a total D95 PTVboost;ERM ≥ 80 Gy could be planned (Figure 2A; Table 
4). The summed D95 of PTVboost minus overlap with PRV was ≥ 80 Gy in seven patients 
and for another patient this summed D95 was 79 Gy (Figure 2B).  
V18, which equals an ablative dose, was ≥ 80% for the whole PTVboost in six patients 
(Figure 2D) and ≥ 80% in eight patients for PTVboost minus overlap with PRV (Figure 2E).  
In clinical practice, clinical target volume (CTV) coverage is also evaluated in case of 
overlap with OAR. D95 BTVboost (considering BTVboost as CTV) was considerably larger 
than D95 PTVboost (Figure 2C): for seven patients a summed BTV dose of ≥ 80 Gy could 
be planned. BTVboost;ERM V18 was (almost) 100% in six patients (Figure 2F). In the other 
patients, BTV-PRV overlap hampered planning of an ablative dose for the complete 
BTVboost.  
 
TABLE 2. Boost planning target volume determined on pre-treatment PET and on 
ERM-PET 
 
Patient PTV0 (cm3) PTV2 (cm3) Absolute 
difference (cm3) 
Relative difference 
(%) 
1 19 19 0 0 
2 214 183 -31 -15 
3 14 21 7 50 
4 164 98 -66 -40 
5 94 56 -38 -40 
6 127 133 6 5 
7 43 34 -9 -21 
8 208 189 -19 -9 
9 14 15 1 7 
10 15 16 1 7 
 
Abbreviations: PTV0: boost planning target volume determined on pre-treatment PET; 
PTV2: boost planning target volume determined on the early response monitoring PET; 
Absolute difference: PTV2 volume minus PTV0 volume; Relative difference: (absolute 
difference/PTV0)*100  
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DISCUSSION 
 
This study compared the maximum achievable dose escalation for locally advanced 
NSCLC treated with concurrent chemoradiation by using a stereotactic boost directed to 
radioresistant subvolumes of the primary tumour as determined by a pre-treatment PET 
and an ERM-PET. In five of ten patients, PTVboost;ERM was 9–40% smaller relative to 
PTVboost;pre-treatment. However, differences between the planned dose before and during 
treatment were minimal because the overlap of PTVboost;ERM with PRVs remained in most 
patients. V18, which equals an ablative dose, was ≥	80% for PTVboost in six patients.  
Some studies have investigated the feasibility of dose escalation in locally advanced 
NSCLC, all with different treatment strategies (12,17,18). For example, a prospective single 
institution trial examined stereotactic boosting (two fractions of 10 Gy, or three fractions 
of 6.5 Gy) of residual primary tumour < 5 cm 1–2 months after chemoradiation (60 Gy). 
Mean coverage of SBRT boost was 96.4% but was not described for patients individually 
(17). A disadvantage of this strategy is prolonging of OTT, which is biologically less 
effective. Furthermore, only small tumours were eligible. Delivering three additional SBRT 
boost fractions immediately after 60 Gy results in a minimal prolongation of the OTT and 
the boost dose is not delivered simultaneously with chemotherapy.  
Another study, the RTOG 1106 study, is an ongoing phase 2 randomised trial 
comparing 60 Gy in 30 fractions (IMRT) versus adaptive radiotherapy to residual tumour 
TABLE 3. Dose limiting organs at risk for boost planning 
Patient Dose limiting OAR 
1 Oesophagus 
2 Oesophagus 
3 Heart 
4 Lungs 
5 Heart, bronchial tree and oesophagus 
6 Oesophagus 
7 Heart 
8 Heart, oesophagus, brachial plexus and spinal cord 
9 Lungs 
10 Heart 
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based on during-treatment 18F-FDG- PET (fraction 18–19) to deliver a boost in the final 
nine fractions (2.2–3.8 Gy/fraction) to a maximum total physical dose of 80.4 Gy in thirty 
fractions. The primary goal of this study is to determine whether the dose can be escalated 
to improve locoregional control. Contrary to our study, a simultaneously integrated boost 
(SIB) is planned. The SBRT boost may be advantageous over this SIB procedure due to its 
dose inhomogeneity with high Dmax resulting in a higher biologically effective tumour dose.  
Van Elmpt et al. reported on the PET-boost randomised phase II trial that 
randomised patients between dose-escalation (IMRT-SIB) of the entire primary tumour or 
dose-escalation of the high FDG-uptake region (> 50% SUVmax) inside the primary 
tumour (12). Mean boost dose was 79.2 Gy for the entire tumour and 86.9 Gy for the high 
FDG-uptake area (P = 0.001). However, in case of overlap of PTV with an OAR, PTV 
was allowed to have reduced coverage for 15% of the volume. D95-99 for boost volumes 
were not described.  
In general, the feasibility of dose escalation entirely depends on the accepted dose to 
OAR and related toxicity. For example, it is suggested that the negative result of the 
RTOG 0617 trial is due to cardiac toxicity as compliance with normal tissue dose 
constraints was encouraged but not necessary. The effect of heart dose on overall survival 
is complex. It is advised to keep heart V50 < 25% (19). This constraint was met in our 
study (Supplementary material 4). Hepel et al. tried to deliver an SBRT boost in two fractions 
with a total boost dose of 16–28 Gy on primary and nodal disease after 50.4 Gy concurrent 
chemoradiation (phase I dose escalation trial) (18). There was no dose constraint for the 
proximal bronchial-vascular tree. One of twelve patients (8.3%) died due to fatal 
bronchopulmonary haemorrhage. The dose delivered to 4 cm3 of the bronchial-vascular 
tree was substantially higher in this patient: 20.3 Gy (EQD2 53.4 Gy, α/β-value 3 Gy) for 
SBRT boost and total dose of 73.5 Gy (EQD2 105.5 Gy, α/β-value 3 Gy). So, a mediastinal 
SBRT boost may increase the risk of fatal toxicity substantially and therefore a dose 
constraint to the bronchial-vascular tree is mandatory. Our maximum dose of 94 Gy 
(EQD2) delivered to the bronchial-vascular tree PRV is considered safe (12). Severe late 
oesophageal toxicity (stenosis and fistula) is observed in 6% of patients receiving a 
maximum dose of ≥ 70 Gy (16). Based on these results we set a maximum of 70 Gy to the 
oesophagus with 0.5 cm margin. However, the RTOG 1106 protocol allows a maximum 
dose of 74–76 Gy.  
Besides the issue as mentioned earlier regarding treatment-related toxicity, some 
technical aspects such as boost volume definition and tumour motion management need 
further discussion. It is not known which segmentation method is optimal for boost 
volume segmentation. Aerts et al. conclude that residual metabolic-active areas after 
(chemo)radiation have a high overlap with pre-treatment volume defined by 
50% SUVmax (7). However, defining the boost volume using a threshold of 50% SUVmax 
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may result in too large boost volumes because this threshold is in general regarded as a 
segmentation method to quantify 18F-FDG-avid areas of the entire tumour (20). Therefore, 
it is likely that residual metabolic active disease remains within this 50% SUVmax volume. 
Calais et al. propose a 70% SUVmax threshold on pre-treatment 18F-FDG-PET/CT scans 
to define treatment-resistant tumour subvolumes (9). This smaller volume will facilitate 
radiotherapy dose escalation. Therefore, we decided to use this segmentation method 
notwithstanding that a threshold of 80–90% could be sufficient as well resulting in even 
smaller boost volumes.  
For adequate radiotherapy delivery, determination of tumour movement is important. 
The ERM study by Usmanij et al., however, was performed when four-dimensional 
planning CT was not standard of care yet. Therefore, for this planning study, three-
dimensional planning CTs were used. It was therefore not possible to assess individual 
PTV margins for BTVboost such as with the mid-ventilation approach in stereotactic 
radiotherapy (21). We decided to use a 7 mm PTV margin for BTVboost, as this is a fair 
PTV margin for the mid-ventilation concept in our experience. However, in case of 
implementation of this stereotactic boost planning study into clinical practice, a four-
dimensional CT should be performed for all patients to assess individual PTV margins for 
the BTVboost (21).  
In conclusion, a stereotactic boost to primary tumour subvolumes with initially high 
or persistent 18F-FDG uptake (poor-responding areas) could be planned in combination 
with 60 Gy concurrent chemoradiation. V18, which equals an ablative dose, was ≥ 80% 
for PTVboost in six out of ten patients. Therefore, a stereotactic boost to regions with high 
18F-FDG-uptake is an attractive treatment strategy to optimise NSCLC therapy. 
Differences between the planned dose before and during treatment were minimal since 
overlap of PTVboost;ERM with PRVs remained in most patients. However, as an ERM-PET 
also monitors changes in tumour position, planning the boost on the ERM- PET should 
be considered.  
6 
  
PET based stereotactic boost in NSCLC | 109 
 
References 
 
1. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on 
survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 
1986;12(4):539–47.  
2. Kalman NS, Weiss E, Walker PR, Rosenman JG. Local radiotherapy intensification 
for locally advanced non-small-cell lung cancer – a call to arms. Clin Lung Cancer 
2018;19:17–26.  
3. Ramroth J, Cutter DJ, Darby SC, Higgins GS, McGale P, Partridge M, et al. dose and 
fractionation in radiation therapy of curative intent for non-small cell lung cancer: 
meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 2016;96(4):736–47.  
4. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. 
Standard-dose versus high-dose conformal radiotherapy with concurrent and con- 
solidation carboplatin plus paclitaxel with or without cetuximab for patients with stage 
IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by- two 
factorial phase 3 study. Lancet Oncol 2015;16(2):187–99.  
5. Belderbos J, Walraven I, van Diessen J, Verheij M, de Ruysscher D. Radiotherapy dose 
and fractionation for stage III NSCLC. Lancet Oncol 2015;16(4):e156–7.  
6. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced 
toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: 
a comparison of intensity-modulated radiation therapy (IMRT), 3D con- formal 
radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003;57(3):875–
90.  
7. Aerts HJ, Bussink J, Oyen WJ, van Elmpt W, Folgering AM, Emans D, et al. 
Identification of residual metabolic-active areas within NSCLC tumours using a pre- 
radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 
2012;75(1):73–6.  
8. Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, 
Kaanders JH, et al. 18F-FDG PET early response evaluation of locally advanced non-
small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med 
2013;54(9):1528–34.  
9. Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, et al. Areas of 
high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local 
relapse after chemoradiotherapy for non-small cell lung cancer. J Nucl Med 
2015;56(2):196–203.  
10. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. 
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non- 
small-cell lung cancer. J Clin Oncol 2010;28(6):928–35.  
6 
  
 
110 | Chapter VI 
 
11. Brown JM, Brenner DJ, Carlson DJ. Dose escalation, not “New Biology,” can ac- 
count for the efficacy of stereotactic body radiation therapy with non-small cell lung 
cancer. Int J Radiat Oncol Biol Phys 2013;85(5):1159–60.  
12. van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans 
D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell 
lung cancer. Radiother Oncol 2012;104(1):67–71.  
13. Khalil AA, Hoffmann L, Moeller DS, Farr KP, Knap MM. New dose constraint re- 
duces radiation-induced fatal pneumonitis in locally advanced non-small cell lung 
cancer patients treated with intensity-modulated radiotherapy. Acta Oncologica 
2015;54(9):1343–9.  
14. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of 
treatment-related pneumonitis in advanced-stage non-small-cell lung cancer pa- tients 
treated with concurrent chemotherapy and intensity-modulated radio- therapy. Int J 
Radiat Oncol Biol Phys 2007;68(1):94–102.  
15. Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, et al. Long-term clinical 
outcome of intensity-modulated radiotherapy for inoperable non-small cell lung 
cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys 2012;83(1):332–
9.  
16. Chen C, Uyterlinde W, Sonke JJ, de Bois J, van den Heuvel M, Belderbos J. Severe 
late esophagus toxicity in NSCLC patients treated with IMRT and concurrent che- 
motherapy. Radiother Oncol 2013;108(2):337–41.  
17. Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, et al. Stereotactic 
body radiation therapy can be used safely to boost residual disease in locally advanced 
non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 
2013;85(5):1325–31.  
18. Hepel JT, Leonard KL, Safran H, Ng T, Taber A, Khurshid H, et al. Stereotactic body 
radiation therapy boost after concurrent chemoradiation for locally advanced non- 
small cell lung cancer: a phase 1 dose escalation study. Int J Radiat Oncol Biol Phys 
2016;96(5):1021–7.  
19. Speirs CK, DeWees TA, Rehman S, Molotievschi A, Velez MA, Mullen D, et al. Heart 
dose is an independent dosimetric predictor of overall survival in locally advanced 
non-small cell lung cancer. J Thorac Oncol 2017;12:293–301.  
20. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. 
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J 
Nucl Med Mol Imaging 2015;42(2):328–54.  
21. Wolthaus JW, Sonke JJ, van Herk M, Belderbos JS, Rossi MM, Lebesque JV, et al. 
Comparison of different strategies to use four-dimensional computed tomography in 
6 
  
PET based stereotactic boost in NSCLC | 111 
 
treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 
2008;70(4):1229–38.  
 
  
6 
  
 
112 | Chapter VI 
 
Supplementary data 1 
 
Radiation treatment planning for PTV60Gy 
Both 18F-FDG-PET/CTs were transferred to the Pinnacle3 treatment planning system 
(Version 9.10; Philips Radiation Oncology Systems, Fitchburg, WI) and rigid fusion of 
these images with the initial radiotherapy planning CT was performed. The initial gross 
target volume (GTV) had been depicted on the 3-dimensional (3D) radiotherapy planning 
CT using the information of the pre-treatment 18F-FDG-PET/CT and consisted of the 
primary tumour and involved lymph nodes. The clinical target volume (CTV) enclosed the 
GTV of the primary tumour and lymph nodes with 10 mm and 5 mm margins, respectively. 
Isotropic expansion of 5 mm of the CTVs created the planning target volume (PTV). Dose 
coverage for all the initially created PTVs was re-planned by an experienced radiation 
treatment planning technician (PvK, 25 years of experience in radiation treatment 
planning). Using a VMAT technique, a prescription dose of 60 Gy in 30 fractions was 
applied, based on our national treatment protocol and ESMO guideline (1). A standard 10 
MV photon arc beam set-up was used avoiding the contralateral uninvolved lung. Predicted 
dose deposition was calculated using a 3D collapsed-cone convolution superposition 
algorithm. According to the ICRU 50/62 guidelines, the -5% and +7% dose heterogeneity 
criteria for the PTV were aimed for (2, 3). Planning parameters for PTV60Gy are described 
in the table below. 
 
1. Eberhardt WEE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference 
in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology 
2015;26(8):1573-1588 
2. Prescribing, recording and reporting photon beam therapy. Report 50. Bethesda: 
International Commission on Radiation Units and Measurements; 1993. 
3. Prescribing, recording and reporting photon beam therapy. Report 62; supplement to 
report 50. Bethesda: International Commission on Radiation Units and 
Measurements; 1999. 
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Supplementary data 2. Pre-treatment and early response monitoring 18F-FDG-
PET/CT based boost target volumes and their overlap with PRVs. 
 
 
Pt PTV0 
in 
PRV 
(cm3) 
PTV3 
in 
PRV 
(cm3) 
Absolute 
difference 
(cm3) 
Relative 
difference 
(%) 
PTV0 
min 
PRV 
(cm3) 
PTV3 
min 
PRV 
(cm3) 
Absolute 
difference 
(cm3) 
Relative 
difference 
(%) 
1 - - - - - - - - 
2 4 3.5 -0.5 -12.5 208.8 179.1 -29.7 -14.2 
3 0 1 1 100 13.5 19.5 6 44.4 
4 0.3 0 -0.3 -100.0 163.5 98.4 -65.1 -39.8 
5 21.8 13.7 -8.1 -37.2 70 40.9 -29.1 -41.6 
6 37.3 35 -2.3 -6.2 86.7 94.2 7.5 8.7 
7 11.80 7.8 -4 -33.9 29.30 24.9 -4.4 -15.0 
8 2.2 3.7 1.5 68.2 205.5 184.9 -20.6 -10.0 
9 - - 
 
- - - - - 
10 1.6 1.6 0 0 12.7 13.9 1.2 9.4 
 
Patient 1 and 9 did not have an overlap of boost planning target volume with planning organ at risk 
volume. 
 
Abbreviations: PRV: planning organ at risk volume; PTV0 in PRV: overlap of boost planning target 
volume determined on pre-treatment 18F-FDG-PET/CT with planning organ at risk volume; PTV0 
min PRV: part of boost planning target volume determined on pre-treatment 18F-FDG-PET/CT 
without overlap with planning organ at risk volume; PTV3 in PRV: overlap of boost planning target 
volume determined on early response monitoring 18F-FDG-PET/CT with planning organ at risk 
volume; PTV3 min PRV: part of boost planning target volume determined on early response 
monitoring 18F-FDG-PET/CT without overlap with planning organ at risk volume; Absolute 
difference: PTV3 volume minus PTV0 volume; Relative difference: (absolute difference/PTV0)*100  
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Supplementary data 3. Allowed and planned dose to organs at risk based on planning 
on early response monitoring 18F-FDG-PET/CT 
 
 
 Spinal cord Lungs minus GTV60Gy Contralateral lung 
Pt Allowed 
Dmax 
Planned 
Dmax 
MLD 
60 Gy plus 
boost 
V20 
60 Gy plus 
boost 
V5 
60 Gy plus 
boost 
V5 
60 Gy plus 
boost 
1 17.3 4.4 15.7 26.3 53.6 54.2 
2 29.9 15.2 16.1 22.6 68.8 64.5 
3 14.7 3.6 18.3 30.3 66.6 52.2 
4 5.8 4.3 20.4 33.9 49.7 15.5 
5 15.1 7.5 18.4 28.4 61.8 54.9 
6 11.7 3.8 14.9 24.5 46 36.3 
7 20.1 1.8 13.2 22 46.8 40.6 
8 3.8 3.6 11.2 16.6 40.9 36.3 
9 13.6 1.1 19.9 38.8 80.8 64.5 
10 7.4 2.0 16.5 25.2 57.6 54.5 
 
Allowed and planned dose in EQD2 (except for mean lung dose) for stereotactic boost planning 
based on early response monitoring 18F-FDG-PET/CT. Abbreviations: Dmax: maximum dose; MLD: 
mean lung dose; GTV60Gy: gross target volume receiving 60 Gy; PRV: planning organ at risk volume; 
V20: percentage receiving ≥20 Gy; V5: percentage receiving ≥5 Gy; 60 Gy plus boost: summed 
physical dose of the total radiation treatment plan (60 Gy plus stereotactic boost). 
 Heart Bronchial tree Oesophagus Brachial plexus 
Pt Allowed 
Dmax 
Planned 
Dmax 
Allowed 
Dmax 
Planned 
Dmax 
Allowed 
Dmax 
Planned 
Dmax 
Allowed 
Dmax 
Planned 
Dmax 
1 27.1 13.6 31.5 9.7 8.7 8.7 6.9 3.8 
2 29.7 26.7 30.6 23.1 6.6 6.6 N/A N/A 
3 29.3 29.3 28.9 23.8 7.0 2.6 N/A N/A 
4 27.6 11.1 27.1 18.8 7.9 5.1 N/A N/A 
5 30.6 30.6 30.6 30.4 8.3 7.9 8.2 0.5 
6 28.0 26.5 28.0 25.1 7.0 7.0 7.3 0.7 
7 31.0 30.9 30.6 18.9 7.0 3.0 N/A N/A 
8 30.6 30.6 33.2 11.2 10.0 9.7 4.6 4.3 
9 39.4 9.1 33.6 1.9 22.1 2.3 N/A N/A 
10 29.3 29.2 29.3 6.8 11.7 4.7 N/A N/A 
6 
  
PET based stereotactic boost in NSCLC | 115 
 
Supplementary data 4 
 
Heart dose 
Patient Heart V50 Heart Dmean 
1 4.5 7.9 
2 6.6 32.4 
3 15.0 19.3 
4 7.7 17.6 
5 5.2 11.3 
6 9.4 11.2 
7 5.6 7.5 
8 0.0 2.1 
9 5.7 17.0 
10 12.0 16.1 
 
Mean dose (Dmean) and percentage of heart receiving ≥50 Gy (V50) (summed physical dose) 
for individual patients of total radiation plan (60 Gy treatment plan plus boost planned on 
early response monitoring 18F-FDG-PET/CT). 
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ABSTRACT 
 
Objective 
18F-fluorodeoxyglucose-positron emission tomography/computed tomography 
(18F-FDG-PET/CT) is potentially applicable to predict response to chemotherapy in 
combination with bevacizumab in patients with advanced non-small cell lung cancer 
(NSCLC). 
 
Materials and Methods 
In 25 patients with advanced non-squamous NSCLC, 18F-FDG-PET/CT was 
performed before treatment and after two weeks, at the end of the second week of first 
cycle carboplatin – paclitaxel and bevacizumab (CPB) treatment. Patients received up 
to a total of 4 cycles of CPB treatment. Maintenance treatment with bevacizumab 
monotherapy was continued until progressive disease without significant treatment-
related toxicities of first-line treatment. In the case of progressive disease, bevacizumab 
was combined with erlotinib. Standardised uptake value (SUV) corrected for lean body 
mass (SUL and SULpeak) were obtained. PET response criteria in solid tumours 
(PERCIST) were used for response evaluation. These semi-quantitative parameters 
were correlated with progression-free survival (PFS) and overall survival (OS).  
 
Results:  
A metabolic response, defined by a significant reduction in SULpeak ≥30% after two 
weeks of CPB, was predictive of PFS and OS. For partial metabolic responders 
(n  = 19) median OS was 22.8 months. One year and 2-y OS were 79% and 47%, 
respectively. Non-metabolic responders (n = 6) (stable metabolic disease or progressive 
disease) showed a median OS of 4.4 months (1-y, and 2-y OS was 33% and 0% 
respectively) (P < 0.001). 
 
Conclusion 
18F-FDG-PET/CT after one treatment cycle is predictive of outcome to first-line 
chemotherapy with bevacizumab in patients with advanced non-squamous NSCLC. 
This enables identification of patients at risk of treatment failure, permitting treatment 
alternatives such as an early switch to a different therapy. 
 
Key Words 
Early response prediction, advanced non-small cell lung cancer; carboplatin-paclitaxel 
chemotherapy; bevacizumab, 18F-FDG PET/CT, PERCIST 
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INTRODUCTION 
 
Lung cancer is the major cause of cancer-related death in the Western World (1). Non-
small cell lung cancer (NSCLC) represents about 80% of all lung cancer. In the majority of 
cases, patients already have locally advanced or metastatic disease at presentation. Vascular 
endothelial growth factor (VEGF) is an important mediator in tumour angiogenesis, which 
plays an essential role in cancer cell survival in local tumour growth and the development 
of distant metastases. A strongly increased expression of VEGF has been found in non–
small-cell lung cancers (2) and is associated with an unfavourable impact on survival (3). 
Bevacizumab, a monoclonal antibody against VEGF-A, interacts with this pathway by 
blocking the effect of VEGF. A landmark phase 3 trial has shown that the addition of 
bevacizumab to carboplatin and paclitaxel in NSCLC improved overall survival (4). Recent 
American Society of Clinical Oncology guideline recommends adding bevacizumab to 
carboplatin plus paclitaxel (5). One explanation is that bevacizumab leads to vascular 
normalisation of tumour vasculature (6), thus increasing delivery and of cytotoxic therapy 
to the tumour leading to improved treatment efficacy. The evaluation of tumour volume 
response by conventional imaging techniques using Response evaluation criteria in solid 
tumours (RECIST) criteria has its limitations in detection of early therapy response (7), 
especially in the case of targeted treatment. FDG-PET/CT provides rapid, non-invasive, 
in vivo assessment and quantification of glucose metabolism and might be a powerful tool 
for measurement of treatment response. Changes in tumour glucose metabolism precede 
changes in tumour size and can possibly reflect drug effects at a cellular level, resulting in 
a potential advantage over morphological imaging. Molecular imaging using FDG-
PET/CT has shown in NSCLC patients to be a valuable tool for early detection of 
treatment response in chemotherapy (8), chemo-radiotherapy (9-13) and targeted 
treatment (14-19). The prediction of response using FDG-PET/CT may enable a 
distinction between patients who are going to benefit from treatment. Early detection of 
non-responders allows for treatment adaptation or earlier switch to other treatment lines. 
Ultimately, this can lead to a reduction in ineffective and potentially toxic therapy, a 
reduction in costs and a more personalised tumour-oriented approach. Few FDG-
PET/CT response-monitoring studies have been performed to evaluate anti-angiogenic 
treatment in NSCLC (20,21). To address this issue, a side-study for early FDG-PET/CT 
response monitoring study was performed, alongside a phase 2 trial in patients with newly 
diagnosed advanced NSCLC treated with first-line chemotherapy carboplatin, paclitaxel 
and bevacizumab (CPB). We explored the value of FDG-PET/CT to predict clinical 
outcome by using an early in-treatment FDG-PET/CT. 
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MATERIALS AND METHODS 
 
Patients 
 
From January 2009 to January 2013, patients with newly diagnosed locally advanced or 
metastatic NSCLC without prior systemic treatment were enrolled in this prospective 
single centre study. Patients with histologically or cytologically confirmed non-squamous 
NSCLC (stage IIIB or stage IV) and at least one measurable lesion (based on RECIST 1.1) 
were eligible. Exclusion criteria were previous chemotherapy or systemic anti-tumour 
therapy, previous radical radiotherapy, performance score ≥2 (Eastern Co-operative 
Oncology Group) or another active malignancy except for non-melanoma skin cancers in 
the last five years. This study was approved by the institutional review Board of the 
Radboud university medical centre Nijmegen. All patients provided written informed 
consent. 
 
Treatment 
 
Patients were treated with bevacizumab (15 mg/kg every three weeks), paclitaxel 
(200 mg/m2 body surface area on day 1 every three weeks) and carboplatin (area under 
concentration-time curve of 6, on day 1 every three weeks). Patients received a maximum 
of 4 cycles of therapy, after which monotherapy of bevacizumab was continued as long as 
patients had no evidence of progressive disease and no significant treatment-related 
toxicities. In the case of progressive disease bevacizumab 15 mg/kg every 3 weeks 
continued and erlotinib 150 mg/day (second-line treatment) added. Both epidermal growth 
factor receptor (EGFR) mutated and EGFR wild type genotypes were included in the 
study. 
 
Study design 
 
The primary objective of this phase II study was to monitor the efficacy of erlotinib plus 
bevacizumab (BE) subsequent to a progressive disease on CPB as determined by the 
maximum achieved disease control rate. One of the secondary objectives was the 
determination of early response, and FDG-PET/CT was performed before treatment and 
after one cycle of treatment (before the second cycle of treatment). Other secondary 
objectives were to monitor disease control rate and time to progression of CPB and BE 
respectively, and overall survival. The study design is shown in Figure 1. Clinicians were 
blinded to the results of the in-treatment FDG-PET/CT. Standard clinical response 
evaluation was done using contrast-enhanced computed tomography (CT) every 6 weeks 
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until disease progression. A response was assessed according to RECIST 1.1 (22) every 
6 weeks (or every 9 weeks after week 18 in the BE treatment phase), at the onset of clinical 
signs of progression and in case of premature discontinuation of study treatment. Partial 
response (PR) or complete response, had to be confirmed after a minimum of 4 weeks. In 
case of stable disease (SD), follow-up measurements must have met the stable disease 
criteria at least once after study entry at a minimal interval of 6 weeks.  
 
FDG-PET/CT 
 
For each patient baseline and in-treatment FDG-PET/CT was performed with the same 
hybrid PET/CT scanner (Siemens Biograph Duo or Siemens Biograph 40 mCT, Siemens 
Medical Solutions USA, Inc.) according to the guidelines of the European Association of 
Nuclear Medicine (23). At least 6 hours before 18F-FDG injection, the patients fasted, 
FIGURE 1. Study design. 
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including discontinuation of any tube or PEG-feeding and any glucose-containing i.v. 
fluids. Immediately before 18F-FDG injection, the blood glucose level was checked. 
According to protocol FDG-PET/CT scans were performed at mean 66 minutes 
(range 58 – 73) after 18F-FDG injection and furosemide 10 mg, covering the neck, thorax, 
abdomen and pelvis. The PET acquisition time was 4 minutes per bed position. PET scans 
from the Siemens Biograph Duo were processed using iterative reconstruction with the 
ordered subsets expectation maximisation algorithm (image matrix size, 128 x 128, 
4 iterations, 16 subsets; and a 5-mm 3-dimensional Gaussian filter). PET images from the 
Siemens Biograph 40 mCT were reconstructed with the TrueX algorithm (with a spatially 
varying point spread function and the incorporation of time-of-flight measurements (Ultra-
HD PET). Image reconstruction was performed with three iterations, 21 subsets, and a 
matrix size of 400 × 400 (pixel spacing of 2.04 mm). Reconstructed images were corrected 
for injected dose, the decay of 18F-FDG, patient body weight, and attenuation using a low-
dose CT scan. Correction for breathing motion using a 4D mode was not used. 
 
Analysis of FDG-PET 
 
FDG-PET/CTs were analysed on Pinnacle3 (version 8.0d; Philips Radiation Oncology 
Systems). At baseline, FDG-PET/CT was analysed visually (number and localisation of 
lesions) and quantitatively. SUV was normalised by lean body mass using Janmahasatian 
formula (24). The SULpeak of target lesions at baseline was at least 1.5× mean liver SUL 
+ 2 standard deviations of mean SUL. At follow-up, FDG-PET/CT was analysed visually 
(number and localisation of lesions, new lesions, visual change in uptake and size) and 
quantitatively (SUV, SUL, SULpeak). A maximum of five target lesions was selected and 
delineated using a 50% iso-contour threshold, according to PERCIST criteria (up to a 
maximum of two lesions per organ). New FDG-avid lesions, suspect for metastasis, were 
considered progressive disease. For evaluation of response predefined response criteria 
(PERCIST criteria) were used (25): A complete metabolic response (CMR) was defined as 
a complete resolution of FDG-uptake within the measurable target lesions and other 
lesions (less than mean liver activity and at the level of surrounding background blood pool 
activity) without the advent of new suspicious FDG-avid lesions. Partial metabolic 
response (PMR) was defined as a reduction of ≥30% in the target tumour SULpeak (and an 
absolute drop of at least 0.8 SUL). PMD was a ≥30% increase in SULpeak or advent of new 
FDG-avid lesions typical of cancer. Stable metabolic disease (SMD) (reduction < 30% and 
increase < 30%) was disease other than CMR, PMR or PMD. Two independent readers, 
blinded to the results of the CT-scans, performed reading of the FDG-PET/CTs and vice 
versa.  
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Statistical analysis 
 
Patients were considered evaluable for analysis if they underwent both pre-treatment FDG 
PET/CT and in-treatment FDG PET/CT. OS was measured from the date of treatment 
start to time to disease-related death. PFS was measured from the date of treatment start 
to time of disease progression on contrast-enhanced CT. In-treatment response evaluation 
on CT was measured at 6-weeks after treatment start. On FDG-PET/CT (measured 
2 weeks in-treatment) metabolic response was defined as CMR or PMR and metabolic non-
response was defined as SMD or PMD. Concordance between in-treatment PERCIST and 
RECIST was assessed using Cohen’s κ coefficient and Wilcoxon’s signed-ranks test. OS 
and PFS survival analysis were performed using Kaplan-Meier-method. Responders and 
non-responders were compared using log-rank statistics. Statistical analysis was performed 
using SPSS 22.0 (SPSS Inc.) for Windows (IBM Corp, Armonk, NY). The level of statistical 
significance was defined as a P < 0.05 based on two-sided tests. No time-dependent 
adjustment was needed because no progression or death was observed before the RECIST 
assessment.  
 
RESULTS 
 
Patients Characteristics and Follow-up 
 
Thirty-two patients were enrolled in the phase 2 study, of which 26 patients had a baseline 
FDG-PET/CT. Patient characteristics are shown in Table 1. One patient did not receive 
in-treatment FDG-PET/CT after the first treatment cycle and therefore was excluded 
from further analysis. Of the remaining 25 patients, 22 patients (88%) received 4 cycles 
(out of 4) CBP, while three patients (12%) received only 2 cycles first-line treatment, due 
to early disease progression. 21 patients (84%) continued monotherapy bevacizumab. 
19 patients (76%) received second-line treatment of erlotinib plus bevacizumab after they 
progressed on (CP)B. One patient receiving second-line erlotinib and bevacizumab had an 
EGFR mutation. In the present study, an EGFR mutation was found in two patients. 
Baseline FDG-PET/CT was always performed before treatment; the median time of 
baseline FDG-PET/CT was 13 days (range 2 – 35d) before treatment. There was no 
relation between delay on treatment start and outcome (PFS or OS) in Cox proportional 
hazards analysis (hazard ratio of 0.997 (0.963 – 1.033) (P = 0.871) for OS and hazard ratio 
of 0.987 (0.952 – 1.023) for PFS (P = 0.470). The in-treatment FDG-PET/CT was 
performed after one cycle of treatment at day 14 (13 – 20 d), always before the second 
cycle of treatment. Median time to second-line treatment was 9.3 months (range 1.4 – 
21.9 mo). Kaplan Meier analysis for PFS and OS stratified using RECIST (6-weeks after 
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treatment start) is shown in Figure 2, no significant difference between response groups was 
found (log-rank P = 1.000 and P = 0.468 for PFS and OS, respectively). During follow-up, 
all 25 patients died due to disease progression. 
 
 
 
 
 
TABLE 1. Patient Characteristics 
Characteristics Value 
Median age (y) (range) 54 (42 - 81) 
Gender  
Male 15 (47%) 
Female 17 (53%) 
EGFR mutation status  
EGFR mutation 2 (6%) 
No EGFR mutation 30 (94%) 
TMM-stage (7th edition)  
IIIB 1 (4%) 
IV 31 (96%) 
Smoking status  
Current smoker 15 (47%) 
Former smoker 17 (53%) 
Previous malignancy  
No 6 (19%) 
Yes 26 (81%) 
CPB treatment cycles  
<4 6 (19%) 
4 26 (81%) 
Maintenance bevacizumab cycles  
0 6 (19%) 
≥ 1 26 (81%) 
BE maintenance cycles  
0 11 (34%) 
≥ 1 21 (66%) 
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Predictive value of FDG-PET/CT 
 
Median baseline SUV was 6.8, and after 15 days of CPB treatment, median SUV was 5.0 
in the target lesions. In all cases, SUL versus SUV response categories (using the same cut-
off levels of 30%) were 100% concordant. According to PERCIST, no patient had CMR, 
2 (8%) patients had PMD, while 4 (16%) patients had stable metabolic disease (SMD). 
19 (76%) patients had PMR. For non-responders (both PMD and SMD) median PFS was 
1.7 months (range 1.0 – 6.1 mo). For patients with PMR median PFS was 8.7 months 
(range 3.7 – 35.7 mo), 1-y and 2-y PFS were 21% and 5%, respectively. For SMD and PMD 
FIGURE 2. Kaplan-Meier analysis of progression free survival (PFS) and overall survival (OS) 
stratified using in-treatment CT (RECIST). For SD median PFS was 8.4; median OS was 14.5 
months; For PR median PFS was 7.4 months; median OS was survival was 17.6 months. 
Log-rank test, P = NS. 
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TABLE 2. Comparison of in-treatment response between PERCIST and RECIST 
 
PERCIST 
                                           RECIST 
CR (n = 0) PR (n = 6) SD (n = 19) PD (n = 0) 
CMR (n = 0) 0 0 0 0 
PMR (n = 19) 0 5 14 0 
SMD (n = 4) 0 1 3 0 
PMD (n = 2) 0 0 2 0 
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median OS was 4.4 months (range 1.7 – 14.1 mo); 1-y and 2-y OS was 33% and 0% 
respectively. For PMR median OS was 22.8 months (range 4.3 – 54.6 mo), 1-y and 2-y OS 
were 79% and 47%, respectively. The Kaplan-Meier analysis of PFS and OS stratified using 
PERCIST is shown in Figure 3. Two examples of patients with stage IV disease are shown 
in Figure 4 and 5, with their baseline and in-treatment FDG-PET/CT.  
 
Comparison of treatment response between RECIST and PERCIST 
 
Nineteen patients were classified as SD on CT (6-weeks in-treatment), while four patients 
were classified as SMD according to FDG-PET/CT. 15 patients were classified as PMR. 
RECIST and PERCIST classifications are shown in Table 2. PERCIST and RECIST were 
discordant in 16 patients (64%). Of the 19 patients having SD according to RECIST, 
14 patients were reclassified as having PMR according to PERCIST. One patient was 
classified as PMD due to the advent of new FDG-avid lesions suspected of bone 
metastasis. However, these lesions were not detected on the 6-week in-treatment CT 
(patient died 52 days after treatment start). Cohen’s coefficient κ = 0.023 was indicating 
minimal agreement between RECIST and PERCIST. Wilcoxon’s signed-ranks test was 
P < 0.01 indicating a significant difference between RECIST and PERCIST. 
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FIGURE 3. Kaplan-Meier analysis of progression free survival (PFS) and overall 
survival (OS) stratified using PERCIST criteria. For SMD and PMD median PFS was 
1.7 months; median OS was 4.4 months; For PMR median PFS was 9.1 months; OS 
was 22.8 months; Log-rank test, P < 0.001. 
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DISCUSSION  
 
This prospective study showed that early in-treatment FDG-PET/CT in advanced NSCLC 
after two weeks of first chemotherapy and bevacizumab is predictive of PFS and OS. 
Compared to CT, PET detected response earlier during treatment and more frequently. 
Therefore, the predictive potential of an early in-treatment FDG-PET/CT, performed at 
two weeks after the start of treatment, is better than measurement of size changes on CT 
according to RECIST at six weeks after the start of treatment. This resulted in discordance 
between PERCIST and RECIST in 16 patients (64%). These differences can only partially 
be explained by the difference in timing of the response evaluation of FDG-PET/CT 
(2 weeks in-treatment) and diagnostic CT (6 weeks in-treatment). Early after treatment 
initiation, tumour size changes as a result of, both tumour reduction (i.e. mitotic cell death 
and cell loss) and tumour growth (i.e. cell division). As a result, small size changes, i.e. 
actual response or actual tumour growth or progression are underestimated when tumour 
FIGURE 4. Baseline (A) and in-treatment (B) FDG-PET/CT in a 51-year-old female patient with 
NSCLC, stage IVB, with a Pancoast tumour in the left lung with metastasis in the right adrenal 
gland (white and black arrows). In-treatment FDG-PET/CT showed apparent decrease in uptake 
classified as partial metabolic response. Survival was 12.4 months.  
 
 7 
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size is used as an early predictive marker. According to PERCIST, a significant reduction 
in FDG-uptake after one treatment cycle was associated with favourable outcome in terms 
of both PFS and OS. In this study, 6 out of 25 patients (24%) were classified as non-
responders (SMD or PMD), showing significantly lower median OS and PFS when 
compared to patients with a PMR (P < 0.001). Of the 19 patients having SD according to 
RECIST, 14 patients were reclassified as having PMR according to PERCIST, showing 
that metabolic changes exceeded the threshold criteria earlier than morphological changes. 
A prospective study by Shang et al. (26) comparing RECIST, EORTC and PERCIST 
criteria for evaluation of early response (after two weeks) to chemotherapy in NSCLC 
patients showed that both EORTC and PERCIST criteria were more accurate in predicting 
early response to treatment. 
FIGURE 5. Baseline (A) and in-treatment (B) FDG-PET/CT in a 67-year-old female patient with 
NSCLC, stage IVB, with a tumour in the left lower lobe with metastases in lymph nodes, lung, liver 
and bones. In-treatment FDG-PET/CT showed apparent increase in uptake (open arrows) and 
new FDG-avid bone lesions (black arrows), classified as progressive metabolic disease. Survival was 
1.7 months. 
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Studies addressing response prediction in advanced NSCLC treated with first-line 
chemotherapy and bevacizumab are limited. De Langen et al. (21) demonstrated in (locally) 
advanced NSCLC patients treated with erlotinib and bevacizumab that a decrease in SUV 
of more than 20% after three weeks was associated with increased progression-free 
survival. In oncology practice, it is important to identify effective biomarkers for prediction 
of failure or success of treatment. In contrast to our study, other response-monitoring 
studies (9-14) did not use PERCIST criteria for response evaluation (25). Predefined 
response criteria, are not only essential tools to assess an objective early response but are 
also crucial in the harmonisation of FDG-PET/CT studies and facilitate reproducibility 
across response assessment trials.  
A major concern during anti-VEGF treatment is tumour evasion and resistance from 
VEGF blockage, involving several possible escapes mechanisms (27). An apparent increase 
in FDG-uptake during treatment might suggest resistance mechanisms resulting in an 
increase in anaerobic metabolism and an increase in glycolysis. Alternatively, the decrease 
of tumour vascularity due to anti-angiogenic agents could also lead to an increase in hypoxia 
and glycolysis. However, 18F-FDG alone is not capable of discriminating between hypoxic 
and non-hypoxic regions. Tumour hypoxia and metabolism are independent events, which 
was shown in a study comparing 18F-FAZA and 18F-FDG in NSCLC (28). The effects of 
anti-angiogenic treatment could negatively affect the efficacy of FDG-PET/CT early 
response monitoring in NSCLC. However, in our report, we show that early response 
monitoring in NSCLC patients treated with chemotherapy the addition of bevacizumab 
seems feasible. Another entirely different approach is 89Zr-bevacizumab to visualise 
targeting of VEGFR for prediction of treatment efficacy (29), however further studies are 
needed to establish a potential role for 89Zr-bevacizumab in NSCLC.  
A limitation of our study is the relatively small number of patients. For the 
development of a clinical application of metabolic treatment response studies, larger series 
are necessary. In our analysis, PMD and SMD patients were defined as non-metabolic 
responders. These two categories may have outcome differences can only be detected by a 
much larger study population. When effective surrogates for early prediction are 
established, treatment decision-making based on the early in-treatment FDG-PET/CT 
seems feasible. In our study, we showed that as early as two weeks into first-line treatment, 
early metabolic changes predict clinical outcome. The majority of other FDG-PET/CT 
response assessments studies were performed at relative late time-point during treatment, 
not allowing any treatment adaptation based on the response assessment (30-32). Early 
discontinuation of an ineffective treatment regimen can possibly prevent unnecessary 
treatment toxicity. Moreover, earlier switch to a potentially beneficial different therapy 
could result in early tumour consolidation, better outcomes and better cost-effectiveness.  
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Another limitation of our study is the second line bevacizumab and erlotinib therapy 
started after progression on CPB or on bevacizumab maintenance. This investigational 
second line approach (given in 76% of the patients) showed only modest clinical benefit 
(33), where OS and PFS on first line CPB were in line with published data (4). However, 
the optimal strategy of anti-angiogenic therapy in the treatment of advanced NSCLC is still 
subject to randomised trials and large observational studies. Continuation of bevacizumab 
treatment in the absence of disease progression is a new treatment strategy in NSCLC, 
which is less toxic than traditional chemotherapy agents (34) and well tolerated (35). The 
concept of continuing bevacizumab treatment beyond progression is under investigation 
(36). More recently, the role of erlotinib with bevacizumab as first-line therapy is being 
explored (37).  
 
CONCLUSION 
 
The current study in advanced non-squamous NSCLC patients treated with first-line 
chemotherapy and bevacizumab showed that early in-treatment FDG-PET/CT is 
predictive of response to treatment and overall survival, already after two weeks of therapy. 
This enables identification of patients at risk of treatment failure, permitting an early and 
more individualised treatment modification. 
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 ABSTRACT 
 
Background 
Clinical studies in non-small cell lung cancer (NSCLC) have suggested a difference in 
metastatic patterns between adenocarcinoma (AC) and squamous cell carcinoma (SCC), 
which might be relevant for treatment and follow up.  
 
Methods 
A nationwide retrospective review was performed of pathology records in the 
Netherlands of all patients with NSCLC who underwent an autopsy between January 
2001 and December 2010. These autopsies were selected from the Dutch pathology 
registry (PALGA) and the presence and location of metastatic disease were retrieved. 
Clinical relevance of these findings was validated in a single centre cohort on all patients 
with NSCLC who underwent 18F-fluoro-deoxy-glucose positron emission 
tomography/computed tomography (FDG PET/CT) between January 2012 and May 
2013 for initial staging workup. 
 
Results 
From the total of 2798 NSCLC patients, 1128 were diagnosed as AC and 875 as SCC. 
Patients with AC more frequently developed metastases (49.7% versus 24.8% in SCC, 
P < 0.001) and had metastases at multiple sites more often (77.2% versus 66.8%, 
P = 0.004). Especially metastases to the adrenal gland and bone were more common in 
AC. SCC metastasised twice as often to the kidney compared with AC (23.2% vs 12.8%) 
(P < 0.001). Female AC patients developed significantly more lung metastases compared 
with male AC patients. Liver metastases were observed more frequently in female AC 
patients (49.1% vs 40.5%, P = 0.044). Validation with the FDG-PET/CT cohort was 
performed in a total of 143 NSCLC patients, of which 42 had metastases. Results from 
this cohort confirmed our findings from the autopsy study.  
 
Conclusion 
There are differences in metastatic patterns between AC and SCC. Also, gender-specific 
differences in AC were found. Both histopathological and gender-specific risks should 
be considered a stratification factor in future research initiatives focusing on advanced 
disease and should be routinely considered during future staging and follow-up of 
NSCLC. 
 
Key Words 
nationwide autopsy, non-small-cell lung cancer, metastasis, gender specific risks 
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INTRODUCTION 
 
Lung cancer is the most common cancer worldwide, with about 1.8 million new cases and 
1.6 million deaths in 2012 (1). In women, it is the leading cause of cancer-related death in 
developed countries (2). It is estimated that with the rise of lung cancer in women, the 
incidence rates of lung cancer might be identical in both sexes in the next decade. 
Approximately 83% of lung cancers are non–small cell lung cancer (NSCLC) of which 
adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the two most common 
types, accounting for 43% and 23% of all lung cancers (3). Lung cancer most commonly 
metastasises to the lymph nodes, brain, adrenal glands, bones and liver (4-6). A majority of 
NSCLC patients presented with (locally) advanced disease. The addition of 18F-fluoro-
deoxy-glucose positron emission tomography / computed tomography (FDG-PET/CT) 
in the workup of patients with lung cancer has improved staging, re-staging and detection 
of recurrent disease (7-10).  
 
Knowledge of clinical characteristics of metastatic disease is important to inform clinical 
decision-making. Previous single-centre studies showed data on metastatic patterns in 
different histological subtypes of NSCLC (11-15), suggesting that the metastatic pattern is 
influenced by histological subtype (11-15). AC developed more distant metastases 
compared to other NSCLC subtypes (15). Gender-specific differences in lung cancer 
development have been reported, including more women with AC and more lung cancer 
in female non-smokers, which can possibly be attributed to genetic and biologic factors. 
Especially due to the rise of lung cancer in women, predictive factors for metastatic 
patterns in lung cancer need to be updated, since historical data are based on a 
predominantly male population. 
 
Post-mortem studies offer a possibility to register both the extent and the location of 
metastatic disease in different subtypes of NSCLC. Here, we analysed data from the 
nationwide network and registry of histopathology and cytopathology Dutch Pathology 
Registry (PALGA) (16), which is used for all pathology data collection in the Netherlands. 
This provides a unique opportunity for complete nationwide assessment metastatic 
NSCLC. The pathology data were compared with the distribution of metastasis at the time 
of diagnosis based on a single-centre retrospective cohort of patients receiving FDG-
PET/CT for initial staging of lung cancer. 
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MATERIALS AND METHODS 
 
A nationwide retrospective review was performed of pathological and autopsy records of 
3489 patients diagnosed with lung cancer between January 2001 and December 2010. In 
the Netherlands, a post-mortem examination is performed at the request of the family or 
treating physician. All autopsies included in this study were performed in order to obtain 
information on the medical status of the deceased or to determine the exact cause of death. 
Only whole-body autopsies were included in this study, and no forensic autopsies were 
included. Small-cell lung cancer was excluded. Tumour histology had been assessed by 
different pathologists in all cases. Local staging according to the TNM classification 
(7th edition of the American Joint Committee on Cancer) was reconstructed from the 
reports of the pathology records. No clinical information on patient characteristics and 
treatment was available. To validate the clinical relevance of the autopsy results, the 
pathology data were compared with a single centre retrospective cohort of patients 
receiving FDG-PET/CT for initial staging of lung cancer. 
 
FDG-PET/CT Cohort 
 
A retrospective review was performed on all consecutive patients with a non-small cell lung 
carcinoma who underwent a (standard work-up) FDG-PET/CT scan for initial staging at 
the Radboud University Medical Centre between November 2011 and May 2013. The 
reports of the FDG-PET/CT scans and the pathological analyses were evaluated. The 
reports of the FDG-PET/CT scans were generated by different nuclear medicine 
physicians in all cases. Exclusion criteria were: patients with NSCLC other than AC or 
SCC, patients with inconclusive pathological data and patients with a synchronous double 
tumour (with different histology). Histological subtype was determined by the pathologist 
according to the IASCL revised 2011 criteria (17) in this cohort. Staging using the PET/CT 
scan was determined according to TNM staging 7th edition (18). This study was approved 
by the regional medical ethical review board. 
 
Statistical analysis 
 
Differences between categorical variables were calculated using the chi-squared test for 
normally distributed variables or the Fisher exact test for not normally distributed variables. 
All statistical analyses were performed using SPSS 23.0 (SPSS, Inc., Chicago, IL, USA). 
Two-sided P-values of < 0.05 were considered significant.  
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RESULTS 
 
A total of 3489 autopsies was available of lung cancer patients in the PALGA database: 
691 patients presented with small cell lung cancer and were excluded from the analysis. 
Patients with large cell carcinoma (LCC) (676 patients, 24.2%), carcinoid (97 patients, 
3.5%), giant-cell carcinoma (4 patients, 0.1%) and other NSCLC histology (9 patients, 
0.2%) were excluded from the analysis. In AC distant metastases were found in 561 out of 
1128 (49.7%) versus 220 out of 875 (24.8%) in SCC (P < 0.001). In Figure 1. the selection 
of NSCLC with AC and SCC is shown. For AC and SCC clinicopathological data are 
summarised in Table 1. Metastases were found in 781 out of 2003 autopsies in AC and SCC 
patients (39.0%). The median age of all patients at autopsy with metastases was 68 years 
(range 33 – 92), the median age at initial diagnosis was 68 years. Brain autopsy was 
performed in 230 patients (of 781), of which 140 with AC and 90 with SCC. 
 
FIGURE 1. Diagram with selection of stage IV non-small cell lung cancer (NSCLC) patients 
between 2001 and 2010 from the Nationwide Histopathology and cytopathology data network in 
the Netherlands. Small cell lung cancer (SCLC), adenocarcinoma (AC), squamous cell carcinoma 
(SCC). 
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Metastatic patterns between AC and SCC 
 
Single site metastasis was present in 132 out of 561 AC patients (23.5%) and in 73 out of 
220 SCC (33.2%). AC more frequently showed metastases at multiple sites (≥ 2) 77.2% 
(433/561) versus 66.8% (147/220) in SCC, P = 0.004 (Figure 2). Different sites of 
metastasis are summarised in Table 2. In AC, 225 out of 561 (40.1%) patients developed 
pulmonary metastases (one or more pulmonary metastases at a contralateral lobe of the 
primary tumour), while in SCC 80 out of 220 (36.4%) developed pulmonary metastases. 
Adrenal gland metastases were found in 240 out of 561 (42.8%) of AC patients, versus 54 
out of 220 (24.5%) in SCC patients (P < 0.001). Bone metastases were more frequently 
detected in AC than in SCC (181 out of 561 (32.3%) versus 43 out of 875 (19.5%) (P = 
0.001). Pleural metastases were found in 59 out of 561 (10.5%) in AC, compared with 19 
out of 220 (8.9%) in SCC. Kidney metastases were more frequently detected in SCC than  
 TABLE 1. Clinicopathological features of AC versus SCC 
 
Features AC (n = 1128) % SCC (n = 875) % P 
Sex 
 Men 
 Women 
 
709 
419 
 
62.9 
37.1 
 
710 
165 
 
81.1 
18.9 
< 0.001 
Age at autopsy 
 Median (range) 
 < 45 
 45 - 59 
 60 - 74 
 ≥ 75 
 
70 (33-96) 
29 
222 
473 
404 
 
 
2.6 
19.7 
41.9 
35.8 
 
72 (39-95) 
9 
87 
430 
349 
 
 
1.0 
9.9 
49.1 
39.9 
 
NS 
Stage at autopsy (TNM7) 
  M0 
  M1 
 
567 
561 
 
50.3 
49.7 
 
655 
220 
 
74.9 
25.1 
 
< 0.001 
no. of metastatic sites 
  1 
  2 
  3 
  4 
  ≥ 5 
  unknown 
 
128 
140 
112 
80 
94 
7 
 
11.3 
12.4 
9.9 
7.1 
8.3 
0.6 
 
73 
60 
39 
16 
27 
5 
 
8.3 
6.9 
4.5 
1.8 
3.1 
0.6 
 
< 0.001 
 
AC: adenocarcinoma, SCC: squamous cell carcinoma 
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in AC (51 out of 220 (23.2%) versus 72 out of 561 (12.8%), P < 0.001). Brain autopsy was 
performed in 90 patients with SCC and 140 patients with AC. In AC brain metastases were 
found in 66 out of 140 brain autopsies (47.1%) compared with 24 out of 90 brain autopsies 
in SCC (26.7%), P = 0.001.  
Uncommon sites of metastases (<5%) in both AC and SCC were small and large 
intestine and pancreas; there was no significant difference between AC or SCC for these 
uncommon sites. Rare sites of metastases (<1%) were the stomach, uterus, urinary bladder, 
gallbladder, ovary, prostate, breast and oesophagus. Gallbladder, ovary and uterus 
 
FIGURE 3. Distribution of metastasis in adenocarcinoma (AC) and squamous cell carcinoma 
(SCC). * P < 0.001, ** P < 0.001, *** P < 0.001 
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FIGURE 2. Number of metastases in stage IV adenocarcinoma (AC) versus squamous cell 
carcinoma (SCC) 
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metastases were only found in AC. Rare metastasis in the breast or prostate metastasis were 
found only in SCC. Differences in metastatic patterns between AC and SCC are shown in 
Figure 3.  No significant difference in metastatic site or number of metastases was found 
between male and female patients with SCC. In contrast, female patients with AC showed 
significantly more lung metastases (47.0% vs 35.4%, P = 0.006) (Figure 4). Liver metastases 
were also observed more frequently in female AC patients; 49.1% vs; 40.5%, P = 0.044. 
The combinations of metastasis in AC and SCC are shown in Table 3. 
 
Clinical relevance: validation with initial staging FDG-PET/CT 
 
Between November 2011 and May 2013, a total of 143 patients underwent an FDG-
PET/CT for initial staging of newly diagnosed NSCLC: 70 patients with AC (49%) and 73 
patients with SCC (51%). The PET cohort consisted of 36 (25%) patients with stage I, 17 
(12%) stage II, 48 (34%) stage III and 42 (29%) stage IV. Of these 42 patients with 
metastatic disease, 14 patients had SCC and 28 had AC. In stage IV patients the most 
common metastatic sites were bones, adrenal gland and liver (Figure 5). In the stage IV 
group, bone metastases were found in 57% of AC patients (16/28) versus (43%) of SCC 
(6/14) patients (P = 0.02). There was no difference in the incidence of liver metastases. 
Brain metastases were found in 4 out of 28 patients with AC (14%) versus 0 out of 14 in 
SCC (P = 0.04). Adrenal gland metastases were found in 16 out of 28 patients with AC 
(57%) versus 5 out of 14 patients with SCC (36%) (P < 0.01).  
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FIGURE 4. Distribution of metastases in adenocarcinoma (AC) in male (M) and female (F). * P = 
0.006, ** P = 0.044, *** P = 0.07 (NS) 
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FIGURE 5. Metastases found for each histological subtype in stage IV disease on initial staging; 
adenocarcinoma (AC) and squamous cell carcinoma (SCC). LN, lymph node. * P = 0.01, ** P = 
0.02, *** P = 0.10 (NS) 
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TABLE 2. Metastatic sites of AC versus SCC  
 
Site of distant 
 metastases 
AC  
(n = 561) 
% SCC  
(n = 220) 
% P 
Liver  247 44.0 91 41.4 NS 
Lung 225 40.1 80 36.4 NS 
Adrenal 240 42.8 54 24.5 < 0.001 
Bone 181 32.3 43 19.5 0.001 
Brain* 66 11.8 24 10.9 NS 
Kidney 72 12.8 51 23.2 < 0.001 
Peritoneum 36 6.4 14 6.4 NS 
Pericardium 60 10.7 15 6.8 NS 
Pleura 59 10.5 19 8.6 NS 
Pancreas 28 5.0 9 4.1 NS 
Spleen 32 5.7 10 4.5 NS 
Thyroid 30 5.3 8 3.6 NS 
Myocardium 19 3.4 13 5.9 NS 
Intestine, small 18 3.2 8 3.6 NS 
Intestine, large 14 2.5 2 0.9 NS 
Stomach 5 0.9 2 0.9 NS 
Skin 13 2.3 10 4.5 NS 
Uterus 2 0.4 0 0.0 NS 
Urinary bladder 1 0.2 1 0.5 NS 
Gallbladder 4 0.7 0 0.0 NS 
Ovary 5 0.9 0 0.0 NS 
Prostate 0 0.0 1 0.5 NS 
Oesophagus 1 0.2 0 0.0 NS 
Breast 0 0.0 1 0.5 NS 
AC: adenocarcinoma, SCC: squamous cell carcinoma 
* Brain autopsy was performed in 90 patients with SCC and 140 patients with AC. In 
AC brain metastases were found in 66 out of 140 (47.1%) brain autopsies compared 
with 24 out of 90 brain autopsies in SCC (26.7%). 
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DISCUSSION 
 
In this nationwide autopsy study, we showed that histological subtypes in NSCLC are 
important predictors of patterns of metastatic spread. Interestingly, gender-specific 
differences were revealed, showing women to have adenocarcinoma more frequently with 
a different distribution of metastatic disease than men. 
 
We showed that differences in metastatic patterns metastases exist between AC and SCC. 
Compared to SCC, AC metastasised to different sites, in various combinations and was 
more likely to have a higher number of metastases. Knowledge of these differences has 
implications for initial staging decisions, selection of appropriate treatment and follow-up. 
Also, this may have implications for treatment of oligo-metastatic NSCLC. Currently, the 
influence of histology in metastatic potential in NSCLC is often disregarded when 
discussing management options in NSCLC. Moreover, historical information and studies 
are based on a predominantly male population. The incidence in female patients, however, 
is rapidly rising whereas it is slowly declining in males (2). It is estimated that with the 
continuing rise of lung cancer in women, the incidence of lung cancer might be identical 
in both sexes in the next decade. While clinical staging and performance score are 
significant determinants in the decision making of patients with NSCLC, we demonstrated 
that histology-specific risks of metastatic potential exist and, surprisingly, the metastatic 
spread is also gender specific.  
 
Previous studies have shown that most common metastatic sites for NSLSC are liver, bone, 
brain, pericardium, adrenal glands and pleura (14). However, the size of these studies is 
often small (with a maximum of several hundred patients), compared with our nationwide 
study including 2798 NSCLC patients. We demonstrated that differences in the metastatic 
potential of AC and SCC exist. AC showed significantly more distant metastases compared 
to SCC. AC presents with a higher incidence of metastases in the adrenal glands and bones, 
while more kidney metastases were found in SCC. We showed that in SCC kidney 
metastases occur in up to 23.2% of patients with metastatic disease. While metastases to 
the kidneys are seldom encountered clinically, renal metastases are found more frequently 
at autopsy (19). Detection of renal metastases with FDG-PET/CT is limited due to the 
excretion of FDG in the urinary tract. The autopsy data, however, revealed 123 patients 
with renal metastases, of which 7 had isolated renal metastasis. In those particular 
situations, it could have changed treatment decision making, currently unknown due to the 
inability to detect small renal metastases by CT and/or PET. Metastases often develop late 
in the course of the disease and small metastases can be detected that might not be clinically 
relevant.  
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Currently, FDG-PET/CT is established as the standard of care to characterise mediastinal 
lymph nodes and detect unexpected extrathoracic metastases. FDG-PET/CT can identify 
previously unsuspected distant metastases in approximately 10–20% of patients, with high 
accuracy (20-22). Furthermore, characteristics between lesions allow for a distinction 
between metastasis and second primary tumours (23). To establish the clinical value of 
differences in metastatic patterns in autopsy studies, we verified these with initial staging 
cohort of 143 patients and found a similar difference in metastatic pattern between AC and 
SCC, with increased bone and adrenal gland metastases for AC.  
 
Gender differences in lung cancer pathogenesis are becoming increasingly important. In 
male patients, SCC is the main NSCLC, while in females AC is more common. Smoking 
history may partly explain this difference (24, 25) and several other hypotheses exist for 
these gender differences: a decreased DNA repair capacity in women, a higher 
susceptibility of tobacco carcinogens in women and an increased frequency of mutations 
in tumour suppressor genes (26-30). From a clinical perspective, female patients with 
NSCLC have favourable survival rates, but different treatment-related toxicity profiles (31, 
32). Despite these differences, earlier in the literature, no significant influence of gender on 
metastatic potential or metastatic locations was found (5, 13, 14), possibly due to smaller 
cohorts. Absolute differences in the prevalence and locations of the tumours and the 
significance of variables in other studies might be due to a selected study population with 
differences in treatment. In our large nationwide autopsy study, we found no significant 
gender differences in the metastatic pattern in SCC. However, women with metastatic AC 
had significantly more metastases to both lung and liver, compared to men. It can be 
hypothesised that a different biological behaviour or a different homing of tumour cells 
exist in female patients. Hormonal influences may play a role in cancer progression and 
formation of metastases as well. Oestrogen receptors are frequently present in lung cancer 
(ERβ expression of 52 – 69% of cases) and have been linked to the pathogenesis of lung 
cancer (29, 33, 34) and a role of differences in tumour immunology and a difference in 
oestrogen receptor signalling has been suggested in tumour genesis (35). Also, molecular 
signatures, like epidermal growth factor receptor (EGFR) mutations in adenocarcinomas, 
have been found to be present more often in women, but also in Asians and never smokers 
(36). The microenvironment of the target organ is thought to be an important factor in 
metastasis. It was hypothesised that tumour-stromal interactions could influence 
differences in metastatic patterns (37). When tumour cells enter the circulation, they do 
not spread to every organ randomly, but they tend to seed in selected organs as 
hypothesised by the “seed and soil” theory. Some histological subtypes may have a better 
ability to thrive in specific target organs. For example metastases from small cell lung 
cancer have a predilection for the brain (38). The NSCLC subtypes AC and SCC are distinct 
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clinical entities that have different embryologic origins and arise in different anatomic 
locations. However, the difference in the genotype of the tumour cells is not the only 
explanation for a potential difference in metastatic patterns. As mentioned previously, 
target organ tumour microenvironment plays a vital role in metastases.  
 
This autopsy study focusing on the metastatic disease from NSCLC showed differences in 
metastatic patterns between AC and SCC in a large nationwide population. Autopsy studies 
offer a unique opportunity to study the distribution of metastases and arguably can be seen 
as the gold standard in the study of cancer metastases. Clinically based studies have the 
advantage that metastasis at various sites can be analysed as time-dependent variables, 
allowing for a better evaluation of metastasis as a prognostic factor. 
 
One limitation of an autopsy study is that it unequivocally leads to a biased population, 
complicated by lead time and length time biases. Secondly, correlation with clinical factors, 
like treatment regimens, performance score, smoking habits, molecular profiling and 
clinical outcome were not available, due to the anonymisation of the pathology database. 
Therefore, a possible effect of specific organ metastasis on overall survival could not be 
confirmed. Interestingly, previous studies found that bone metastases and liver metastases 
were associated with shortened survival (39-41). Although we included only whole-body 
autopsies, metastases outside of routinely examined regions (especially for brain and bone) 
may have been missed. Brain autopsy was only allowed in a limited number of NSCLC 
patients (319 out of 2798). The limitation in the number of brain autopsies inevitably leads 
to an underestimation of brain metastases. Earlier an epidemiological study in a cohort of 
patients with brain metastasis showed that the incidence of patients with NSCLC was 
12.6% out of 742 patients (42). We found a small difference between proven brain 
metastases in AC and SCC (5.9% vs 2.7%, respectively) (P = 0.07) suggesting that the 
prevalence of brain metastases might be different between AC and SCC. A possible 
explanation is that brain metastasis are increasingly seen in adenocarcinomas with EGFR 
mutations and EML4-ALK1 rearrangements (43). A non-invasive method for staging with 
FDG PET/CT is becoming widely available and is currently a standard procedure for the 
staging of lung cancer. While the sensitivity of FDG-PET/CT for brain metastases is 72% 
(44) current NSCLC guidelines advise screening all stage III patients for brain metastases, 
preferably by magnetic resonance imaging (MRI), or otherwise a contrast-enhanced CT. 
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CONCLUSION 
 
In this nationwide autopsy study, we showed that different metastatic patterns exist in 
NSCLC, that are determined by tumour type and gender. AC showed significantly more 
metastases in adrenal glands and bone, while SCC showed more kidney metastases. In 
women with AC liver and lung metastases are more frequently present, compared to men. 
Biological differences in lung cancer between men and women are increasingly being 
recognised. Knowledge of these factors is particularly important because of the continuing 
rise in the incidence of lung cancer in women. Further research on genetic, metabolic, 
immunogenic and hormonal factors and gender-based clinical trials are warranted since 
historical data are based on a predominantly male population. Both histopathological and 
gender-specific risks should be considered for stratification in future research initiatives 
focusing on advanced disease.  
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Despite significant changes in diagnosis and treatment of patients with non-small cell lung 
cancer (NSCLC) over the last decade, NSCLC remains a leading cause of cancer-related 
mortality worldwide. In an effort to improve survival of NSCLC there has been an 
emphasis on early diagnosis, selection of optimal treatment and improved radiotherapy 
planning and more recently, adjuvant treatment with immune checkpoint inhibitors. 
Advances in conformal radiotherapy techniques allowed high dose irradiation with near-
surgical precision. Targeted treatments have considerably expanded treatment options for 
NSCLC patients. These recent developments emphasise the need to change from ‘a one 
size fits all’ treatment paradigm for NSCLC towards a personalised approach of treatment. 
  
 
Treatment response monitoring in NSCLC 
 
Molecular imaging using FDG-PET/CT provides an opportunity to investigate in a non-
invasive way the biology of cancer in vivo and to measure the impact of treatment. The 
rationale of metabolic imaging is that acquired mutations in oncogenes and tumour 
suppressor genes and loss of cell viability affects glucose metabolism (1, 2). FDG-PET/CT 
can provide patient-specific quantitative information of tumour metabolism before, during 
and after treatment. Molecular imaging can characterise some biological features of 
malignant tissue and reduction of FDG uptake that often precedes structural changes that 
are typically correlated with tumour response (3). Individualised treatment strategies 
become more relevant as our knowledge about tumour-specific drivers and specific tumour 
targets increases and the choice in anti-tumour agents has expanded considerably. 
Consequently, there is a rising need to identify pre-treatment factors that can potentially 
predict outcome. FDG-PET/CT is a non-invasive approach and might overcome issues 
of intra-tumoural and inter-tumoural heterogeneity, since biomarkers derived from biopsy 
material of tumour samples may significantly confound the analysis.  
Chapter III described a prospective study of the role of early in-treatment response 
assessment with FDG-PET/CT performed in patients with locally advanced NSCLC. An 
early in-treatment evaluation was performed after two weeks, after the first treatment cycle 
of chemoradiation and 10 Gy of radiotherapy. In this study we showed that a decrease in 
FDG-uptake, calculated as the percentage decrease in total lesion glycolysis (∆TLG) is a 
superior predictor of progression-free survival (PFS), compared to RECIST. 
Unexpectedly, already at an early time point, there were significant morphologic changes 
resulting in changes in tumour volume on in-treatment low dose CT after two weeks of 
treatment. However, this was not predictive of long-term PFS. For the definition of 
metabolic response, only a limited number of semi-quantitative parameters were retrieved 
using semi-automatic fixed threshold methods. For response calculation, a semi-
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quantitative parameter calculated as a percentage change to baseline was used. We showed 
that ∆TLG performed better in early response prediction than a decrease in standardised 
uptake value (SUV) or maximum SUV (SUVmax); both ∆SUV and ∆SUVmax were not a 
significant predictive factor. Interestingly, in our study, the end-of-treatment FDG-
PET/CT (2-5 months after completion of chemoradiotherapy) was not predictive of 
response. This suggests that persistent FDG-uptake is not always indicative of treatment 
resistance or associated with a poor clinical outcome. Radiation-induced inflammation 
could play an important role and mask true biological responders from non-responders. 
FDG-uptake is not limited to accumulate in tumour tissue, but also accumulates in 
macrophages, neutrophils and fibroblast. Multiple biological processes, such as 
proliferation, cell repair and inflammation, may conceal vital tumour residue and non-vital 
tumour tissue.  
In this prospective study, patients with a (pathological) response after 
chemoradiotherapy with IIIA/N2 disease with a resectable tumour were potential 
candidates for curative resection. Eight patients received a lobectomy; however, the 
potential role of surgery in patients who could be downstaged after chemoradiotherapy 
remains controversial. In a phase III trial induction chemoradiotherapy plus surgery were 
compared with definitive CRT in patients with stage IIIA/N2 showing no difference in 
overall survival (OS) between the two groups (4). However, in a subgroup analysis, patients 
that received a lobectomy had an improved OS compared to patients with only 
chemoradiotherapy. A considerably high mortality rate was observed in patients 
undergoing a pneumectomy. 
 
In Chapter VII the predictive value of early in-treatment FDG-PET/CT response 
to chemotherapy in combination with bevacizumab in advanced non-squamous non-small 
cell lung cancer is demonstrated. The early in-treatment evaluation was performed with 
FDG-PET/CT after two weeks. In this study, metabolic changes preceded morphologic 
changes. Many patients with stable disease (SD) according to RECIST could be reclassified 
as a partial metabolic response (PMR) based on FDG-PET/CT. We showed that only 
FDG-PET/CT was predictive of overall survival (OS). In this study predefined response 
criteria were used, the PET response criteria in solid tumours (PERCIST), for evaluation 
of in-treatment response. To facilitate the clinical implementation of early response studies, 
the use of predefined criteria is crucial. To establish a role of FDG-PET/CT for 
bevacizumab and chemotherapy, more studies are needed. The number of response 
monitoring studies in NSCLC treated with bevacizumab and first-line chemotherapy is still 
very limited. It could be argued whether a metabolic non-responder in our study had 
suffered from resistance to anti-VEGF treatment or whether it was caused by a resistance 
to chemotherapy. However, from a clinical perspective, the addition of bevacizumab to 
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chemotherapy is of limited value, as it only improved PFS but not OS in the phase II trial 
AVAiL (5). For therapy response monitoring of bevacizumab specifically, antibody-based 
positron emission tomography imaging with Zr-89 (89Zr-bevacizumab) could be used to 
visualise targeting of VEGFR. A limitation of this antibody PET imaging is that targeting 
does not necessarily imply treatment efficacy. Other VEGF-axis dependent resistance 
mechanisms (PIGF, VEGB, VEGFC and VEGFD) may contribute to the signalling of 
VEFGR and ultimately lead to tumour angiogenesis (6).  
One limitation of the prospective studies in Chapter III and Chapter VII is that the 
number of included patients is limited. This precludes subgroup or multivariate analysis. 
However, these studies do add to the growing support of evidence in favour of early 
response monitoring using FDG-PET/CT in NSCLC.  
 
Methodological aspects of response monitoring with FDG-PET/CT 
 
FDG-PET/CT is a suitable non-invasive tool for response evaluation and prediction of 
response and patient outcome. An increasing number of studies regarding early in-
treatment response monitoring in NSCLC using FDG-PET/CT has become available. 
Papers from 2003 to 2017 with studies involving response monitoring using FDG-
PET(/CT) in patients treated with chemotherapy or chemoradiotherapy are summarised 
in Table 1. These studies show that FDG-PET/CT is an effective method for early response 
prediction in NSCLC patients treated with chemotherapy and chemoradiotherapy. In 
general, a substantial reduction in FDG-uptake, evaluated with a quantitative or semi-
quantitative method, defines a favourable therapeutic response. However, the definition of 
‘metabolic response’ has generally been a matter of post hoc determination, with the use 
of receiver operating characteristics curves of the threshold of change in parameters that 
provides the best stratification of the patient population. One important consideration is 
that there is an intrinsic variability of the quantitative measure, as well as that magnitude of 
change (i.e., threshold) for defining response. Many differences in ‘early metabolic 
response’ can be expected due to a variation in the selected imaging variables and timing 
of FDG-PET/CT. Identification of predictive metabolic factors for early tumour 
response is important for exploring the potential role of early in-treatment FDG-
PET/CT. However, this also leads to large variability in the definition of early metabolic 
response in these response monitoring studies. Apart from the differences in the definition 
of a metabolic response, differences in chemotherapy, radiotherapy schedules, the timing 
of in-treatment scans and disease stages, make pooling of data very difficult. This hampers 
a meta-analysis of early response prediction in NSCLC with FDG-PET/CT and can partly 
explain why early in-treatment response monitoring in current clinical practice is lacking. 
One technical aspect is to harmonise acquisition processing and analysis of FDG-PET/CT 
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in clinical trials, earlier been described by Boellaard et al. (7). Standardisation of response 
monitoring for further prospective response monitoring studies is warranted. 
 
Interpretation of FDG-PET/CT 
 
The application of response monitoring studies with FDG-PET/CT has been routine 
clinical practice for many types of tumours for many years. However, categorisation of 
response into responders or non-responders has not been that easy. Let alone, exact criteria 
for early in-treatment response evaluation lack in many solid tumours. An objective and 
reliable assessment of treatment response require a detailed description of how to perform 
qualitative or (semi-)quantitative PET response.  
The FDG uptake can be assessed by qualitative methods (i.e., visual analysis), semi-
quantitative and quantitative methods. When a qualitative assessment is used to decrease 
the potential of the subjectivity of visual analysis, normalisation to an appropriate reference 
tissue is needed. Most often the liver is used as a reference since under fastening conditions 
the hepatic glucose uptake is relatively stable in the non-diseased liver. The mean liver SUV 
is expected to be within 1.0 and 2.2. Another reference point is the mediastinal blood pool 
and is often used as a cut-off for normal and pathophysiological uptake. Blood pool SUV 
measurements are estimated to be around 1.6. For evaluation of malignant lymphoma’s, 
for example, it has been used for the interim and end-of-treatment evaluation of response 
to therapy (Deauville criteria).  
 (Semi-)quantitative analysis is one of the assets of FDG-PET/CT to measure 
changes in tumour metabolism objectively. Uptake measurement using SUV is most widely 
used. For reproducible data strict adherence to acquisition parameters, patient preparation 
and image reconstruction is needed. Many factors do have a significant influence on 
quantitative parameters, like physiologic, technical and biological factors (8). Therefore, 
adherence to acquisition and analysis protocols, including the use of the same preparation 
regimen, uptake time and scanning parameters are needed for response monitoring. In an 
ideal case, the FDG-PET/CT should be performed on the same scanner, maintained with 
regular quality assurance using calibration phantoms. Variations in acquisition and analysis 
can introduce changes that do not reflect an underlying biological effect. In other words, 
differences in scanning acquisition and analysis protocol could induce changes that can 
falsely be interpreted as a significant decrease or an increase and might cause changes more 
substantial than shown in repeatability studies. Also, differences between centres, due to 
different PET/CT systems, differences in acquisition and imaging reconstruction can result 
in an increase in variability in SUV. Ideally, a comparison from institutions with a uniform 
approach to imaging procedures is needed. To minimise these differences in performance 
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between different centres, adherence to EARL accreditation is essential to increases the 
SUV reproducibility (9).  
With regard to response monitoring, full quantitative data is used infrequently. A 
quantitative method using kinetic modelling or Patlak analysis includes the need for arterial 
blood sampling or dynamic imaging of the blood pool. These study protocols are very 
complex and time-consuming and result in much discomfort for the subjects and negatively 
affect patient throughput. One crucial limitation of dynamic imaging is that it does not 
include the whole body when using the currently commercially available PET/CT systems. 
Only one bed position, consisting of a field of view of approximately 15-20 cm, can be 
measured. This requires prospective determination of the region to be imaged and the 
target lesions need to fit within one bed position. Previous studies showed that intra-
individual comparison of SUV before and during or after the treatment highly correlated 
with changes in Ki. This correlation has already also been confirmed by Weber et al. (10), 
showing that the changes in Ki and changes in SUV both showed high diagnostic accuracy 
for the prediction of pathological response and prediction of OS. Additionally, previous 
chemotherapy response evaluation study in NSCLC showed that ∆SUV and ∆MRglu are 
predictive of response (11). Concluding, simplified semi-quantitative methods based on 
static imaging are suitable for response monitoring and has currently replaced complex 
dynamic quantitative measurements.  
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Standardised uptake value 
 
Historically, the SUVmax reflecting the maximum voxel of the tumour is most often used. 
It is an intra-observer reproducible parameter and is often used for assessment of 
therapeutic response. However, this parameter has many limitations. Due to considerable 
fluctuations in this parameter in repeated measurement studies, it is not useful as a robust 
response parameter. SUVmax can be heavily influenced by variations in acquisition and 
reconstruction methods and image ‘noise’ (12). In an attempt to overcome this issue, 
SUVpeak was introduced and is based on the maximum average SUV within a 1 mL spherical 
volume. Compared to SUVmax it can be argued that SUVpeak is a more robust alternative 
and is less dependent on noise typically associated with clinical whole-body studies (12). 
Nevertheless, even this parameter only reflects a small percentage of the tumour. 
Weber et al. (13) showed in a repeated measurement study that variability in SUVmax and 
SUVpeak could decrease by up to 30% or increase up to 40%, while not receiving treatment, 
showing that repeatability of both SUVmax and SUVpeak in these repeatability measurements 
were not fundamentally different. It is important to realise that smaller changes than the 
measurement error might not reflect biological or predictive significance. One of the 
limiting factors using SUVmax and SUVpeak is that changes in the extent of the pathologic 
metabolic activity are ignored. Especially in tumours with central necrosis, a rapidly 
growing tumour may show a reduction in SUVmax or SUVpeak as the thin rim of viable tissue 
becomes subject to partial volume effects. Also, in tumours with a decrease in metabolism 
in most parts of the tumour, but a small part with persistently high FDG-uptake resulting 
in an unchanged SUVmax or SUVpeak.  
In Chapter III a simple normalisation method based on ‘simple body’ weight was 
performed for calculation of the SUV parameter. This normalisation of SUV using body 
weight has one potential weakness. Body composition can change significantly during 
chemotherapy. A normalisation of SUV using body weight seems less suitable since in a 
fasting state fat accumulates little FDG. To overcome this issue, other methods are 
introduced for normalisation based on body surface area (BSA) or lean body mass (LBM). 
SUV corrected for LBM (SUL) is becoming a popular metric for semi-quantitative 
assessment. Especially in obese patients, SUV normalisation using BSA or LBM have been 
shown to provide a more reliable estimate of FDG-uptake during significant weight 
loss (14). In Chapter VII we used predefined PERCIST criteria that require these SUV 
corrections based on LBM. However, in this early response monitoring study, the change 
in body weight and LBM between baseline and in-treatment FDG-PET/CT was minimal. 
Consequently, when normalisation was performed based on body weight instead of LBM, 
it did not affect the classification of metabolic response. 
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Total lesion glycolysis 
 
For response assessment, volumetric parameters such as metabolic active tumour volume 
(MTV) and total lesion glycolysis (TLG) (15) are often used. TLG, historically known as 
the Larson-Ginsberg index, reflects both tumour volume as well as metabolic data and is 
defined as the product of SUV and MTV. Studies already showed the prognostic value of 
pre-treatment TLG in osteosarcoma (16), malignant mesothelioma (17, 18) head and neck 
cancer (19) and multiple myeloma (20). Other studies have shown the usefulness of TLG 
for evaluating treatment response in different tumours. Both volumetric parameters have 
resulted in significant predictive factors for outcome in breast cancer (21) and oesophageal 
cancer (22). However, one crucial factor is that the definition of metabolic tumour volume, 
i.e., the method of tumour delineation has a significant impact on the absolute value of 
TLG.  
 
Delineation of Region of Interest 
 
The definition of the metabolic tumour volume, the region of interest (ROI) of the tumour, 
has a substantial effect on the measurement of SUV, MTV and TLG. Tumours are 
heterogeneous and can contain non-tumour elements like fibrous tissue and necrosis. 
During treatment, the distribution of viable tumour and total tumour volume may change 
over time. This becomes more likely as the period between the pretherapy, and the in-
treatment scan is extended, and ROI definition may be further compromised. Especially 
during treatment non-ideal shapes could be expected with non-uniform FDG-distribution 
and low tumour-to-background contrast. Different methods for ROI definition exist, and 
the chosen method could significantly affect the quantification of tumour response. 
Various approaches exist to delineate metabolic active tumour volume and are ranging 
from manually drawn ROI’s to (semi)automatic methods. A critical limitation of manually 
defined ROI’s is the relatively large inter-observer variability as compared to semi-
automatic methods, especially in tumours with surrounding high physiologic FDG-uptake 
(such as the heart) or low FDG-uptake (such as atelectasis). Therefore, (semi)automatic 
methods are preferred, ranging from absolute thresholds (e.g., SUV 2.5), a fixed threshold 
of 41% or 50% of maximum SUV, relative threshold methods or adaptive thresholds. 
Chapter V describes the effects of different response delineation methods and the 
effect on early response parameters. Different segmentation techniques are tested in this 
prospective response monitoring study and its impact on ∆TLG. This study showed 
different limitations of relative threshold methods. There was both an association between 
whole body ∆TLG and outcome, both OS and PFS. The segmentation performance of the 
primary tumour was analysed between relative threshold segmentation and adaptive 
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methods. All different ROI methods come with strengths and weaknesses. An absolute 
threshold method would fail in targets with a high background activity (like liver metastasis) 
since the threshold would be too low to exclude normal background tissue. On the other 
hand, lung lesions with a relatively low FDG-uptake delineated with absolute thresholding 
would only include a small portion of the lesion. For fixed threshold methods (41% or 
50% of maximum SUV) the true tumour volume is underestimated since low activity areas 
in the periphery of the tumour are not included. Also, when FDG-uptake decreases during 
treatment, a lower SUVmax on follow-up would result in a lower absolute threshold, 
sometimes leading to a paradoxical increase in MTV and possibly a higher TLG. Adaptive 
methods, such as the fuzzy locally adaptive Bayesian (FLAB) method, try to overcome 
segmentation problems in heterogeneous metabolic active tumour volumes. Despite these 
fundamental differences in segmentation, relatively small differences in terms of predictive 
performance were found between these methods. However, for lymph node segmentation, 
the signal-to-background (SBR) method outperformed all other methods. This is caused 
by the relatively high background of the mediastinal blood pool against the affected 
mediastinal lymph nodes. The inclusion of involved lymph nodes is important since the 
predictive performance ∆TLG was marginally stronger when affected lymph nodes were 
included in the analysis. Later during treatment, when the tumour-to-background ratio has 
further declined, semi-automatic delineation methods become less reliable in the actual 
delineation of the residual MTV and the SBR method seems to overcome this issue. 
 
Criteria for metabolic tumour response 
 
For response assessment in clinical practice and further clinical trials, a widely accepted 
definition of metabolic response is of high importance. Different attempts have been made 
in the past to define metabolic tumour response criteria. Currently, there is a lack of 
univocal PET parameters for an early in-treatment metabolic response. FDG-PET/CT is 
a powerful tool for early response monitoring in NSCLC as many exploratory response 
monitoring studies already have demonstrated (Table 1) in many different (post-hoc) 
definitions of early metabolic response. However, the lack of implementation of predefined 
criteria for early metabolic response makes adoption in routine clinical practice challenging. 
Different criteria have been proposed for the definition of metabolic response. As 
discussed earlier, for measurement of response it is most often quantified by measurement 
of the relative change in uptake of the lesions. The European Organization for Research 
and Treatment of Cancer (EORTC) proposed criteria defined a 15% to 25% decrease in 
SUV as a partial metabolic response after one cycle of chemotherapy and greater than 25% 
after more than one treatment cycle. However, these criteria do not provide any details on 
the preferred method of delineation or what PET parameter. As discussed previously, the  
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delineation method for ROI has a significant effect on the absolute values of SUVmean, 
MTV or TLG. Also, response calculation in multiple lesions is unclear in EORTC criteria 
since they lack recommendations for evaluation of the response of multiple lesions. Most 
studies that examined the role of therapeutic response assessment in NSCLC, focused on 
a response in either the primary tumour alone or the most metabolically active lymph node. 
This aggregation process is not always clear in response monitoring studies. Proposed by 
Wahl et al. (23) are PERCIST, which is of great value since it gives more guidance for 
selection of lesions to include, what measurements to use and added quantification of a 
complete metabolic response. This can ultimately lead to a lower interobserver variability 
and higher reproducibility of the results. A short overview of the differences between 
EORTC and PERCIST criteria is shown in Table 2. For routine clinical practice, these 
response criteria need to be robust, non-laborious and operator-friendly so that results are 
reliable and reproducible. So, are the PERCIST criteria ‘the holy grail’? There are some 
practical problems with PERCIST that need to be addressed. The selection of tumour 
lesions is (analogous to RECIST 1.1) a maximum of five lesions (up to two targets in the 
same organ). One important criterium is to only include lesions with a diameter of at least 
1.5 cm. However, it is known that bone metastases on CT cannot always be reliably 
assessed when they lack sufficient sclerotic or lytic component. Consequently, FDG-avid 
bone metastases are often ruled out solely based on these size criteria. Also, the criterium 
that FDG-avidity SULpeak needs to be least 1.5-fold greater than liver SULmean+2SD, this 
can result in the exclusion of FDG-avid pulmonary lesions due to their low background 
activity. Due to the selection of highly avid lesions, many liver lesions (with higher FDG-
uptake and background activity) are preferred over many lung lesions (with lower absolute 
FDG-uptake and background activity). For response measurement, it is not necessary to 
measure the same lesion and different lesions can be considered in the follow-up scans. 
The selection of measured tumour lesion is a major contributor to variability in the 
assessment of treatment response with FDG-PET/CT (24). 
 
Timing of in-treatment evaluation 
 
The crucial question is: when is it the most optimal time to examine the reduction in FDG-
uptake? Ideally, the timing of in-treatment should be as early during treatment as possible, 
since it then leaves enough possibility to escalate or de-escalate treatment. On the other 
hand, it may take some time for the treatment to affect the tumour. Timing FDG-PET/CT 
relatively short after specific treatments might reflect a temporary phenomenon rather than 
a true response to treatment. Also, the change in FDG-uptake needs to reflect an actual 
significant metabolic change rather than measuring a small difference that lies within the 
measurement error of the PET acquisition. Still, there are few data about the optimal timing 
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for evaluation of in-treatment response in NSCLC and there is no consensus regarding the 
optimal timing of early in-treatment FDG-PET/CT. While chemotherapy can decrease 
tumour metabolism during treatment due to direct cytotoxic effects and cell kill, normally 
in end-of-treatment evaluation it can point to residual or resistant disease. However, when 
evaluating early during treatment, there is still considerable FDG-uptake is remaining in 
the tumour, even in patients responding to the treatment (25, 26). When radiation is added, 
there is also a possible effect of radiation-induced inflammation that can produce possible 
misinterpretations. In our prospective clinical studies discussed in Chapter III and VII, 
the timing of the in-treatment FDG PET was chosen to be as early as two weeks in-
treatment. An earlier overview of clinical studies (Table 1) concerning early response 
monitoring reveals a broad range in the timing of interim evaluation, ranging from 1 to 6 
weeks in-treatment. The timing of in-treatment evaluation should be dependent on the 
schedule and type of cytostatic or cytoreductive treatment. Waiting too long for in-
treatment response could result in delayed treatment adaptation for the patient or 
misclassification of patients as responders. Also, a time point chosen too early can reflect 
a possible flare phenomenon. Assessments performed too early might not correlate with 
the biological effect, since glucose metabolism can still be present in cells that have received 
lethal damage. On the other hand, FDG-uptake is also possible in sub-lethal damaged cells 
which are unable to proliferate but are still viable. It can be expected that at a later time-
point during treatment the proportion of surviving clonogenic cells in the entire population 
of the tumour is still decreasing and differences in measured metabolic activity will be larger 
as compared to the FDG-PET/CT at baseline. The timing of in-treatment FDG-PET/CT 
should highly depend on the treatment, and that seems more than reasonable. In a large 
prospective study of stage IV NSCLC patients treated with paclitaxel-carboplatin and 
bevacizumab, FDG-PET/CT was performed shortly (within three days) after 
administration of bevacizumab of the second cycle of chemotherapy (27). Many patients 
showed a significant decrease in FDG-uptake, however, the response on FDG-PET/CT 
was not predictive of OS (with or without the use of nitro-glycerine patches). In this 
specific study, a possible substantial decrease in FDG-uptake might not be related to direct 
cytotoxic effects or cell kill of treatment, but rather a direct anti-angiogenic effect of 
bevacizumab resulting in lower tumour perfusion. This finding seems to be inconsistent 
with the widely accepted mechanism of action of anti-angiogenic drugs that they transiently 
normalise structurally and functionally abnormal tumour vasculature, improving drug and 
chemotherapy penetration in tumour tissue (28). Also contrary to this hypothesis, another 
study showed an adverse effect of bevacizumab on 11C-docetaxel uptake and a reduction 
of tumour perfusion instead (29). This effect of a decrease in perfusion in tumour tissue 
was seen within a few hours and persisted for at least four days after bevacizumab 
administration. 
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Metabolic response assessment with FDG-PET/CT can also yield false positive 
results due to inflammation and early post-radiotherapy changes. This is the direct 
consequence of FDG being an imaging biomarker of metabolism and not a specific tracer 
for cancer. Especially after radiotherapy, infiltration of lymphoid cells could be responsible 
for an increase of FDG-uptake. Serial imaging studies during and after radiotherapy suggest 
that inflammatory FDG uptake in normal tissues only increases after the first few months 
after treatment rather than occurring early during therapy. Especially inflammatory lung 
tissue uninvolved with tumour is unable to be separated from viable tumour tissue, possibly 
limiting an accurate region of interest definition. An in-treatment evaluation after two 
weeks seems to be a good compromise between early evaluation without a possible 
confounding effect of tissue inflammation, and it provides a time window for treatment 
adaptation. 
Another important factor is that delineation of metabolic active tumour becomes 
more problematic later on during treatment. Edit-Sanson et al. have demonstrated the time-
course of FDG-uptake in 10 NSCLC candidates for curative radiotherapy (60-70 Gy) (30). 
FDG-PET performed every seven fractions showed that later during the time course of 
treatment, fixed threshold and adaptive methods failed to delineate the tumour in a 
significant number of cases. Consequently, SUV and other volumetric parameters like 
MTV and TLG become more and more unreliable later during the treatment course. Due 
to the decrease in tumour FDG-uptake later during the treatment, (semi-)automatic 
delineation methods have more problems in a separation of the tumour volume from 
background tissue. After two weeks there is still significant FDG-uptake left for automatic 
segmentation methods to delineate the metabolic active tumour volume. Therefore, a 
choice for treatment evaluation later than two weeks after the start of treatment can only 
be based on manual delineation. This comes at the cost of low repeatability since manual 
delineation is highly subjective, potentially resulting in inconsistent outcomes. 
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FDG-PET/CT and radiotherapy 
 
Advances in conformal radiotherapy techniques like intensity modulated radiotherapy 
(IMRT) and volumetric modulated arc therapy (VMAT) combined with FDG-PET/CT 
allowed precise dose delivery and individualised treatment with near surgical precision. 
FDG-PET/CT is recommended for radiotherapy planning, since FDG-PET/CT 
significantly improves target delineation accuracy, especially in specific cases with lung 
atelectasis and nodal disease. Biologically adaptive radiotherapy is an approach that 
modifies the initial treatment planning during the course of radiotherapy. Geometrical and 
biological variations induced by radiotherapy could be accounted for, instead of applying 
the same baseline characteristics to all radiotherapy fractions. After initial treatment 
delivery of a specific dose, the treatment plan is re-optimised aiming the boost of radiation 
therapy to the residual tumour, while sparing healthy tissues. One crucial factor is that the 
target tissue does not have uniform radiological properties. Differences in sub-volumes can 
exist due to radio-resistance and hypoxia. Areas of high uptake on pre-treatment FDG-
PET/CT identify preferential sites of local relapse after chemoradiotherapy for NSCLC 
(31). 
In Chapter III we discussed early response assessment in locally advanced NSCLC 
and showed that change in TLG was predictive of progression-free survival. In theory, 
those patients who showed a minimal or no decline in TLG might be candidates for 
treatment adaptation, i.e., treatment intensification. For dose escalation, it is possible to 
boost based on the pre-treatment FDG-PET/CT while boosting based on in-treatment 
FDG-PET/CT allows identification of radio-resistant disease. Careful selection of patients 
is needed as treatment intensification should only be applied when unnecessary radiation 
to organs at risk could be avoided. In selected cases, dose escalation was possible for 
smaller tumour volumes than the original tumour volume. In Chapter VI an FDG-
PET/CT guided dose escalation study was performed to improve local tumour control in 
stage III NSCLC. On these patients, who were treated with 60 Gy chemoradiotherapy, 
dose escalation simulations were performed on subvolumes with markedly increased 
uptake, based on pre-treatment and early in-treatment FDG-PET/CT. Based on the in-
treatment FDG-PET/CT planned target volume could be reduced in 5 out of 10 patients. 
One limitation is that no respiratory gating was applied during the FDG-PET/CT 
acquisition. Due to the long acquisition time of FDG-PET/CT with typical acquisition 
times of 3 to 4 minutes per axial view, motion artefacts due to free breathing can occur. 
This can result in an underestimation of FDG-uptake and an overestimation of MTV. 
Optimally respiratory gating (ORG) during acquisition of PET results in a significant 
increase in SUVmean and a significant decrease in MTV can be used to increase target 
accuracy further (32). ORG also resulted in a more accurate alignment between PET and 
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CT and an increase in TLG and SUVmean, compared to non-gated CT (33). Implementation 
of ORG improves quantitative accuracy however with the targeting of radioresistant 
disease did not result in a clinically relevant difference in radiation dose to the organs at 
risk (34).  
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With an increasing spectrum of developments in treatment strategies and target therapies, 
personalised decision making is becoming increasingly relevant. With spiralling costs of 
treatment, this further presses the need to optimally select specific treatments for the 
individual patient, while minimising the costs and side effects of ineffective treatment. We 
demonstrated that the concept of early in-treatment response monitoring using FDG-
PET/CT in NSCLC is valid and that metabolic changes during the treatment course are 
predictive of clinical outcome. Measurement of the tumour response to treatment based 
on metabolic activity, rather than size alone, reflects a fundamental advantage to investigate 
the biology of cancer in vivo prior to and during treatment. Each of these additional FDG-
PET/CT may add significantly to the costs and time of treatment. However, they also 
might prevent costs by early discontinuation of in-effective treatment. Investigations of the 
comparative effectiveness and cost-effectiveness of FDG PET/CT in assessing treatment 
response are still needed.  
The methodology of the current early in-treatment response monitoring studies and 
clinical endpoints are still heterogeneous and uniform quantitative cut-off points are 
lacking. The sample size is a critical defect in the current early in treatment response 
monitoring studies. Therefore, it is essential to pool data from multiple centres. In order 
to compare different results from different studies, more standardisation is needed for 
image analysis. Currently, there is a consensus in quantitative analysis in FDG-PET/CT 
and are already described in protocols from Europe (35) and the USA (36). Implementation 
of predefined criteria, like PERCIST, in response monitoring studies would greatly aid 
future pooling and meta-analysis of response monitoring studies. With current advances in 
computing power and (semi)automated quantitative assessment of FDG-PET/CT based 
on PERCIST criteria may provide an immediate and objective report of treatment 
response. Prospective adaptive multicentre trails PET-guided treatment needs to be 
conducted to establish a foundation for clinical practice. Current initiatives of adaptive 
PET-based studies are being started and the results of these adaptive PET-based studies 
are waited for with great interest (37). 
Other than chemoradiotherapy in NSCLC, there is an increasing body of evidence 
for early response assessment with FDG-PET/CT in targeted treatments, like EGFR-TKI 
(38-42) and immune checkpoint inhibitors such as nivolumab (43). Also, the 
implementation of other PET traces could be more specific for treatment response 
evaluation. During treatment as the tumour changes, the interplay between proliferation, 
angiogenesis, and hypoxia will show areas of active tumour repopulation, resistant areas 
and regressing tumour areas. To visualise tumour resistant areas, hypoxia tracers (like 
Fluoro-misonidazole, 18F-FMISO) could be used for quantification of hypoxia. For 
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targeting cell proliferation, Fluoro-thymidine (18F-FLT) has been used for early response 
assessment in patients treated with EGFR-TKI (44). 
Various textural features and parameters reflecting tumour heterogeneity have shown 
much potential for response assessment (45). Differences in aggressive and heterogeneous 
features caused by various clones harbouring various mutations can contribute to inter-
tumoural and even intra-tumoural heterogeneity. One limiting factor of (semi)quantitative 
parameters is that they ignore changes not only in the extent of the pathologic metabolic 
activity but also inadequately describes the heterogeneous distribution of FDG within a 
tumour. Current research on intra-tumour heterogeneity in solid malignancies is rapidly 
increasing. In particular, there is an increasing interest in using intra-tumour heterogeneity 
to correlate with tumour type, aggressiveness, tumour grade, metastatic potential, hypoxia 
and treatment resistance. This concept of radiogenomics is aimed at developing tools for 
non-invasive genotyping by identifying imaging biomarkers. Different parameters could be 
correlated to different aspects of the tumour microenvironment, such as proliferation, 
angiogenesis, hypoxia, inflammation, and expression of specific receptors or mutations. 
Identification of a subset of features that are most relevant to the underlying biological 
mechanism can improve our understanding of tumour response. Eventually, we hope to 
find radiomic features that can serve as predictive markers similar to CT based radiomic 
features (46). It is increasingly recognised that genetic heterogeneity exists within the 
tumour and between metastatic sites in the individual patient. As many different features 
have been described and as more different samples are tested, the need for large patient 
datasets are a necessity.  
Current practice for treatment selection in NSCLC has evolved from a mostly empiric 
method, based on known prognostic factors like performance status, weight loss, and stage 
to a more integrated approach where clinical factors, histological and molecular factors are 
included. Especially with a sustained increase in lung cancer rates in females, further 
research on the effect of gender and outcome in NSCLC is important. Gender is not only 
a prognostic factor, but there might be differences in response to targeted treatments in 
females, compared to men (47). With modern techniques, the identification of specific 
genetic factors that may play a role in disease progression should direct research to identify 
the clinical predictors of outcome for NSCLC. Ultimately, all known prognostic factors 
like performance status, weight loss, stage and metabolic parameters, gender, histology, 
mutation status together with in-treatment parameters should lead to an integrated and 
personalised approach. Pooling of relevant patient data into large (nationwide) sets of ‘big 
data’ can eventually lead to more predictive models to forecast clinical outcome and 
optimise treatment strategy (48). 
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Measurement of the tumour response to treatment based on metabolic activity, rather than 
size alone, reflects a fundamental advantage to investigate the biology of cancer in vivo and 
to measure the impact and change in metabolism. Traditional chemotherapy is still the 
cornerstone of treatment of NSCLC, but still, the overall survival in advanced stage disease 
remains dismal. With the advent of tyrosine kinase inhibitors, anaplastic lymphoma kinase 
and monoclonal antibodies, analysis of underlying mutations, the effective use of treatment 
combinations and early discontinuation of in-effective treatment are crucial. With this 
increasing pallet of treatment choices, there is a potential increasing role of PET for early 
in-treatment response measurement. Selection of highly effective treatments and 
subsequently early discontinuation of in-effective treatment should ultimately lead to an 
improved outcome and a reduction of adverse events. Personalised medicine for NSCLC 
is a reality now, and its use will only increase in the future. 
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Lung cancer is a common type of cancer and it represents a substantial social and economic 
burden. Despite intensive efforts for lung cancer screening and follow-up, it is still the 
leading cause of cancer-related death. With intensive systemic treatment with 
chemotherapy, overall response rates are far from optimal and patients experience 
significant treatment-related toxicity. In order to identify non-responders, molecular 
imaging with 18F-fluoro-deoxy-glucose positron emission tomography/computed 
tomography (FDG-PET/CT) can be used. In this thesis, the results of FDG-PET/CT for 
early in-treatment response in non-small cell lung cancer (NSCLC) are described. For 
delineation of metabolic active tumour, different methods are explored. With modern 
radiotherapy techniques, it is possible to direct a dose escalation to tumour subvolumes 
with increased metabolism, without a significant increase in treatment toxicity. Finally, 
gender-specific and histopathological differences in NSCLC are addressed in a nationwide 
autopsy study. 
 
Role of FDG-PET/CT in characterisation and staging NSCLC 
 
In Chapter II the current role of FDG-PET/CT in NSCLC is discussed. In vivo 
measurement of glucose metabolism with FDG-PET/CT is currently advised in clinical 
guidelines for characterisation of malignancy in pulmonary nodules. While in a majority of 
cases nodules are benign, FDG-PET/CT is useful for intermediate risk lesions as it can 
help to distinguish between benignity and malignancy with high accuracy. However, in 
endemic regions with pulmonary infections, the false positive rate with FDG-PET/CT is 
high. Apart from characterisation, FDG-PET/CT has a prominent role in staging. The 
introduction of FDG-PET/CT resulted in a significant number of management changes 
due to the detection of locoregional FDG-avid lymph node metastases and unexpected 
distant metastases. As a consequence, FDG-PET/CT reduces futile thoracotomies and 
reduce associated morbidity. For patients with FDG-avid lymphadenopathy, mediastinal 
staging by means of mediastinoscopy, endobronchial ultrasound-guided transbronchial 
needle aspiration or endoscopic ultrasound fine needle aspiration, is required. Only in 
patients with an FDG-avid primary tumour without FDG-avid lymph nodes in hilar or 
mediastinal lymph nodes, invasive pathologic examination of the mediastinum can be 
omitted. 
 
10 
  
 
194 | Chapter X 
 
FDG-PET/CT response prediction 
 
This thesis focussed on the application of FDG-PET/CT as a predictive biomarker. These 
markers can be used to define early sensitivity to treatment and response. Treatment-
induced changes in FDG-PET/CT early during chemotherapy (after the first treatment 
course) correlate with patient outcome. Chapter III described the clinical outcome in 
patients treated with concomitant chemo-radiotherapy evaluated with early in-treatment 
FDG-PET/CT. Twenty-eight patients with locally advanced (stage IIIA-IIIB) non-small 
cell lung cancer were included. A whole-body FDG-PET/CT was performed and, for 
response measurements, standardised uptake value (SUV) and total lesion glycolysis (TLG) 
were determined. Baseline FDG-PET/CT before treatment start and in-treatment FDG-
PET/CT was performed. Pre-treatment TLG and a percentage change from baseline for 
each patient (∆TLG) and correlated with outcome with a Cox-proportional Hazards 
analysis. Median cut-off of ∆TLG was a decrease of 45% on the in-treatment scan. These 
results showed that early in-treatment FDG-PET/CT was predictive of outcome in 
NSCLC patients treated with concomitant chemoradiotherapy. The volumetric parameter 
TLG, therefore, seems promising as a predictive and prognostic biomarker. In Chapter IV 
we briefly discuss the predictive value of FDG-PET/CT for neoadjuvant therapy and the 
importance of early in-treatment assessments. With early in-treatment FDG-PET/CT, 
image-guided treatment algorithms can be designed, to adjust treatment to the individual 
patient, minimising treatment toxicity of ineffective treatment and enabling fast switching 
to effective treatment.  
For the definition of early metabolic response, it is important to realise that (apart 
from biological and patient-related factors) technical factors could have a significant 
influence on semiquantitative measurement with FDG-PET/CT. Apart from the choice 
of the semi-quantitative measurement (SUVmax, SUVpeak, SUVmean, MTV and TLG), the 
method of delineation of the metabolic active tumour volume has a significant effect on 
the absolute FDG-uptake measurement and on the percentage change on the in-treatment 
scan. In Chapter V different semi-automatic methods for segmentation of the target 
lesions (primary tumour and metastatic lymph nodes) on early response FDG-PET/CT 
were studied. Also, the aggregation process, with or without the inclusion of the metastatic 
lymph nodes was assessed. Different segmentation methods were used: fixed threshold 
methods (40- 50% of SUVmax), relative threshold methods (signal-to-background method, 
relative-threshold-method) and adaptive methods (fuzzy locally advanced Bayesian). From 
a clinical perspective, the differences between segmentation methods were small, however, 
from a practical point of view the signal-to-background method resulted in more successful 
(semi)automatic segmentation of the primary tumour and affected lymph nodes. Especially 
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difficulties on the in-treatment scan emerged due to lymph node segmentation failures for 
fixed and adaptive delineation methods, due to the low signal-to-background ratio. 
 
FDG-PET/CT and radiotherapy planning 
 
In radiotherapy planning, FDG-PET/CT can assist the radiation oncologist for optimal 
dose delivery to the tumour, while sparing healthy tissues. FDG-PET/CT improves target 
accuracy for nodal radiation and has an advantage over CT in borderline sized nodes. For 
radiotherapy planning, FDG-PET/CT has the potential to allow radiation-dose escalation 
without increasing the dose to the organs at risk. Specifically, for locally advanced NSCLC 
the number of patients with local recurrence is significant, despite intensive concurrent 
treatment. In Chapter VI a PET-based planning study was performed in these patients 
with an early in-treatment metabolic non-response to explore the feasibility of radiation 
dose escalation and the effect on organs at risk. Ten patients, with a TLG decrease lower 
than 45% on the in-treatment scan, were selected for this planning study. A stereotactic 
boost was planned to the most radioresistant subvolumes of the primary tumour, on both 
pre-treatment FDG-PET/CT and in-treatment evaluation before the second cycle of 
treatment. A significant dose escalation was achievable while meeting strict dose 
constraints on organs at risk. In five patients the boost planned tumour volume (PTVboost) 
was 9-40% smaller compared to the PTVboost based on the pre-treatment FDG-PET/CT.  
 
Response assessment in locally advanced (inoperable) NSCLC and 
metastatic NSCLC 
 
The majority of patients who present with NSCLC have inoperable stage IIIB and IV 
disease. While chemotherapy is still the cornerstone of treatment, different targeted 
treatment strategies have been introduced. For example, vascular endothelial growth factor 
(VEGF) is an important mediator in tumour angiogenesis, which plays a vital role in cancer 
cell survival, local tumour growth and the development of distant metastases. In 
Chapter VII patients with newly diagnosed non-squamous NSCLC were treated with first-
line chemotherapy (carboplatin and paclitaxel) in combination with bevacizumab, a 
monoclonal antibody against vascular endothelial growth factor. Twenty-six patients were 
treated and received a baseline FDG-PET/CT and an in-treatment FDG-PET/CT 
between 13-20 days, always before the second cycle of treatment. For response criteria, 
predefined criteria (PERCIST) were used. Early in-treatment FDG-PET was predictive of 
progression-free survival and overall survival, already after two weeks of therapy. 
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Distribution of NSCLC metastasis 
 
Chapter VIII demonstrates the results of a nationwide autopsy study in NSCLC, showing 
different metastatic patterns between the two major histological subtypes, adenocarcinoma 
(AC) and squamous cell carcinoma (SCC). Patients with AC more frequently developed 
metastases (50% versus 25% in SCC, P < 0.001) and had metastases at multiple sites more 
often (77% versus 67%, P = 0.004). AC showed significantly more metastases in adrenal 
glands and bone, while SCC showed more kidney metastases. In women with AC, liver and 
lung metastases are more frequently present, compared to men. As biological differences 
in lung cancer between men and women are increasingly being recognised, knowledge of 
these factors is particularly important because of the continuing rise in the incidence of 
lung cancer in women. Knowledge of the distribution of metastatic patterns based on 
different prognostic factors could possibly improve the clinical assessment of unclear 
clinical findings. 
 
Final remarks 
 
The predictive performance of FDG-PET/CT is increasingly being recognised. In the 
general discussion different methodological considerations are presented for early response 
measurement. Differences in the quantification methods of metabolic active tumour 
volume and differences in quantitative parameters in current response monitoring studies 
are addressed. The primary challenge for early response monitoring is that the proper 
timing of FDG-PET/CT during treatment is crucial and it should depend on the treatment 
schedule and regimen. As there are numerous methods for defining metabolic response 
post-hoc, the use of prospectively defined criteria is of importance to avoid bias in 
interpretation. Moreover, for clinical implementation, harmonisation of response 
prediction methods is crucial. With the increasing treatment options, advances in targeted 
treatment and the promise of personalised treatment, the selection of effective treatment 
is becoming increasingly important. 
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SAMENVATTING 
 
In Nederland is longkanker een veel voorkomende vorm van kanker met een incidentie 
van circa 13.300 in 2018. Hierdoor heeft het een aanzienlijke impact op de zorg en de totale 
kosten van oncologische zorg. Een groot gedeelte van deze patiënten presenteert zich met 
lokaal uitgebreide of gemetastaseerde ziekte en dit gaat gepaard met een slechte prognose. 
Bij lokaal uitgebreide ziekte is met intensieve systemische therapie zoals chemotherapie, al 
dan niet gecombineerd met radiotherapie, het percentage dat reageert op de behandeling 
relatief beperkt. Bovendien ervaren patiënten een significante toxiciteit van deze 
behandelingen. Om patiënten die mogelijk geen baat hebben van de behandeling zo vroeg 
mogelijk op te sporen, kunnen veranderingen in het glucosemetabolisme worden 
geanalyseerd middels moleculaire beeldvorming met 18F-fluor-deoxy-glucose positron 
emissie tomografie/computer tomografie (FDG-PET/CT). In dit proefschrift worden de 
resultaten van FDG-PET/CT voor vroege response evaluatie bij niet-kleincellig 
longcarcinoom (NSCLC) beschreven bij stadium III en IV patiënten. Voor de kwantificatie 
van metabole respons worden verschillende kwantificatie methoden onderzocht. Verder 
wordt de rol van vroege response evaluatie FDG-PET/CT onderzocht voor beeld 
gestuurde radiotherapie. Hierbij is het mogelijk om een dosisverhoging te bereiken op 
therapieresistente gebieden in de tumor met een verhoogd glucosemetabolisme. Deze dosis 
verhoging is mogelijk, zonder een toename van de radiatie geïnduceerde toxiciteit. Ten 
slotte worden genderspecifieke en histopathologische verschillen in metastasen bij NSCLC 
bekeken in een landelijke obductie studie. 
 
De rol van FDG-PET/CT in karakterisatie en stadering van NSCLC 
 
In Hoofdstuk II wordt de huidige rol van FDG-PET/CT in NSCLC besproken. 
FDG-PET/CT speelt een belangrijke rol in het karakteriseren van een pulmonale nodus. 
Hoewel nodi in de meeste gevallen goedaardig zijn, is FDG-PET/CT nuttig voor 
aspecifieke laesies, waarbij op basis van FDG-opname een onderscheid is te maken tussen 
benigniteit en maligniteit, met een hoge nauwkeurigheid. Alleen in endemische regio's met 
veel longinfecties is het aantal vals-positieve uitslagen van FDG-PET/CT relatief hoog. 
Naast karakterisering van pulmonale nodi speelt FDG-PET/CT een prominente rol bij de 
stadiering. Door de introductie van FDG-PET/CT is er een betere detectie (t.o.v. 
diagnostische contrast CT) van locoregionale lymfekliermetastasen en metastasen op 
afstand, wat uiteindelijk een significante verandering in de besluitvorming tot gevolg kan 
hebben voor de patiënt. FDG-PET/CT vermindert het aantal onnodige thoracotomieën 
en vermindert daarmee ook geassocieerde morbiditeit. Voor patiënten met FDG-avide 
lymfeklieren wordt mediastinale stadiëring door middel van mediastinoscopie, 
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endobronchiale ultrasound geleide transbronchiale naaldaspiratie of endoscopische 
ultrasone fijne naaldaspiratie geadviseerd. Alleen bij patiënten met een FDG-avide primaire 
tumor zonder FDG-avide lymfeklieren in hilaire of mediastinale lymfeklieren, kan 
(invasief) pathologisch onderzoek van het mediastinum achterwege worden gelaten. 
 
FDG-PET/CT respons predictie  
 
Dit proefschrift onderzoekt de toepassing van FDG-PET/CT als een predictieve 
biomarker om vroege respons of non-respons op de behandeling vast te stellen. Vroeg 
tijdens het behandeltraject (na de eerste behandelingskuur) kan met een FDG-PET/CT de 
therapie geïnduceerde verandering worden bekeken. Deze metingen worden vervolgens 
gecorreleerd met de (progressie vrije) overleving van de patiënt. Hoofdstuk III beschrijft 
de klinische uitkomst van patiënten die zijn behandeld met concomitante chemo-
radiotherapie. Deze patiënten werden geëvalueerd met een vroege FDG-PET/CT verricht 
2 weken na start van de behandeling. Achtentwintig patiënten met lokaal uitgebreid 
(stadium IIIA-IIIB) niet-kleincellige longcarcinoom werden geïncludeerd. Een FDG-
PET/CT van het lichaam werd uitgevoerd voor beoordeling van de respons. Hiervoor 
werd tijdens de behandeling gestandaardiseerde parameters zoals standardised uptake value 
(SUV) en total lesion glycolysis (TLG) gemeten. De FDG-PET/CT vóór aanvang van de 
behandeling en FDG-PET/CT vroeg in het behandeltraject werden met elkaar 
gecorreleerd. Baseline TLG en een procentuele verandering ten opzichte van de 
uitgangswaarde voor elke patiënt (ΔTLG) werd statistisch gecorreleerd aan progressie vrije 
overleving. De mediane afkapwaarde van ΔTLG was een afname van 45% op de vroege 
respons FDG-PET/CT. De analyses toonden aan dat vroege FDG-PET/CT-behandeling 
in de behandeling voorspellend was voor de uitkomst bij NSCLC-patiënten die werden 
behandeld met concomitante chemoradiotherapie. In dit onderzoek is de parameter TLG 
zowel een predictieve en prognostische biomarker. In Hoofdstuk IV bespreken we de 
voorspellende waarde van FDG-PET/CT bij neoadjuvante therapie en het belang van 
vroege evaluaties. Met de vroege FDG-PET/CT-behandeling kunnen beeldgeleide 
behandelingsalgoritmen worden ontworpen om de behandeling aan de individuele patiënt 
aan te passen, de behandelingstoxiciteit van niet-effectieve behandeling te minimaliseren 
en een snelle switch naar een effectieve behandeling mogelijk te maken. 
 
Voor het definiëren van vroege metabole respons is het belangrijk om te realiseren dat 
naast biologische en patiënt gerelateerde factoren, ook technische factoren een significante 
invloed kunnen hebben op de semi-kwantitatieve metingen van FDG-PET/CT. Afgezien 
van de keuze van de semi-kwantitatieve meting (SUVmax, SUVpeak, SUVmean, MTV en TLG), 
heeft de methode voor segmentatie van het metabole actieve tumorvolume een significant 
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effect op de hoogte van gemiddelde SUV (SUVmean). Indirect heeft het ook een effect op 
de procentuele veranderingen in de parameter die worden berekend tijdens de vroege 
response evaluatie FDG-PET/CT. In Hoofdstuk V werden verschillende semi-
automatische segmentatie methoden van de aangedane laesies (primaire tumor en FDG-
avide lymfeklieren) op de vroege respons FDG-PET/CT geanalyseerd. Ook werd het 
aggregatieproces, de berekening met of zonder de inclusie van FDG-avide lymfeklieren, 
beoordeeld. Verschillende segmentatiemethoden werden gebruikt: vaste drempelwaarden 
(fixed threshold 40-50% SUVmax), relatieve drempelwaarden (signal-to-background, relative 
threshold method) en adaptieve methoden (fuzzy locally adaptive Bayesian method). Vanuit een klinisch 
perspectief waren de verschillen tussen de segmentatiemethoden klein als het gaat om de 
exacte verschillen in predictieve waarde, maar vanuit een praktisch oogpunt resulteerde de 
signaal-tot-achtergrond methode in meer succesvolle (semi)automatische segmentaties van 
de primaire tumor en de aangedane lymfeklieren. De meeste segmentatie problemen 
ontstonden als gevolg van segmentatie fouten bij vaste en adaptieve drempelwaarden op 
de vroege respons evaluatie FDG-PET/CT, vanwege de lage signaal-achtergrond door een 
lage FDG opname in de primaire tumor en/of aangedane lymfeklieren. 
 
FDG-PET/CT en radiotherapie planning 
 
Bij radiotherapieplanning kan FDG-PET/CT de radiotherapeut ondersteunen om 
enerzijds een optimale dosisafgifte in de tumor te bereiken en anderzijds zoveel mogelijk 
toxiciteit te besparen door radiatie op gezonde weefsels zoveel mogelijk te beperken. FDG-
PET/CT verbetert de doelnauwkeurigheid voor bestraling van aangedane lymfeklieren en 
heeft hierdoor een zeker voordeel ten opzichte van CT bij lymfeklieren die niet-
pathologisch vergroot zijn. Ten behoeve van de radiotherapieplanning kan FDG-PET/CT 
worden gebruikt om hoge stralingsdosis mogelijk te maken op actieve gebieden in de 
tumor, zonder een duidelijke toename te geven in de te verwachten toxiciteit op het 
aangrenzende gezonde weefsel. Dit is met name van belang voor patiënten met lokaal 
uitgebreid niet-kleincellig longcarcinoom waarbij het aantal patiënten met uiteindelijk een 
lokaal recidief significant is, ondanks de introductie van concomitante chemoradiatie. In 
Hoofdstuk VI werd een op FDG-PET/CT gebaseerd planningsonderzoek uitgevoerd bij 
patiënten die een metabole non-respons vertoonden op de vroege FDG-PET/CT. Het 
doel van deze studie was om de haalbaarheid van dosisescalatie en het effect hiervan op 
toxiciteit te onderzoeken. Tien patiënten, met een TLG-daling minder dan 45% op de 
vroege evaluatie scan, werden geselecteerd voor deze planningsstudie. Er werd een 
stereotactische boost gepland op de meest radioresistente subvolumes van de primaire 
tumor (de meest FDG-avide gebieden in de primaire tumor), voor zowel de baseline FDG-
PET/CT als de evaluatie FDG-PET/CT welke werd verricht vóór de tweede 
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behandelingscyclus. Een aanzienlijke dosisverhoging was haalbaar, terwijl tegelijkertijd ook 
aan strikte dosisbeperkingen voor het gezonde weefsel en organen werden voldaan. Bij vijf 
patiënten was het boost-geplande tumorvolume (PTVboost) 9-40% kleiner in vergelijking 
met de PTVboost op basis van de FDG-PET/CT-behandeling vóór de behandeling. 
 
Response beoordeling bij lokaal uitgebreid (inoperabel) NSCLC en 
gemetastaseerd NSCLC 
 
De meerderheid van de patiënten met NSCLC presenteert zich met inoperabele ziekte 
(stadium IIIB) of gemetastaseerde ziekte (stadium IV). Chemotherapie speelt nog steeds 
een belangrijke rol in de behandeling, ook na introductie van verschillende doelgerichte 
behandelingsstrategieën. Vasculaire endotheliale groeifactor (VEGF) is bijvoorbeeld een 
belangrijke mediator bij tumorangiogenese, en speelt een vitale rol de bij overleving van 
kankercellen, lokale tumorgroei en de ontwikkeling van metastasen op afstand. In 
Hoofdstuk VII worden patiënten met een nieuw gediagnosticeerd niet-squameuze 
NSCLC behandeld met eerstelijns chemotherapie (carboplatin en paclitaxel) in combinatie 
met bevacizumab, een monoklonaal antilichaam tegen vasculaire endotheliale groeifactor. 
Zesentwintig patiënten werden behandeld in deze studie. Ze ondergingen een baseline 
FDG-PET/CT en een vroege respons evaluatie FDG-PET/CT na 13 tot 20 dagen, 
voorafgaand aan de tweede behandelingscyclus. Voor het beoordelen van metabole 
respons werden vooraf gedefinieerde PET-criteria (PERCIST) gebruikt. In deze studie 
werd aangetoond dat FDG-PET/CT voorspellend was voor progressievrije overleving en 
totale overleving, al zeer vroeg tijdens de behandeling. 
 
Patroon van metastasen bij NSCLC 
 
Hoofdstuk VIII toonde de resultaten van een landelijke obductiestudie bij NSCLC, 
waarbij verschillende patronen van metastasen tussen de twee belangrijkste histologische 
subtypes, adenocarcinoom (AC) en plaveiselcelcarcinoom (SCC) werden onderzocht. 
Patiënten met AC ontwikkelden vaker metastasen (50% versus 25% in SCC, P <0.001) en 
hadden vaker metastasen op meerdere plaatsen (77% versus 67%, P = 0.004). AC 
vertoonde significant meer metastasen in de bijnieren en bot, terwijl SCC meer nier-
metastasen liet zien. Bij vrouwen met AC kwamen lever- en longmetastasen vaker voor 
dan mannen. Aangezien de biologische verschillen bij longkanker tussen mannen en 
vrouwen in toenemende mate worden erkend, is kennis van deze factoren belangrijk. Dit 
geldt des te meer gezien de stijging in het aantal gevallen van longkanker bij vrouwen. 
Kennis van de verdeling van metastase patronen op basis van verschillende prognostische 
factoren zou de klinische beoordeling van onduidelijke bevindingen kunnen verbeteren. 
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10 
Slotopmerkingen 
 
De predictieve waarde van FDG-PET/CT wordt steeds meer erkend. In de discussie in dit 
proefschrift worden verschillende methodologische overwegingen genoemd bij vroege 
respons evaluatie met FDG-PET/CT. Verschillen in de kwantificatie van metabole actieve 
tumorvolumes, de definitie van het metabool actieve tumorvolume en de verschillen in 
kwantitatieve parameters bij respons evaluatie worden behandeld. Een belangrijke 
uitdaging bij vroege respons evaluatie is dat de juiste timing van FDG-PET/CT tijdens de 
behandeling cruciaal is en dat de timing mede afhankelijk is van het gekozen 
behandelingsschema. Omdat er verscheidene methoden zijn om een metabole respons te 
definiëren, is het gebruik van gevalideerde metabole respons criteria van belang om bias in 
de interpretatie en de resultaten te voorkomen. Bovendien is voor de klinische 
implementatie een standaardisering van metabole respons methoden essentieel. Met de 
toenemende behandelingsopties, de vooruitgang in doelgerichte behandeling en de komst 
van therapie op maat, is een goede en nauwkeurige selectie van effectieve behandelingen 
in toenemende mate belangrijk. Het uiteindelijke doel is het verbeteren van de overleving 
en de kwaliteit van leven. 
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List of abbreviations  
 
AC  adenocarcinoma 
AS-NSCLC advanced stage non-small cell lung cancer 
ASCO  American Society of Clinical Oncology 
AUC  area under the curve 
BE  bevacizumab erlotinib 
BED  biologically effective dose 
BSA  body surface area (m2) 
BTV  biological target volume 
CE  chemotherapy regimen consisting of cisplatin and etoposide 
CI  confidence interval 
CMR  complete metabolic response 
CPB  carboplatin paclitaxel and bevacizumab 
CP  carboplatin paclitaxel 
CR  complete response 
CRT  chemo-radiotherapy 
CT  computed tomography 
CTV  clinical target volume 
CTx  chemotherapy 
Dmax  maximum dose within the planned target volume  
EANM  European Association of Nuclear Medicine 
EARL  EANM Research Limited 
EBUS  endobronchial ultrasound 
EGFR  epidermal growth factor receptor 
EORTC  European Organization for Research and Treatment of Cancer 
EQD2  equivalent dose in 2 Gy fractions  
ERM  early in-treatment response monitoring 
ESMO  European Society for Medical Oncology 
EUS  esophageal ultrasound 
FAZA  18F-fluoro-azomycin-arabinoside 
FDG  18F-fluoro-deoxy-glucose 
FLAB  fuzzy locally adaptive Bayesian method 
FLT  18F-fluoro-thymidine 
FMISO  18F-fluoro-misonidazole 
FWHM  full width at half maximum 
GLUT  glucose-transporter 
GTV  gross tumour volume 
Gy  Gray 
HR  hazard ratio 
IGART  image guided adaptive radiotherapy 
IMRT  intensity modulated radiotherapy treatment 
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IRB  institutional review board 
IRW  Inveon Research Workplace 
JI  Jaccard Index 
k  Cohen k coefficient for agreement 
LBM  lean body mass 
LRFS  local recurrence free survival 
MTV  metabolic tumour volume (cm3) 
MRI  magnetic resonance imaging 
NE  not evaluable (response) 
NSCLC  non-small cell lung cancer 
OAR  organs at risk 
ORG  optimally respiratory gating 
OS  overall survival 
OSEM  ordered subsets expectation maximization 
OTT  overall treatment time 
P  level of significance 
PALGA Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief (Dutch 
pathology registry)  
PD  progressive disease 
PERCIST PET response criteria in solid tumours 
PET  positron emission computed tomography 
PFS  progression-free survival 
PMD  progressive metabolic disease 
PMR  partial metabolic response 
PR  partial response 
PRV  planning organ at risk volumes 
PTV  planned target volume 
PVE  partial volume effect 
ρ  Spearman’s non parametric rank correlation coefficient 
R  Pearson  
RCT  randomised controlled trail 
RECIST  response evaluation criteria in solid tumours 
ROC  receiver operating characteristic 
ROI  region of interest 
RT  radiotherapy 
RTL  relative threshold level 
RTOG  Radiation Therapy Oncology Group 
SBR  signal to background ratio 
SBRT  stereotactic body radiation therapy 
SCC  squamous cell carcinoma 
SD  stable disease 
SIB  simultaneously integrated boost 
SMD  stable metabolic disease 
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SPN  solitary pulmonary nodule 
SPSS  statistical package for the social sciences 
SUL  standardised uptake value corrected for lean body mass 
SULpeak maximum average standardised uptake value corrected for lean body mass 
within a 1-cm3 spherical volume 
SUV  standardised uptake value (g . cm-3) 
SUVpeak maximum average standardised uptake value within a 1-cm3 spherical volume 
SUVmax  maximum voxel based on standardised uptake value 
T40 segmentation theshold 40% of maximum standardised uptake value 
T50  segmentation theshold 50% of maximum standardised uptake value 
TBNA  transbronchial needle aspiration 
TKI  tyrosine kinase inhibitor 
TLG  total lesion glycolysis 
ΔTLG  relative change in total lesion glycolysis (%) 
TLGLN total lesion glycolysis of affected lymph nodes 
TLGS summed total lesion glycolysis of both primary tumour and affected lymph 
nodes 
TLGT total lesion glycolysis of primary tumour only 
ToF  time-of-flight 
TPI  total proliferation index 
UICC  Union for International Cancer Control 
VDT  volume doubling time 
VEGF  vascular endothelial growth factor 
VMAT  volumetric modulated arc therapy 
VOI  volume of interest 
A 
  
 
208 | Appendices 
 
ACKNOWLEGMENTS | DANKWOORD 
  
Het onderzoek en dit proefschrift zouden niet tot stand zijn gekomen zonder de 
waardevolle bijdrage van velen. Allereerst wil ik alle patiënten bedanken, die ondanks hun 
ziekte, de toewijding hebben getoond om te participeren aan de klinische studies en 
kostbare tijd hebben vrijgemaakt om de medische wetenschap vooruit te helpen. 
Enkele personen in het bijzonder wil ik nog graag bedanken voor hun bijdrage aan dit 
proefschrift.  
 
Prof. dr. Lioe-Fee de Geus-Oei, beste Lioe-Fee, veel dank voor deze opportuniteit 
die ik van je heb gekregen. Naast vakinhoudelijke kennis van de nucleaire geneeskunde heb 
ik ook het doen van klinisch onderzoek van je aangeleerd. Ik waardeer het laagdrempelige 
overleg en je organisatie. Ondanks je drukke banen wist je wel altijd tijd vrij te maken voor 
begeleiding en sturing. Je was kritisch, rechtvaardig en complimenteus. Dank dat je altijd 
vertrouwen hebt uitgesproken, ook op momenten dat ik het misschien wat minder zag 
zitten. Promoveren was gelukkig veel meer dan het verdwaald raken in het bos van de 
wetenschap. Gelukkig kon ik door jou, Lioe-Fee, de weg altijd weer terugvinden. 
Prof. dr. Johan Bussink, beste Jan. Je vurige passie voor wetenschap en tegelijkertijd 
de rust en het geduld wat je altijd uitstraalt zijn bewonderenswaardig. Fijn dat ik mocht 
meewerken aan een prachtig project voor m’n onderzoeksstage. Toen ik nog als coassistent 
een kijkje in de keuken mocht nemen op de afdeling Radiotherapie was ik dan ook meteen 
verkocht. Dank voor je vertrouwen en veel dank voor de prettige begeleiding en je immer 
kritische, maar ook zeer pragmatische aanpak. 
Prof. dr. Wim Oyen, beste Wim. Je was altijd zeer betrokken als promotor. Ondanks 
dat we elkaar niet heel veel zagen, mede gezien je eerdere werkzaamheden in Londen, was 
het contact altijd zeer prettig en laagdrempelig. Het mailcontact was altijd snel en je 
antwoord zeer doelgericht. Je commentaar was altijd zeer waardevol en je besluiten 
doortastend. Verder wil ik nog veel bewondering uiten voor al je toonaangevende 
wetenschappelijke werk. 
  
Dr. Eric Visser, dank voor al je uitleg en je geduld. Dank voor je wetenschappelijke 
inzichten en je altijd kritische blik op het schrijven. Ik kan mij nog het eerste moment 
herinneren dat wij elkaar spraken over segmentatie methoden, niet zozeer inhoudelijk 
(want daar begreep ik op dat moment eerlijk gezegd nog niet zoveel van!) maar wel je 
aanstekelijke passie voor de fysica en dat was zeer inspirerend.  
Dr. Willem Grootjans, beste Willem, dank voor de prettige samenwerking tijdens ons 
onderzoek. Je manifesteerde je daadwerkelijk als de brug tussen de nucleaire geneeskunde 
A 
 	
A 
Appendices | 209 
 
en de klinische fysica. Alle kostbare tijd en de noeste arbeid van het segmenteren (achter 
het IRW-station) …. Gedeelde smart is halve smart! 
  
Dat moleculaire beeldvorming verder gaat dan alleen de afdeling Nucleaire 
geneeskunde, blijkt ook uit alle andere afdelingen die betrokken zijn geweest bij het huidige 
werk. Daarom wil ik ook alle betrokkenen vanuit de Radiologie, Longgeneeskunde, 
Radiotherapie en Pathologie bedanken voor de prettige samenwerking. 
Prof. dr. Hans Kaanders, prof. dr. Esther Troost, dr. Tineke van der Zon-Meijer, 
dr. Robin Wijsman. Het is prachtig om te zien hoe de radiotherapie een sterke relatie heeft 
opgebouwd met de nucleaire geneeskunde. Jullie omarmen moleculaire beeldvorming om 
o.a. biologische mechanismen van radioresistentie te onderzoeken. Bedankt voor de 
prettige samenwerking! Dr. P. Span, beste Paul, dank dat je als vraagbaak wilde fungeren 
voor m’n statistiek. Altijd zeer behulpzaam was je als ik weer eens was verdwaald in de 
wondere wereld van SPSS. 
Dr. Liesbeth P. Peters-Bax, beste Liesbeth, veel dank voor je begeleiding bij de 
respons beoordelingen op de CT-scans.  
Dr. Olga Schuurbiers, beste Olga, dank voor je begeleiding tijdens de vroege fase van 
het student zijn en je input tijdens de onderzoeksstage die uiteindelijk hebben geleid tot 
m’n allereerste publicatie. 
Dr. Miep van der Drift, dr. Erik H.F.M. van der Heijden, dr. Anja Timmer-Bonte, 
veel dank voor jullie tijd en inzet bij onder andere de inclusie van alle patiënten en het 
beoordelen van de manuscripten.   
Prof. dr. Iris Nagtegaal, dank voor alle input bij de obductie studie. 
Voor zover nog niet genoemd, wil ik alle overige co-auteurs van bedanken voor alle 
gedachtewisselingen, correcties, ideeën en input. 
De leden van de manuscriptcommissie, prof. dr. C.M.L van Herpen, prof. dr. M. van 
der Heijden en prof dr. E.F.I. Comans, wil ik bedanken voor het beoordelen van dit 
proefschrift.  
 
Opleiding en wetenschap gingen in de praktijk hand in hand. Aan alle stafleden van 
de Nucleaire geneeskunde, Marcel, Martin, Anne, James, Maartje, Fred, wil ik veel dank 
uitspreken voor alle begeleiding tijdens de opleiding. Prof. dr. M. Gotthardt, beste Martin, 
veel klinische vaardigheden heb ik van je aangeleerd, waarvoor dank, maar bovenal ook 
dank dat je mij hebt gered in Winterberg. Dr. M.J.R. Janssen, beste Marcel, zonder jou was 
ik wellicht niet eens zover gekomen. Het combineren van een opleiding en een promotie 
traject is niet altijd even makkelijk geweest. Onze gesprekken en je geduld hebben mij 
uiteindelijk ook geholpen om te komen op een plek waar ik nu sta in het leven en daarvoor 
ben ik je nog altijd dankbaar. 
  
 
210 | Appendices 
Verder wil ik ook alle laboranten van de nucleaire geneeskunde bedanken, Michel, 
Martin, Bernadette, Jurrian, Marie-Claire, Eddy, Marjo, Marga, Merijn (mogelijk ben ik nog 
een aantal anderen vergeten, bij deze excuus!), veel dank voor jullie ondersteuning en 
onuitputtelijke inzet op de nucleaire geneeskunde! De oud-AIOS, Christel, Sabine, Tom, 
Linda, Willemijn, Erik. In ons hart blijven wij altijd “Nijmegen”. Dank voor de gezellige 
tijd op de werkvloer en daarbuiten. 
Ook wil ik mijn huidige collegae, de afdeling Nucleaire geneeskunde te Dordrecht, de 
maten, Shiuw en Boudewijn bedanken. Dank voor jullie begrip en de steun die ik kreeg om 
onder andere ook deze laatste horde te nemen.  
De familie, broers, aanhang, schoonfamilie, dank voor jullie oprechte interesse. Pa en 
ma, veel dank voor jullie onuitputtelijke steun, bemoedigende woorden en vertrouwen. 
Jullie hebben altijd klaargestaan en mij ook altijd op persoonlijk vlak bijgestaan.  
Michael, brother for life. Weinig woorden zijn nodig. Patrick van de Camp, altijd oog 
voor detail en bovendien sparringpartner op het digitale slagveld. Dank dat jullie mijn 
paranimfen wilden zijn. 
Lieve Ellen, de allerliefste, dit proefschrift zou niet compleet zijn zonder een ode aan 
jou. Behind every man’s success is a woman. Jij zorgde voor de stabiele basis en gaf mij de 
ruimte en de tijd om aan dit proefschrift te werken. Jij stimuleerde en ondersteunde 
mij. Dank voor je geduld, je wijze raad, liefde en aandacht. Met dit proefschrift wordt een 
drukke periode afgesloten. Op ons volgende project samen! 
 
 
 
A 
 	
Appendices | 211 
 
Curriculum vitae 
 
Edwin Usmanij werd op 29 juni 1988 geboren in Tiel, Gelderland. 
Hij groeide op in Oosterhout, Noord-Brabant. In 2006 behaalde hij 
zijn diploma aan het Sint-Oelbert gymnasium te Oosterhout, waarna 
hij geneeskunde ging studeren in Nijmegen. In 2012 rondde hij 
geneeskunde af met een wetenschappelijke stage op de afdeling 
Radiotherapie en Nucleaire geneeskunde van het Radboudumc 
Nijmegen. In 2013 startte hij met de opleiding nucleaire geneeskunde, 
eveneens aan het Radboudumc (opleiders prof. dr. W.J.G. Oyen en 
prof. dr. L.F. de Geus-Oei en later dr. M.J.R. Janssen). Het begin van de opleiding tot 
specialist werd gecombineerd met een promotieonderzoek wat heeft geleid tot dit 
proefschrift. Het promotieonderzoek naar vroege respons evaluatie met 
18F-fluorodeoxyglucose positron emissie tomografie (FDG-PET/CT) bij niet-kleincellig 
longcarcinoom werd verricht onder begeleiding van prof. dr. L.F. de Geus-Oei, 
prof. dr. J. Bussink en prof. dr. W.J.G. Oyen. 
Na de opleiding te hebben afgerond is hij sinds februari 2018 werkzaam als nucleair 
geneeskundige in het Albert Schweitzer Ziekenhuis te Dordrecht. 
 
A 
  
 
212 | Appendices 
PhD Portfolio E.A. Usmanij 
 
 
 
PhD student: E.A. Usmanij 
Department:   
Radiation Oncology,  
Radiology and Nuclear Medicine 
Graduate school:   
Radboud Institute for Health Sciences 
 
PhD period: 10-7-2012 until 31-12-2018 
Promotors:   
prof. dr. L.F. de Geus-Oei, 
prof. dr. J. Bussink, 
prof. dr. W.J.G. Oyen 
 
pro 
  
TRAINING ACTIVITIES Year(s) ECTS 
a) Courses & Workshops 
- Coordinating radiation protection 
expert (formerly level 3), Radboud 
University 
 
2016 
 
20 
 
b) Seminars & Lectures 
- * Dutch Society of Nuclear Medicine 
(NVNG), Scientific Symposium, 
Nijmegen, The Netherlands  
- * Landelijk platform voor 
Radiotherapie, Annual Meeting, 
Heelsum, The Netherlands 
- * Dutch Society of Nuclear Medicine 
(NVNG), Scientific Symposium, 
Amersfoort, The Netherlands 
 
2012 
 
 
2014 
 
 
2016 
 
0.3 
 
 
0.3 
 
 
0.3 
 
 
c) International Symposia & Congresses 
- * Annual Congress of the European 
Association of Nuclear Medicine, 
Lyon, France.  
- * Annual Congress of the Society of 
Nuclear Medicine, San Diego, 
United States of America.  
- # Annual Congress of the European 
Association of Nuclear Medicine, 
Dusseldorf, Germany.  
- Annual Congress of the European 
Association of Nuclear Medicine, 
Vienna, Germany 
 
2013 
 
 
2016 
 
 
2016 
 
 
2017 
 
1.0 
 
 
1.0 
 
 
1.0 
 
 
1.0 
 
 
d) Other 
- Scientific meeting of the NVNG 
 
2012-2019 
 
2x year, 0.3 
    
Oral (*) and poster presentations (#) are indicated with a * and # before the name of the activity, 
respectively. 
A 
 	
Appendices | 213 
 
Research Data Management 
 
The research described in this thesis, based on the results of human studies, have been 
carried out in accordance with the national applicable rules concerning the review of 
research ethics committees and informed consent, in accordance with the principles of the 
Declaration of Helsinki by the World Medical Association of June 1964. The medical and 
ethical review board has given approval to the human studies in Chapter III, V, VII and 
VIII. All data retrieved have been collected and processed fully anonymised. The patient 
data for the analyses of these studies are stored in the Radiology and Nuclear Medicine trail 
bureau. Published data generated or analysed in this thesis are part of published articles 
and its additional files are available from the associated corresponding authors on 
reasonable request. Further use of these patient data in future research is only possible after 
a renewed permission by the patient as recorded in the informed consent.  
 
The FAIR principles in research data management 
 
A guideline to provide machine-readable data to allow for easy sharing of research data has 
recently been proposed as the FAIR-principles (1). These principles are guidelines to enable 
and improve Findability, Accessibility, Interoperability and Reuse of research data. The 
research data retrieved and stored in this thesis are not adapted to these proposed 
guidelines, since all data collection has been performed and stored before the FAIR 
guidelines were published. The anonymised study databases have been transferred to the 
research group for possible future research projects. 
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